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This longitudinal study explored how health and medical organizations used 
public relations techniques to influence news content about postmenopausal hormone 
therapy (HT) from 1995 to 2011. A theoretical framework that combined agenda 
building, information subsidies, and framing guided the study (Zoch & Molleda, 2006). 
Quantitative content analyses were conducted on 675 press releases about HT distributed 
through PR Newswire and EurekAlert!, and 429 news stories about HT in the Associated 
Press Newswire (AP), The New York Times, The Washington Post, Los Angeles Times, 
and The Wall Street Journal. Supplemental qualitative content analyses of organizational 
websites, annual reports, and scientific publications explored financial relationships and 
potential collaborations between ten organizations that emerged as the most successful 
agenda builders. 
Six types of health and medical organizations produced press releases about HT: 
pharmaceutical companies, academic/medical institutions, nonprofit health advocacy 





for-profit organizations. A positive, statistically significant relationship was found 
between the quantity of press releases and news stories over time (r = .55, p<.001). 
Findings also supported the transference of specific objects, such as brand-name HT 
products, and attributes, such as risks and benefits, from the public relations to the news 
media agenda. Academic/medical institutions and nonprofit health advocacy 
organizations were significantly more likely than pharmaceutical companies to identify 
non-FDA approved, “off-label” benefits. Wyeth Pharmaceuticals, manufacturer of 
leading HT brands Premarin and Prempro, financially subsidized most of the top-ten, 
agenda-building organizations, including four academic/medical institutions and two 
non-profit health advocacy organizations that were frequently cited in news stories. 
Additionally, a substantial degree of synergy was found between these organizations in 
terms of how they framed menopause and HT over the study period. 
This study supported and extended the theoretical framework used by offering 
insights into how organizations may collaborate through funding arrangements and third-
party communication techniques to influence news content in a health and medical 
context. The findings also contributed a new and important dimension to scholarship on 
pharmaceutical promotion of prescription drugs, which has neglected the role of public 
relations and focused almost exclusively on more overt, paid-promotional efforts like 
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Chapter I: Introduction 
Recent years have brought numerous cases of prescription drugs that became 
blockbuster sensations, only to be suddenly withdrawn from the market or the subject of 
consumer alerts due to serious risks and side effects. For example, anti-inflammatory 
Vioxx, taken by an estimated two million Americans, was taken off the market in 2004 
when it became clear that the risks of heart attack and stroke outweighed any of its 
benefits (Batt, 2005; Rubin, 2004). In 2002, several pharmaceutical manufacturers were 
forced to add warning labels to antidepressants about the potential risk of suicidality in 
children and adolescents taking antidepressants. Although only one product, Prozac, had 
ever been approved by the U.S. Food & Drug Administration (FDA) for use in children 
and adolescents, physicians routinely prescribed other brands to this population group, a 
practice commonly referred to as “off-label” prescribing.  
That same year, the National Heart Lung & Blood Institute (NHLBI), part of the 
U.S. National Institutes of Health (NIH), released findings from its Women’s Health 
Initiative (WHI) trial, indicating that postmenopausal women taking estrogen-plus-
progestin hormone therapy were at increased risk for breast cancer, heart disease, blood 
clots, and stroke, which was followed by another announcement by the Institute in 2004, 
indicating that women taking estrogen-only hormone therapy were at risk for stroke and 
serious blood clots (U. S. Department of Health & Human Services, National Heart, 
Lung, and Blood Institute [USDHHS NHLBI], 2005). These announcements shocked 
women, their physicians, and the medical community at large because hormone therapy 
was frequently prescribed off-label to prevent heart disease (Katz, 2003; Roussouw, 





 Although the reasons behind these types of cases are multiple and complex, some 
claim that aggressive pharmaceutical industry promotion of prescription drugs plays an 
important role by stimulating unnecessary prescribing and/or overuse of newer and more 
expensive, brand-name drugs despite their less solid track records of safety (Auton, 2004; 
Brownfield, Bernhardt, Phan, Williams, & Parker, 2004; Fugh-Berman, Alladin, & 
Chow, 2006; Mackowiak & Gagnon, 1985; Royne & Myers, 2008). Spending on 
promotion of prescription drugs increased from $11.4 billion in 1996 to $29.9 billion in 
2005 (Donohue, Cevasco, & Rosenthal, 2007). Promotional dollars typically support a 
range of activities, including, but not limited to, sales visits to physicians known as 
“detailing,” which often includes distribution of free drug samples and small rapport-
building gifts, medical journal advertising, and advertising directed to consumers, 
commonly referred to as direct-to-consumer advertising (DTCA).  
To date, research has primarily focused on the role overtly promotional sources of 
information such as detailing, medical journal advertising, and DTCA play in stimulating 
prescription drug demand by influencing the decision-making processes of consumers 
and/or physicians (Donohue & Berndt, 2004; FDA, 2004; Gonul et al., 2001; Iizuka & 
Jin, 2006; Mizik & Jacobson, 2004; Rizzo, 1999; Rosenthal, Berndt, Donohue, Epstein, 
& Frank, 2003; Wang, Ausiello, & Stafford, 1999; Zachry et al., 2002). News media, 
however, may also play a key role in influencing prescription drug use, by disseminating 
information about the uses, benefits, and risks of prescription drugs in a manner similar to 
other sources of information. The U.S. news media are leading sources of health 
information for consumers, healthcare providers, and policymakers (Martinson & 





Bednarczyk, & Tastad, 1991; Schwartz & Woloshin, 2004; Viswanath et al., 2008), and 
news coverage has been associated with population-level changes in a variety of health 
behaviors (Hornik, 2002), including health care utilization (Grilli, Ramsay, & Minozzi, 
2002). Paid advertising and marketing efforts are regulated by the FDA to make sure only 
FDA-approved products and indications are promoted accurately with a “fair balance of 
efficacy and risk information” (Sheehan, 2003, p. 160). Information distributed by health 
and medical organizations through news media, however, is not subject to FDA 
regulations (Leffler, 1981; Morris & Griffin, 1992; Sheehan, 2003). For this reason, news 
media content about prescription drugs may provide a non-FDA regulated outlet for 
information not easily disseminated by other means, such as promotion of off-label 
indications. 
A substantial portion of health news content is influenced by the public relations 
activities of health and medical organizations, such as pharmaceutical companies, 
government agencies, universities, medical schools, medical professional societies, trade 
associations, and health advocacy groups (Gandy, 1982; IOM, 2009). It is estimated that 
anywhere from 25% to 50% of all news content in the United States is public relations-
generated (Cameron, Sallot, & Curtin, 1997; Sallot & Johnson, 2006) by organizations 
and other actors attempting to influence the decisions of stakeholders and publics who 
consume the news in ways that are favorable to their strategic objectives (Cameron, 
Sallot, & Curtin, 1997; Sallot & Johnson, 2006; Zoch & Molleda, 2006).  
The sources typically relied on by science and health journalists include not only 
government and institutional experts, but also scientists, physicians, and pharmaceutical 





Wallington et al., 2007). Specifically, common sources of information for news about 
health and medicine are: scientific journals and conferences; press releases distributed by 
organizations, such as universities, government agencies, and pharmaceutical companies; 
news wire services and other news media outlets; and individual spokespersons, such as 
scientists, physicians, and government officials who work for a variety of health and 
medical organizations (Corbett & Mori, 1999; Dunwoody, 1986; Entwistle, 1995; Gandy, 
1982; Gans, 1979; Nelkin, 1995; Rogers et al., 1991; Semir et al., 1998; Shoemaker & 
Reese, 1996; Van Trigt et al., 1994; Walters & Walters, 1992; Wilkes, 1997).  
Some public relations scholars have emphasized the need for a greater 
understanding of the role organizations play in influencing the news media agenda, and 
through what processes these efforts might exert societal-level influence by changing the 
attitudes, beliefs, and behaviors of publics (Cameron et al., 1997; Kiousis, Mitrook, Wu, 
& Seltzer, 2006; Kiousis, Popescu, & Mitrook, 2007; Zoch & Molleda, 2006). The news 
media agenda refers to the salience or importance placed on issues or topics by news 
media, which is typically measured by the amount of coverage or prominence afforded to 
issues or topics by news media over a specific time period (Dearing & Rogers, 1996; 
McCombs & Shaw, 1972). News media attention can confer status to an issue or topic, 
draw public attention to it, and increase public perceptions of its importance (Lazarsfeld 
& Merton, 1948, 1964, as cited in Dearing & Rogers, 1996; McCombs & Shaw, 1972). 
Getting issues or topics of strategic interest onto the news media agenda and controlling 
the content of that news coverage can lead to desirable outcomes for organizations.  
Although little research has looked specifically at the quality of prescription drug 





more generally. Common problems cited include news stories that exaggerate the 
incidence or prevalence of diseases or conditions, sensationalize new research findings, 
provide inaccurate and unbalanced information about the benefits and risks of medical 
products, and fail to disclose the financial conflicts of interest of experts and 
organizations that serve as news sources (Nelkin, 1995; Schwitzer et al., 2005; Schwitzer, 
2008). Traditional explanations for these problems have focused on the way journalists 
work or the constraints of their news organizations (Gans, 1979; Nelkin, 1995; Tuchman, 
1972), neglecting the role of organizations that produce, finance, and disseminate sources 
of information to journalists (Gandy, 1982; Manning, 2001; Seale, 2002; Shoemaker & 
Reese, 1996; Tankard, 2001).  
Several scholars have advocated approaches to understanding news content that 
include not just factors internal to the news organization, but factors external to it as well, 
such as the role organizations and other actors play when they attempt to use news media 
to meet their own political and economic interests (Gandy, 1982; Manning, 2001; Seale, 
2002; Shoemaker & Reese, 1996). Little research, however, has looked systematically at 
what types of health and medical organizations produce sources of information about 
prescription drug news; what their resources and goals are; how they act individually, and 
perhaps jointly with other organizations, to influence news content; and how these 
processes might influence the quality of news about prescription drugs.  
Zoch and Molleda (2006) proposed a theoretical framework to discover how 
organizations conduct media relations to actively build and frame the news media agenda 
through various public relations techniques. They combined three existing theoretical 





how individuals and organizations “build” the news media agenda for a public issue 
through various activities (McCombs, 1992; Zoch & Molleda, 2006). Information 
subsidies are materials that public relations practitioners produce or make readily 
available to journalists to build the news media agenda, such as press releases and video 
news releases (VNRs) or individual experts or spokespersons (Gandy, 1982). Framing 
refers to the way information is selectively included, highlighted, or omitted in news 
stories (Entman, 1993), and how different news frames can alter audience perceptions, 
attributions, and decisions (Iyenger, 1991). Zoch and Molleda (2006) suggested that 
organizations attempt to influence the decisions of stakeholders and publics who 
consume the news by framing information subsidies in ways that are favorable to their 
strategic objectives.  
This dissertation research used Zoch and Molleda’s (2006) theoretical framework 
to explore how the public relations efforts of a variety of health and medical 
organizations, such as pharmaceutical companies, government agencies, universities, 
medical schools, medical professional societies, trade associations, and health advocacy 
organizations, influence the news that is available to publics to make decisions about 
prescription drugs. Specifically, the purpose of this study was to apply agenda building, 
information subsidies, and framing theories to a content analysis of organizational 
materials and news to analyze how health and medical organizations built and framed the 
news media agenda for postmenopausal hormone therapy from 1995 to 2011. 
Hormone Therapy (HT) as Context 
HT was selected as the context to test the theoretical framework. This selection 





of HT have been portrayed in news media over time, and what possible role organizations 
played in promoting these portrayals (Felgran & Hettinger, 2002; Fugh-Berman & 
Pearson, 2002; MacLennan et al., 2004; Moynihan et al., 2002; Pines, 2008; Zuckerman, 
2002). Although estrogen and estrogen-plus-progestin HT formulations were only ever 
approved by the FDA for the indications of vasomotor symptoms (hot flashes), vulvar 
and vaginal atrophy, and postmenopausal osteoporosis (USDHHS FDA, 2011b), many 
women and their clinicians believed that hormone therapy could prevent a host of other 
conditions, such as cardiovascular disease, memory loss, and aging of the skin (Fugh-
Berman & Pearson, 2002; Utian & Schiff, 1994), turning leading HT brands, Premarin 
(estrogen-only) and Prempro (estrogen-plus-progestin), into blockbuster drugs in the 
1990s. 
Striking differences in temporal trends of HT prescription use have been observed 
in response to the NHLBI’s WHI trials, which demonstrated that HT use was associated 
with substantial risks and provided no cardiovascular disease benefit. HT use increased 
steadily prior to the 2002 WHI announcement about the risks of estrogen-plus-progestin 
therapy and decreased steadily after, with further reductions occurring after the 2004 
announcement about the risks of estrogen-only HT (Austin et al. 2003; Haas et al., 2004: 
Hersh et al. 2004; Roumie et al., 2004). Women have also reported that news media 
played a role in their decision to discontinue their hormone therapies (see Barber et al., 
2004; Bastian, Breslau, Davis, & Moser, 2005; Ettinger et al., 2003; Huston, Jackowski, 
& Kirking, 2009; MacLennan et al., 2004; McIntosh & Blalock, 2005). Despite 
indications that HT-related news coverage may have played a role in driving or 





studies have been conducted to examine the quantity and quality of news coverage prior 
to, during, or after the WHI announcements. The up-and-down patterns of HT 
prescription use over time, combined with the controversies that have arisen over how the 
benefits and risks of HT have been portrayed in news media, make HT a productive and 
compelling context for this study.  
Summary of Method 
This study used content analysis to examine how health and medical 
organizations used information subsidies to build and frame the news media agenda for 
HT from 1995 to 2011. The public relations agenda of organizations was measured 
through press releases about HT distributed through PR Newswire and EurekAlert!. The 
news media agenda was measured via HT stories in the Associated Press Newswire (AP) 
and four, top-circulating, U.S. newspapers: The New York Times, The Washington Post, 
Los Angeles Times, and The Wall Street Journal. 
Quantitative content analysis procedures were used to describe the over-time 
relationship between the public relations and news media agendas in terms of the quantity 
and quality of HT coverage and to understand how a variety of health and medical 
organizations actively built and framed the news media agenda for HT over the study 
time period. Supplemental qualitative content analysis procedures were applied to a 
subset of the data to provide a more nuanced and contextual understanding of the agenda-
building and framing activities of organizations that emerged from the quantitative 
content analysis as successful agenda builders, as evidenced by frequent mentions of 
these organizations in press releases and news stories. Additional archival/document 





collaborations that existed between organizations that emerged as successful agenda 
builders. 
Significance of Study  
This research contributed to public relations scholarship by exploring how agenda 
building, information subsidies, and framing theories worked together in the context of 
HT. Public relations scholars have stressed the need to understand how organizations use 
information subsidies to build and frame the news media agenda (see Zoch & Molleda, 
2006). To date, most work on information subsidies has been conducted from the 
perspectives of journalists and news organizations rather than from the perspectives of 
organizations that produce, fund, and disseminate information subsidies (Cameron et al., 
1997). By focusing instead on the health and medical organizations that distributed 
information subsidies, this study contributed insights into how organizations influence 
the quantity and quality of news media content in ways that align with their strategic 
interests, and the potential ramifications of these processes on the marketplace of ideas 
and information available to publics to inform decision making.  
This application of this theoretical framework to a health context also provided a 
deeper understanding of commonly cited problems related to the accuracy and quality of 
health and medical journalism. Past research has identified common sources of health and 
medical information used by journalists, but has not gone further to investigate the 
organizations and organized interests that produce, fund, and disseminate these sources of 
information. Comparisons of the content of press releases and news stories provided an 





the organizations that produced information subsidies, leading to practical 
recommendations to improve the quality of health and medical news.  
Finally, this study contributed to the literature on prescription drug promotion. To 
date, research has primarily focused on the role overtly promotional, FDA-regulated 
sources of information, such as detailing, medical journal advertising, and DTCA play in 
stimulating prescription drug demand (Donohue & Berndt 2004; Gonul et al., 2001; 
Iizuka & Jin, 2006; Mizik & Jacobson, 2004; Rizzo, 1999; Rosenthal et al., 2003; Wang, 
Ausiello, & Stafford, 1999). Data from this study indicated that another type of 
prescription drug promotion occurs in the form of news stories created through the media 
relations activities of a variety of health and medical organizations that frame information 
about the uses, benefits, and risks of prescription drugs in ways that align with their 
strategic interests. 
Summary of Dissertation 
This dissertation is organized into five chapters. Chapter one introduced and 
provided background and context for the study. Chapter two reviews the theoretical and 
empirical literature that informed the conceptualization of the study. Conceptual models 
used to guide the research questions and data analyses are presented at the end of chapter 
two, along with a summary of the study’s research questions. Chapter three outlines the 
study methodology in detail. Chapter four presents the study’s detailed results. Chapter 
five discusses the theoretical and practical implications of the study. Study limitations 





Chapter II: Literature Review 
This chapter reviews the theoretical and empirical literature that informed the 
conceptualization of the study. This chapter blends together research from three primary 
perspectives: mass communication scholarship, strategic communication scholarship, and 
critical scholarship to understand how health and medical organizations may use news 
media to communicate strategically about prescription drugs. Specific areas of literature 
reviewed relate to the role prescription drug news may play in consumer and physician 
decision making; the theoretical framework guiding the study, which includes agenda 
building, information subsidies, and framing; the major types of organizations that 
produce information subsidies about health, medicine, and prescription drugs; financial 
conflicts of interest between health and medical organizations; sources of information 
used by journalists to produce health, medicine, and prescription drug news; and the 
quality of health, medicine, and prescription drug news and information subsidies. 
Existing research about HT, the quality of HT-related news, and the types of 
organizations that may have been involved in building and framing the news media 
agenda for HT are also reviewed.  
Conceptual models used to guide the development of the research questions and 
data analyses, along with a summary of the study’s research questions, are presented after 
the review of the literature. The conceptual models were informed by the interactions and 
linkages between the different areas of literatures reviewed, which resulted in a set of 






Potential Role of Prescription Drug News in Health Decision Making 
Prescription drug use is a complex behavior due to the “intermediary role” 
physicians play (Gonul, Carter, Petrova, & Srinivasan, 2001, p. 79). Unlike the 
consumption of other products, it is the physician who decides if a product is needed and 
what specific product should be selected, even though it is the consumer who actually 
purchases and uses the drug (Gonul, et al., 2001). Prescription drug use is a product of 
decision making by physicians and consumers and interactions between both parties. The 
consumer must present to the physician to receive a diagnosis; the physician must 
prescribe the drug; and the consumer must comply by filling the prescription and taking 
the drug (Deshpande, Menon, Perri & Zinkhan, 2004; Ledford et al., 2010; USDHHS 
FDA, 2004).   
The information environment about a prescription drug can influence the 
decision-making processes of physicians and consumers, resulting in increases or 
decreases in prescription drug use. Although many intrapersonal and interpersonal factors 
influence physicians’ prescribing practices and consumers’ prescription drug use, 
considerable focus has been placed on pharmaceutical industry promotions targeted to 
physicians and consumers. Three major promotional sources of information have 
received the most attention in the literature in terms of their potential to stimulate 
prescription drug demand: sales visits to physicians known as “detailing,” which often 
include free product samples and small rapport-building gifts; medical journal 
advertising; and direct-to-consumer advertising (DTCA), which refers to promotional 
efforts that directly target the general public through lay media (Cline & Young, 2004; 





In marketing terms, prescription drug use can be thought of in terms of primary 
demand and selective demand. Primary demand refers to the size of the overall market 
for a therapeutic class of drugs (for example, all HT brands available for menopause). 
Selective demand refers to the market share for a particular drug within its therapeutic 
class (for example, Prempro) (Mackowiak & Gagnon, 1985). Research has indicated that 
DTCA increases primary demand by driving consumers to physicians through help-
seeking behaviors (Donohue & Berndt, 2004; Iizuka & Jin, 2006; Rosenthal, Berndt, 
Donohue, Epstein, & Frank, 2003; Zachry et al., 2002), and perhaps selective demand by 
encouraging consumers to request specific brand-name drugs from their physicians (An, 
2007; Desphande et al., 2004; USDHHS FDA, 2004). Physician-targeted promotional 
activities, such as detailing and medical journal advertising, tend to influence selective 
demand, or brand choice (Donohue & Berndt 2004; Gonul et al., 2001; Iizuka & Jin, 
2006; Mizik & Jacobson, 2004; Rizzo, 1999; Rosenthal et al., 2003; Wang, Ausiello, & 
Stafford, 1999). 
Medical professional journals have also received significant attention for the role 
they play in influencing prescribing patterns. Physicians have reported relying heavily on 
peer-reviewed scientific literature to make prescribing decisions (Avorn, Chen, & 
Hartley, 1982), and publication of new evidence in scientific journals, particularly from 
large clinical trials, has been associated with increases and decreases in physician 
prescribing, depending upon the positive or negative nature of the findings (Col et al., 
1996; Lamas et al., 1992; Majumdar et al. 2003; Majumdar et al., 2004; Stafford et al., 
2004). Medical professional journal articles are used heavily in sales visits to physicians 





Sismondo, 2007; Wilkes, 1997). Information from scientific publications also reaches 
both physicians and consumers indirectly through news media, as medical journals are 
the most frequent sources of information that journalists rely on for health and medical 
stories (Entwistle, 1995; Nelkin, 1995; Van Trigt et al., 1994; Wilkes, 1997). 
The influence of news media on prescription drugs use patterns, however, has 
received little attention. This is surprising given that U. S. news media are leading 
sources of health information for consumers, health care providers, and policymakers 
(Martinson & Hindman, 2005; Pew Project for Excellence in Journalism, 2010; Phillips 
et al, 1991; Schwartz & Woloshin, 2004; Viswanath et al., 2008). Information about 
medical treatments and devices is typically produced by scientific experts, and news 
media play an important role in translating this information to other non-specialist publics 
(Manning, 2001; Nelkin, 1995; Viswanath et al., 2006; Viswanath et al., 2008; Wilson, 
Robertson, McElduff, Jones, & Henry, 2010). News coverage can disseminate 
information about medical treatments directly to consumer publics, through key 
influencers such as physicians, or by stimulating policy actions that change the social, 
political, and economic context in which individuals make choices (Grilli et al., 2002; 
Hornik, 2002; Viswanath, et al., 2006).  
In addition to being frequently cited as an important source of health information, 
news coverage has been associated with population-level changes in health behaviors 
(Hornik, 2002). Studies have demonstrated concomitant variation over time between 
news coverage of adverse events and behavioral changes in a variety of areas, such as 
IUD removal during pregnancy (Cates, Grimes, Ory, & Tyler, 1977) tobacco use, (Pierce 





discontinuation of aspirin for children with flu-like symptoms (Soumerai et al., 1992). 
Increased health screening behaviors have also been detected after highly-publicized 
celebrity events, such as Magic Johnson’s announcement that he was HIV-positive 
(Casey & Allen, 2003) and Katie Couric’s efforts to raise awareness of colon cancer 
screening on the Today Show (Cram et al., 2003). Time series-based analyses have also 
identified news coverage as a temporally prior and significant predictor of behavior 
change in areas such as mammography screening (Yanovitzky & Blitz, 2000), youth 
binge drinking (Yanovitzky & Stryker, 2001), marijuana use (Stryker, 2003), cocaine use 
(Fan & Holway, 1994), high-risk sexual behaviors among gay and bisexual men (Fan, 
2002), and drunk driving (Yanovitzky, 2002).  
News coverage may also play a role in stimulating primary and/or selective 
demand for prescription drugs. News coverage may raise awareness of health conditions, 
leading to increased help-seeking behaviors, or diffuse information about the uses, 
benefits, and risks of specific drugs in a manner similar to that of more extensively 
studied promotional sources of information. As first amendment-protected speech, 
prescription drug information transmitted through news media and medical journals is not 
subject to FDA regulations that prohibit promotion of off-label indications or require  
accurate and balanced information about risks and benefits, as are detailing, medical 
journal advertising, and DTCA (Leffler, 1981; Morris & Griffin, 1992; Sheehan, 2003). 
For this reason, news media might disseminate information about prescription drugs that 
is quite different from FDA-regulated sources of information. Like medical professional 





spreading awareness of health conditions, or about the benefits and risks of specific 
prescription drugs, to consumers and physicians.     
A substantial amount of news coverage is generated by the media relations 
activities of organizations attempting to influence the decisions of stakeholders and 
publics who consume the news in ways that are favorable to their strategic objectives 
(Cameron, Sallot, & Curtin, 1997; Sallot & Johnson, 2006; Zoch & Molleda, 2006). For 
this reason, another major, but infrequently mentioned or studied, form of prescription 
drug promotion and other commentary about prescription drugs may occur in the form of 
news stories created as a result of information subsidies provided to news media by 
organizations. This study took the initial step of examining how health and medical 
organizations, such as pharmaceutical companies, government agencies, universities, 
medical schools, medical professional societies, trade associations, and health advocacy 
groups, used information subsidies to stimulate coverage about prescription drugs that 
furthered their strategic interests. How these processes shaped the quantity and quality of 
news coverage was also be explored. The task of linking resulting news coverage to 
potential outcomes, such as prescription drug use, was reserved for a later project.  
Theoretical Framework 
Organizations conduct media relations to influence the news media agenda for 
specific issues or topics that intersect with their strategic goals. The news media agenda 
refers to the salience or importance placed on issues or topics by news media and is 
typically operationalized by the amount of coverage or prominence afforded to issues or 
topics over a specific time period (Dearing & Rogers, 1996; McCombs & Shaw, 1972). 





and increase public perceptions of its importance (Lazarsfeld & Merton, 1948, 1964, as 
cited in Dearing & Rogers, 1996; McCombs & Shaw, 1972). Getting on the news media 
agenda and controlling the content of that coverage can serve organizations’ strategic 
interests in various ways by helping them to promote products, build reputation, 
distribute financial news to shareholders and investors, manage crises, and engage in 
issues management to promote favorable and avoid unfavorable public policy actions, 
such as legislation or regulation (Heath, 1990; Heath & Cousino, 1990; Lattimore, 
Baskin, Heiman, & Toth, 2007).  
Zoch and Molleda (2006) proposed a theoretical framework to discover how 
organizations actively build and frame the news media agenda through public relations 
techniques by combining three existing theoretical areas: agenda building, framing, and 
information subsidies. Agenda-building theory explores how individuals and 
organizations “build” the news media agenda for a public issue through various activities 
(McCombs, 1992; Zoch & Molleda, 2006). Information subsidies are sources of 
information or materials that public relations practitioners produce or make readily 
available to journalists to build the news media agenda, such as press releases and video 
news releases (VNRs) or individual experts or spokespersons (Gandy, 1982). Framing 
refers to the way information is selectively included, highlighted, or omitted in news 
stories (Entman, 1993), and how different news frames can alter audience perceptions, 
attributions, and decisions (Iyenger, 1991). Zoch and Molleda (2006) suggested that 
organizations attempt to influence the decisions of stakeholders and publics who 
consume the news by framing information subsidies in ways that are favorable to their 





understand how a variety of health and medical organizations used information subsidies 
to build and frame the news media agenda for HT. 
Agenda building. The term agenda building refers to scholarship that explores 
how the news media agenda is set in terms of its priorities and focus on issues and topics 
(Cameron et al., 1997; McCombs 1992; Shoemaker & Reese, 1996; Zoch & Molleda, 
2006). Agenda-building research emerged from the broader area of agenda-setting 
scholarship. McCombs and Shaw (1972) first used the theoretical term agenda setting to 
describe news media’s role in determining what issues undecided voters in Chapel Hill, 
North Carolina, thought were most important during the 1968 Presidential election. They 
found that the news media agenda, as operationalized through content analysis 
procedures to rank order the amount of news coverage dedicated to different issues, and 
the public agenda, as operationalized by survey research to determine how the public 
ranked issues in terms of their relative importance, were highly correlated. Hundreds of 
agenda-setting studies have been conducted since McCombs and Shaw’s (1972) seminal 
study documenting positive rank-order correlations between the amount of coverage 
dedicated to various issues by news media and the public’s relative rankings of the 
importance they assign to those issues (Dearing & Rogers, 1996; McQuail, 2005).  
Dearing and Rogers (1996) divided the scholarly work on agenda setting into 
three categories based on the primary dependent variable of interest: media agenda-
setting research, which focuses on how the news media agenda is set; policy agenda-
setting research, which focuses on how the policy agenda is set; and public agenda-
setting research, which focuses on how the public agenda is set. Many scholars have 





variable and explore in-depth who or what sets the news media agenda from an agenda-
building perspective (Cameron et al., 1997; Dearing & Rogers, 1996; Manning, 2001; 
McCombs 1992; Shoemaker & Reese, 1996; Zoch & Molleda, 2006).  
Explorations of how the news media agenda is set have found that “real-world 
indicators” of “objective reality,” such as national statistics that measure the extent of 
problems, such as crime, women’s rights, race relations, HIV/AIDS infection rates, rates 
of illicit drug use, or the number of deaths attributed to breast cancer play little role in 
setting the news media or public agendas (Corbett & Mori, 1999; Dearing & Rogers, 
1996; Funkhouser, 1973; Gozenbach, 1996; Rogers et al., 1991). Instead, scholars have 
found that the agendas of a variety of political actors and publics and the news media and 
policy agendas all interact with one another through a complex back-and-forth process of 
reciprocal influence (Cobb & Elder, 1972; Corbett & Mori, 1999; Gozenbach, 1996; 
Kiousis et al., 2007; Lang & Lang, 1981; Schneider, 1977; Walters & Gray, 1996). 
Actors that seek to exhibit influence over the agenda-building process include 
individuals, groups, and organizations, which often play a key role in stimulating initial 
news media attention to an issue and sustaining that attention.  
Although public relations scholars have stressed the need to understand the role 
organizations play in building the news media agenda (Kiousis et al., 2007; Zoch & 
Molleda, 2006), little research exists that systematically explores how organizations build 
the news media agenda for health and medical issues. While not identifying their studies 
as part of the agenda-building tradition, some scholars have highlighted the role that 
debates and controversies between organizations play in driving and sustaining health-





level behavioral changes. For example, debates between major organizational players – 
the CDC, FDA, Public Citizen's Health Research Group (HRG), and a pharmaceutical 
industry-based group called the Committee for the Care of Children – about the validity 
of the epidemiological evidence linking aspirin to Reye's syndrome and whether product 
labeling and public education should be mandatory were credited with stimulating 
extensive news media coverage of Reye’s syndrome from the early 1980s until 1986. 
Peaks in coverage over time were associated with substantial reductions in incidence 
rates of Reye’s syndrome, which just about ceased to exist by the time labeling changes 
were made in 1986 (Soumeria, Ross-Degnan, & Kahn, 1992). Similarly, Pierce and 
Gilpin (2001) described how the news media agenda for tobacco from 1950 to 1983 was 
driven by debates between major players in the public health community, medical 
community, and tobacco industry about the epidemiological evidence linking tobacco to 
cancer. They also found substantial associations between peaks in news coverage and 
national smoking cessation rates. 
The agenda-building perspective focuses on the role individuals, groups, and 
organizations play in stimulating news media attention to an issue or problem. Public 
relations scholars are particularly interested in the role organizations play in building the 
news media agenda (Kiousis et al., 2007; Zoch & Molleda, 2006). To date, little research 
exists that systematically explores what types of organizations build the news media 
agenda for health and medical issues and through what processes they gain and sustain 
media attention.            
Information subsidies. To gain access to and influence the content of news 





ready-to-use information, such as press releases, video news releases, fact sheets, public 
opinion polls, memoranda, white papers, scientific research articles, and access to a 
variety of scientific experts and spokespersons (Gandy, 1982; Turk, 1985, 1986; Turk & 
Franklin, 1987). Gandy (1982) described these prepackaged resources as “information 
subsidies” because organizations pay the cost of producing the information, which in turn 
reduces the burden on journalists to gather news. Turk (1985) further distinguished the 
concept by using the term “proactive subsidies” to refer to subsidies initiated by 
practitioners, such as press releases, and “reactive subsidies” to refer to subsidies used to 
respond to journalist-initiated inquiries (p. 12). 
Organizations use information subsidies to get their viewpoints covered by news 
media and often hope to influence the opinions, attitudes, and decisions of individuals 
who consume the news (Turk, 1985, 1986). By strategically trying to control access to 
information through the production and distribution of information subsidies, organized 
interests can succeed in “changing the stock of information” on which decisions are made 
(Gandy, 1982, p. 13). Because substantial economic resources are required to produce 
information subsidies, organized interests with more economic and political power tend 
to supply sources of information for journalists more often (Gandy, 1982; Gans, 1979; 
Manning, 2001; Shoemaker & Reese, 1996). 
News media are frequently targeted by organizations with information subsidies 
because publicity gained through news is free, unlike other forms of paid-media like 
advertising. Information delivered via news is also often regarded as more objective than 
information delivered directly by an organization or actor presumed to have an interest or 





1982; Lattimore et al., 2007; Toth, 2009). Organizations provide journalists with a “direct 
information subsidy,” but the ultimate targets of the subsidized information, such as the 
consumers or policymakers the organization is trying to influence the attitudes, beliefs, 
behaviors, decisions or actions of, receive an “indirect subsidy” when the information is 
passed along as news (Gandy, 1982, p. 62). 
Information subsidies make it difficult for end-users of news to fully understand 
the interests and motivations of the organizations or actors behind the information they 
receive. Newspapers sometimes print material from press releases verbatim and rarely 
credit the organizations or individuals that produced these information subsidies 
(Cameron, Sallot & Curtin 1997; Curtin, 1999). Journalists themselves may not always 
be certain about the interests behind the subsidies they receive. While organizations often 
issue information subsidies directly to journalists, they also do so indirectly through a 
variety of third-party techniques. Third-party techniques have not been clearly defined in 
the literature, but generally refer to getting other experts, organizations, or coalitions that 
are perceived as more disinterested in an issue, and therefore, more credible to journalists 
and publics, to deliver a message (Palenchar & Fitzpatrick, 2009; Rampton & Stauber, 
2002). 
The use of information subsidies by journalists is significant and likely has a 
substantial influence on the content received by news consumers. While estimates vary 
based on the methodological approaches taken, it is estimated that anywhere from 25% to 
50% of news content in the United States is public relations-generated (Cameron et al., 





journalists from 1991 to 2004 found that 44% of news in the U.S. is generated by public 
relations practitioners (Sallot & Johnson, 2006). 
To date, most research on information subsidies has been conducted from the 
perspectives of news organizations and journalists rather than the perspectives of the 
organizations that produce subsidies (Cameron et al., 1997). Research has explored if 
characteristics, such as the size of a news organization, are related to frequency of 
information subsidy use, or what features make a press release more apt to be used by 
journalists (Berkowitz, 1990; Cameron et al, 1997; Gans, 1979; Martin & Singletary, 
1981; Morton, 1986; Tuchman, 1978; Walters & Walters, 1992; Walters, Walters, & 
Starr, 1994). For example, Walters and Walters (1992) found that journalists were more 
likely to use press releases issued by a state agency when the releases conveyed timely 
material and were picked up by a wire service. 
Public relations scholars have stressed the need to understand the role 
organizations play in building and framing the news media agenda for various issues and 
through what processes these efforts may exert societal-level influence by changing the 
attitudes, beliefs, and behaviors of publics (Cameron et al., 1997; Zoch & Molleda, 
2006). Little work exists that attempts to use information subsidies to trace the influence 
of organized interests on the news media agenda, or to understand the ramifications of 
these processes on the marketplace of ideas and information available to publics 
(Cameron et al., 1997). Research that analyzes records of information subsidies and 






Framing. A key component of producing information subsidies involves framing 
the content from the perspective of the organization or organized interests involved (Zoch 
& Molleda, 2006). Framing refers to the way information is selectively included, 
highlighted, or omitted, either consciously or unconsciously, to guide interpretation 
(Entman, 1993). The concept of framing is often attributed to the work of Goffman 
(1974) who described frames as “schemata of interpretation” that guide understanding or 
sense making (as cited in Zoch & Molleda, 2006, p. 281). A substantial literature exists 
on framing across disciplines, including mass communication scholarship (for e.g., 
Entman, 1993; Gitlin, 1980; Iyengar, 1991; McCombs, 1992; Scheufele, 1999; Weaver, 
2007) and public relations scholarship (e.g., Hallahan, 1999; Kiousis et al., 2006; Kiousis 
et al., 2007; Zoch & Molleda, 2006). 
  While framing has been the subject of substantial scholarship, conceptual 
definitions of framing have varied considerably (Entman, 1993). Scheufele (1999) sought 
to clarify conceptual definitions of framing by dividing the literature into a four-cell 
typology formed by two dimensions: whether the frame under consideration is a media 
frame or an audience frame and whether the frame is conceptualized as an independent or 
dependent variable. This study and this literature review section is concerned with news 
media frames as dependent variables, by focusing on what is known about how 
organizations attempt to strategically frame information for news media (Hallahan 1999; 
Zoch & Molleda, 2006). At the same time, it should be noted that while organizations 
engage in frame-building activities to influence the content of news media, the process of 
framing the news is a complex one that is subject to resistance by journalists and publics 





journalists ultimately frame the news, include not just the frames they receive from 
organized interests, but their own ideological and political values, professional norms, 
organizational routines, competition among news outlets, interactions with other 
journalists, and attempts by competing organizations, individuals, and publics to frame an 
issue (see Scheufele, 1999; Scheufele, 2000; Scheufele & Tewksbury, 2007). 
Hallahan (1999) argued that framing is central to public relations, referring to 
public relations professionals as “frame strategists,” (p. 224) who “construct social 
reality” in ways that will help their organizations and clients attain their goals (p. 206).  
Hallahan (1999) discussed several types of frames that public relations professionals 
create for a variety of situations. The frames most relevant to this inquiry related to 
prescription drug news that will be explored are: news frames, which package stories in 
terms of cultural themes that resonate with audiences to gain news attention (Gamson & 
Modigliani, 1987, as cited in Hallahan, 1999; Hallahan 1999; Wallack et al., 1993; Zoch 
& Molleda, 2006); causal explanation and treatment recommendation frames, which 
define issues or problems in terms of their causes and what constitutes appropriate 
treatments or solutions (Entman, 1993, Iyengar, 1991); and attribute frames, which 
highlight some aspects of people, issues, or objects and downplay or ignore others 
(Kiousis et al. 2006, 2007; McCombs 1992; McCombs & Ghanem, 2001). The following 
sections describe how these types of frames can be used to understand how organized 
interests might attempt to frame prescription drugs news. 
News frames/framing for access. An important part of the agenda-building 
process is stimulating and sustaining news coverage. Public relations professionals 





culturally resonating terms” to increase the likelihood of journalists using their materials 
and passing them on to audiences (Hallahan, 1999, p. 221; Zoch & Molleda, 2006). In 
their work on media advocacy, Wallack et al. (1993) described this type of framing as 
“framing for access” to news media (p. 79). This type of framing corresponds most 
closely to Gamson and Modigliani’s (1987) description of news frames as “media 
packages that feature a central organizing idea for events and employ various symbolic or 
framing devices that support the main idea of the story” (as cited in Hallahan, 1999, p. 
222).  
To successfully frame information subsidies for access, public relations 
professionals must understand journalistic norms and values about what makes a good 
news story (Manning, 2001; Tuchman, 1978). Scholars across a variety of disciplines 
have suggested that several types of news frames or angles tend to recur and might 
stimulate coverage of health topics, such as controversy; community events, fundraisers, 
or connections to historical events, milestones, seasons, or holidays; a human interest, 
personal story, or local angle; an ironic, dramatic, or unusual story or event; injustice; 
celebrity involvement; new scientific breakthroughs; the use of numbers or statistics to 
convey that a problem or issue is of large proportion or magnitude; or how business 
interests, such as stock prices, are affected by regulation, licensing, lawsuits, or 
competition (Atkin, Smith, McFeters, & Ferguson, 2008; Cameron et al., 1997; 
Hilgartner & Bosk, 1988; Johnson & Hufbauer, 1985; Lang & Lang, 1981; Moriarty, 
Jensen & Stryker, 2008; Nelkin, 1995; Seale, 2002; Tuchman, 1978; Wallack, Dorfman, 





 Causal explanations and treatment recommendations. While news frames put an 
issue on the news media agenda, other frames within a story serve to define issues or 
problems in terms of their causes, who should take responsibility, and what constitutes 
appropriate solutions and treatments. The relevant conceptual definitions of framing in 
this area focus on frames that guide audience attributions and evaluations. Iyengar (1991) 
described these types of frames as “contextual cues” that lead to perceptions of “causal 
responsibility” and “treatment responsibility” (p. 8). Entman (1993) described how these 
types of frames “promote a particular problem definition, causal interpretation, moral 
evaluation and/or treatment recommendation” (p. 55). While this definition of framing 
has been used to understand how different frames lead audience members to attribute 
responsibility and solutions for issues like crime, poverty, and unemployment (Iyengar, 
1991), this type of framing can be extended to understand the framing of health issues 
and conditions as well.  
According to some medical sociologists, diseases and illnesses are socially 
constructed through definitional processes (for e.g., see Brown, 1995; Bury, 1986). 
Diagnosis plays a central role in the process of social construction because it defines 
illness experiences within the biomedical model of institutionalized medicine (Brown, 
1995). Balint (1957) described diagnosis as the process by which an "unorganized 
illness," which is made-up of various unconnected complaints and symptoms, is turned 
into an "organized illness," which is interpretable and treatable.  Illness experiences range 
from those that are generally accepted by the medical establishment and society, and to 
which a biomedical definition has been applied, to those generally not accepted, for 





In addition to defining and legitimizing the illness experience, definitions of 
disease and illness also shape treatment options. Diagnoses provide physicians and their 
patients with a framework to understand a problem within by suggesting the underlying 
cause of the problem, and in turn, what constitutes viable treatment options (Brown, 
1995; Dardennes et al., 2001). In terms of the framing literature, this could be explained 
as a process by which different disease or illness frames lead to different causal 
attributions and treatment recommendations (Entman, 1993; Iyengar, 1991). For 
example, in the area of mental health, the biomedical model of psychiatry has led to 
greater use of medications as treatment choices rather than other types of  therapeutic 
interventions, such as counseling or support groups (Brown, 1995). Other scholars have 
also noted that biomedical diagnoses often discourage self-help or alternative healing 
approaches in favor of technological interventions (Entwistle, 1995; Zoller, 2005). 
Attribute frames. In addition to framing diseases and conditions in terms of their 
causation and what constitutes appropriate treatment, framing can play a role in 
highlighting or downplaying specific attributes of a treatment. An attribute is “a property, 
characteristic, or quality that describes an object” (Kiousis et al., 2007, p. 151). In 
addition to bringing attention to a medication through repeated coverage in the news, 
framing processes can also structure how people think about that medication by 
including, omitting, highlighting, or downplaying benefit and risk attributes, and perhaps 
shifting decisions about the overall risk-benefit profile of a treatment. Attribute frames 
have been explored in the mass communication literature (e.g., McCombs, 1992; 
McCombs & Ghanem, 2001) and the public relations literature (e.g., Kiousis et al., 2006; 





The framing of attributes is referred to by some mass communication and public 
relations scholars as second-level agenda setting, which has been used as a way to link 
agenda-setting theory to framing. Traditional agenda setting, or first-level agenda setting, 
posits that news media attention to objects or issues can determine if people think about 
an object or issue by making it more salient in their minds. Second-level agenda setting 
posits that news media attention can also influence how people think about a topic by 
selecting and/or emphasizing certain attributes and ignoring or downplaying others 
(McCombs, 1992; McCombs & Ghanem, 2001).  
To date, the framing literature in the mass communication and public relations 
fields has focused on studies of attributes associated with issues, political candidates, and 
organizations (Hester & Gibson, 2003; Kiousis et al., 2007; McCombs, Llamas, & 
Lopez-Escobar, 2000). Two different types of attributes have been studied, substantive 
attributes and affective attributes (McCombs & Ghanem, 2001). Substantive attributes are 
specific factors that might be associated with a candidate in a news story, such as the 
candidate’s integrity or qualifications. Affective attributes refer to the valence of those 
substantive attributes, for example, a candidate’s integrity can be portrayed in a positive, 
negative, or neutral manner (McCombs, Llamas, & Lopez-Escobar, 2000).  
Minimal work exists that systematically looks at the framing of diseases and 
conditions and their treatments by different organizations. Organizations may frame 
information subsidies about health issues in specific ways to gain access to news media, 
promote their preferred definition of a health condition or illness and what constitutes 
appropriate treatment, and accentuate or downplay the attributes of treatments in terms of 





Empirical support for theoretical framework. Zoch and Molleda (2006) argued 
that multi-stage research processes are needed to fully understand the contributions 
organizations make to publics’ perceptions, attitudes, and behaviors through media 
relations activities. They recommended examining information subsidies for specific 
frames that can be quantified and tracking those frames to see if and how they transfer 
onto the news media agenda, along with outcomes measured further out in time to 
measure public understandings of the viewpoints framed by organizations. Scheufele 
(2000) has argued for similar types of process research that begin with agenda-building 
processes to explore how various actors frame information, how those actors pass those 
frames through mass media, and how those frames might lead to audience frames.  
Only a few public relations scholars have begun to explore whether attributes 
highlighted in press releases translate to attribute salience on the news media agenda, and 
in turn, to the salience of those attributes in the public’s mind or to other tangible 
outcomes. In a study focused on 28 large companies, Kiousis et al. (2007) explored 
relationships between corporate attributes highlighted in press releases obtained through 
PR Newswire, news articles in The New York Times and The Wall Street Journal, public 
opinion about corporate reputation, and financial performance data. Similarly designed 
studies were conducted to explore the relationships between press releases posted on 
Speaker of the House Nancy Pelosi’s website, news articles in the New York Times, and 
Congressional policymaking in 2007 (Kiousis et al., 2009), and to explore the 
relationships between candidate news releases, newspaper content, and public 
perceptions of issue salience and substantive and affective candidate images during the 





found positive correlations between object or issue salience in the public relations and 
news media agendas. Substantial support was also obtained to support the transfer of 
attribute salience from public relations agendas to news media agendas. Mixed support 
was found for links between news coverage and public opinion and corporate 
performance data, and no support was found for the link between the news media agenda 
and Congressional policymaking.  
Little research explores how organizations influence the news media agenda for 
prescription drug news, and how those efforts might influence the quality of that news. 
Only one study could be found by Anderson (2001) that compared press releases 
distributed via PR Newswire by Merck and Searle on their competing anti-inflammatory 
arthritis drugs, Vioxx and Celebrex, to news coverage in high-circulation, U.S. daily 
newspapers from 1998 to 2000. A qualitative, thematic analysis revealed that both 
pharmaceutical companies successfully influenced the news media agenda in terms of 
topics discussed. Major topical themes included comparisons of the drugs to older anti-
inflammatories like ibuprofen and aspirin in terms of their gastrointestinal side effects, 
the costs of these newer drugs compared to existing alternatives, and the specific 
advantages of Vioxx vs. Celebrex. Although pharmaceutical companies successfully 
influenced the news media agenda in terms of topical frames, resulting newspaper articles 
tended to be more neutral overall in tone and to cite a greater variety of sources than 
presented in press releases, including physicians, industry analysts, and insurance-
company spokespersons. While insightful, this study, however, did not examine the press 
releases of any other health and medical organizations that also likely tried to influence 





The research on agenda building and information subsidies led to the following 
research questions to determine the role the public relations agenda of organizations 
played in setting the news media agenda, and what types of issues and stories stimulated 
the most news media attention. As will be discussed further in the Method chapter the 
public relations agenda was operationalized as the number of press releases distributed 
about HT over the study time period; the news media agenda was operationalized as the 
number of print news stories over the same time period.  
RQ1: What was the relationship between the quantity of press releases about 
hormone therapy (HT) distributed by organizations via PR Newswire and 
EurekAlert! and the quantity of news stories about HT in AP Newswire and four, 
top-circulating U.S. newspapers from 1995-2011. 
RQ1a: How many press releases about HT appeared between 1995-2011? 
RQ1b: How many news stories about HT appeared between 1995-2011? 
RQ1c: Was the amount of press releases positively correlated with the 
amount of newspaper stories over time?   
RQ1d: What overall story frames or themes were associated with peaks in 
press release and news story activity? 
The framing literature led to the following research questions to measure the 
transference of organizations’ viewpoints from the public relations to the news media 
agenda about the substantive attributes of HT. Each research question was posed 
separately for each body of text, press releases (RQ2 sequence of questions) and news 





the Results section (see summary of research questions at the end of this chapter). For 
brevity, only the research questions that compared the two sequences are listed below. 
RQ4: How did the press releases and news stories compare in terms of content 
from 1995-2011?  
RQ4a: How did press releases and news stories compare in terms of the 
types of organizations mentioned and types of individuals quoted? 
RQ4b: How did press releases and news stories compare in terms of 
benefits and risks associated with HT and risk and benefit presentation 
(qualitative vs. quantitative; relative vs. absolute terms)?   
RQ4c: How did press releases and news stories compare in terms of 
mentioning specific brand-name HT products? 
Sources of Health, Medicine, & Prescription Drug News  
News sources refer not only individuals, but to material sources of information as 
well. Gans (1979) described news sources as “the actors who journalists observe or 
interview, including interviewees who appear on the air or who are quoted in articles, and 
those who only supply background information or story suggestions”(Gans, 1979, p. 80). 
Scientific journals and conferences, press releases, wire services, other newspapers, 
spokespersons, and personal networks of scientific contacts are all common sources of 
information for stories about health and medicine (Dunwoody, 1986; Gandy, 1982; 
Nelkin, 1995; Rogers et al., 1991; Semir et al., 1998; Van Trigt et al., 1994). 
Many of the common sources of information used by journalists are produced, 
financed, or made available by organizations or organized interests that seek to shape the 





goals. These sources of information can also be thought of as information subsidies, as 
they reduce the burden on journalists to gather news (Gandy, 1982). Organizations and 
organized interests with the economic resources to produce commonly-used information 
subsidies for news stories about health and medicine may be in positions of power to 
influence a substantial amount of news content (Gandy, 1982; Manning, 2001). 
 Common information subsidies. Previous research has found that journalists 
typically rely on government, scientific, and medical institutions for information about 
health and medicine (Cho, 2006; Friedman, 1986b; Gandy, 1982; Gans, 1979; Tanner, 
2004; Wallington et al., 2007). Medical professional journals are the most frequent 
sources of information that journalists rely on for information about health and medicine 
(Entwistle, 1995; Nelkin, 1995; Van Trigt et al., 1994; Wilkes, 1997). One study found 
that 35% of journal articles published in the New England Journal of Medicine (NEJM) 
and the Journal of the American Medical Association (JAMA) received coverage in top-
circulating, U.S. newspapers (Burns, Moskowitz, Osband, & Kazis, 1995). Several 
scholars have also found that the number of articles published on a health topic or issue is 
highly correlated with the number of articles published in newspapers on the same health 
topic or issue (Cates et al., 1977; Corbett & Mori, 1999; Rogers et al., 1991; Soumeria et 
al.; Van Trigt et al. 1995). A study that specifically focused on medications found that the 
same medications that were discussed most frequently in the medical professional 
literature were also the ones discussed most frequently in newspapers (Van Trigt et al., 
1995). 
Medical journals also exert considerable control over the flow of scientific 





Ingelfinger Rule, of not publishing research if it was previously published anywhere else, 
including the press, which protects the revenue stream of the journals and keeps 
journalists highly dependent on journals for new research (Association of British Science 
Writers, 2011; Nelkin, 1995; Wilkes, 1997). With the advent of electronic publishing, 
some journals allow researchers to submit drafts of not yet published papers to preprint 
databases, such as arxiv.org or eprints.org, for consumption by the scholarly community 
(Harnard, 2000), but policies vary considerably by publishers and journal. For example, 
JAMA and The Lancet limit preprint publication to preliminary findings in the form of an 
abstract only (JAMA, 2013; The Lancet, 2011); NEJM allows authors who present at 
scientific meetings to post an audio recording and selected slides to the Internet; and 
Science will allow a manuscript to be posted to a not-for-profit preprint server like 
arxiv.org, but to no other places on the Internet (Science, 2013). In addition, most science 
and medical journals, including the four journals mentioned above, still have embargo 
policies in place and distribute advance copies of articles to journalists with embargos 
that specify release dates (Kiernan, 2006; Nelkin, 1995). 
Journalists also depend on press releases as sources of information for news. In 
addition to medical professional journals, which are cited as the most important source of 
information, journalists have cited press releases from universities, hospitals, government 
institutions, and the pharmaceutical industry as important sources, although some have 
expressed reservations about the credibility of information distributed by pharmaceutical 
companies (Van Trigt et al., 1994). A study that compared press releases distributed by 
major scientific journals to U.S. and European newspapers found that across all 





releases, and only 16% of news articles referred to journal articles that were not the 
subject of a press release (Semir et al., 1998). Entwistle (1995) achieved similar results, 
finding that 86% of British newspaper articles that referred to studies in the British 
Medical Journal (BMJ) and the Lancet were also the subject of journal press releases. 
Other news outlets and wire services are also important sources of information. 
The New York Times and The Washington Post often set the agenda of health topics 
covered by other newspaper and television news outlets (Corbett & Mori, 1999; Gans, 
1979; Rogers et al., 1991; Shoemaker & Reese, 1996). Wire services, such as the 
Associated Press (AP), are also important agenda setters, particularly for specialized 
topics like health (Nelkin, 1995). Stories covered by wire services are more likely to get 
coverage (Walters & Walters, 1992) and are often reproduced exactly as written in daily 
papers throughout the United States (Gandy, 1982), particularly in the case of local and 
regional papers with smaller staffs (Nelkin, 1995). The reliance on wire services and 
other media outlets leads to a situation where health and medical news looks similar 
throughout the U.S.  
Individuals also serve as sources of information for journalists, who often cite 
individuals and their quotes as evidence or support in news stories. Individuals frequently 
cited in news stories about science, health, and medicine are most often scientific or 
clinical experts who are perceived as highly authoritative and credible, such as research 
scientists and physicians (Atkin et al., 2008; Dunwoody, 1986; Nelkin, 1995; O’Leary, 
1986). Other sources that tend to be cited somewhat often, but less frequently, include 
patients or “person on the street” sources who are directly or indirectly affected by a 





& Signorielli, 2007, p. 3; Seale, 2002). In their content analysis of breast cancer news 
coverage by top U.S. newspaper, magazine, and television stations, Atkin et al. (2008) 
found that researchers or physicians were cited in (63%) of all stories. More than a third 
cited patients, patient advocates, or family members, and 11% cited celebrities. 
Most individuals who serve as sources, particularly scientific experts, are rarely 
“self-employed” and work for organizations (Dunwoody, 1986, p. 4). Organizations often 
make individuals readily available to journalists as spokespersons as a type of 
information subsidy (Gandy 1982; Sweet & Brown, 2008). Content analysis studies 
suggest that individuals, particularly experts, are rarely cited without their organizational 
affiliations. Atkin et al.’s (2008) content analysis of breast cancer news coverage found 
that 75% of experts cited were associated in the text with an organization, and 90% of 
references to organizations cited or named an individual expert. Scientists consulted as 
sources are most often those that are highly established in their fields and tend to work 
for government institutions and universities rather than private industry because of 
journalists’ skepticism of the public relations agendas of industry scientists and experts 
(Dunwoody, 1986).   
Previous research has found that the types of organizations cited in health and 
medical news include government agencies and academic research institutions, 
foundations and medical societies, pharmaceutical companies and other corporations, and 
health advocacy and consumer groups (Atkin et al., 2008; Manning, 2001; Moriarty et al., 
2008; Nelkin, 1995; Nelson & Signorielli, 2007; Seale, 2002). For example, Atkin et al. 
(2008) found that organizations cited in breast cancer news stories were medical research 





agencies, such as the National Institutes of Health, Centers for Disease Control & 
Prevention, and the Environmental Protection Agency (20%), and pharmaceutical 
companies and other corporations (15%). Another 29% of stories cited medical journals. 
Moriarty et al. (2008) found in their content analysis of cancer news coverage in 44 top- 
circulating, U.S. newspapers in 2003 that large academic research centers were cited 
most frequently (29.7%), followed by medical journals (12.3%). Large organizations like 
the American Cancer Society (9.5%), the National Cancer Institute (4.5%), and 
pharmaceutical companies (5.2%) were also cited by journalists.  
Types of organizations that produce information subsidies. Much of the 
research on sources of health, medicine, and prescription drug news has focused on 
identifying commonly used information subsidies, such as medical journal articles and 
press releases, or describing the types of individuals and organizations that are cited in 
news stories. Relatively unexplored in the literature is the role organizations play in 
shaping health and medical news through the production and dissemination of 
information subsidies, how they frame these subsidies to achieve their goals, and how 
these processes influence the quality of health and medical news. Several scholars have 
advocated approaches to understanding news content that include not just factors internal 
to the news organization, but factors external to it as well, such as the role organizations 
and other actors play when they attempt to use news media to meet their own political 
and economic interests (Gandy, 1982; Manning, 2001; Seale, 2002 Shoemaker & Reese; 
1996).   
This inquiry is particularly important because of widespread concern about the 





areas. Conflicts of interest are defined as “circumstances that create a risk that 
professional judgments or actions regarding a primary interest will be unduly influenced 
by a secondary interest” (IOM, 2009, p. 6). Most definitions of conflict of interest stress 
the potential for biased judgment, not necessarily that any kind of bias actually exists or 
will occur (Batt, 2005). A conflict of interest can be personal or financial, but financial is 
easiest to identify and the type of conflict that often generates the most concern (Batt, 
2005; Cook et al. 2007; IOM, 2009).   
 In 2009 the Institute of Medicine (IOM) convened an expert panel to write a 
report on conflicts of interest in medicine due to growing concerns among the public and 
throughout Congress about highly publicized instances of undisclosed financial ties 
between industry and organizations involved in medical research, practice, and education. 
Conflicts of interest documented in the IOM report were numerous, including but not 
limited to, failures of academic researchers and physicians to disclose industry support on 
medical journal articles; instances of academic researchers who played little-to-no role in 
study design, data analysis, or writing, taking authorship credit on scientific publications 
for honoraria payments; pro-industry publication biases in the medical literature; industry 
sponsorship of medical professional societies that write clinical practice guidelines; and a 
growing concern about pharmaceutical company support of patient- and disease-specific 
health advocacy groups.  
The IOM report (2009) indicated that although both individual-level and 
organizational-level financial conflicts of interest were commonplace, more attention has 
been paid to individual-level conflicts, such as physicians receiving pharmaceutical 





professional societies, or patient advocacy groups receiving industry funding. While 
many of the types of organizations mentioned had conflict of interest policies or codes for 
relationships with industry, the IOM concluded that the policies were often not specific 
enough or enforced in any way to effectively manage potential conflicts. Among its many 
recommendations, the IOM called for the U.S. Congress “to create a national program 
that requires pharmaceutical, medical device, and biotechnology companies and their 
foundations to publicly report payments to physicians, researchers, health care 
institutions, professional societies, patient advocacy and disease-specific groups, 
providers of continuing medical education, and foundations created by any of these 
entities” in the interest of greater disclosure and transparency (IOM, 2009, p. 9). 
Growing evidence suggests that the pharmaceutical industry might make 
substantial use of what could be considered third-party techniques when they fund the 
production of information subsidies through a variety of partnerships and collaborations 
with other organizations, such as academic research institutions and medical schools, 
medical professional societies, and patient advocacy and disease-specific groups. From 
an information subsidies perspective, many of these types of organizations conduct 
substantial media relations activities. It is unclear how proactive these organizations are 
in disclosing financial conflicts when working with news media. Third-party techniques 
that operate through funding support might be a way for industry to build the news media 
agenda through academic and other nonprofit organizations. Nonprofit organizations are 
often perceived by journalists as more credible sources of information than for-profit 





organizations that they perceive to be working in the public interest than any other 
organization type (Berkowitz & Adams, 1990; Curtin, 1999; Qui, 2006).  
Little research has looked systematically at what types of health and medical 
organizations produce information subsidies about prescription drug news; what their 
resources and goals are; and how they act individually, and perhaps jointly with other 
organizations, to influence news content. The following descriptive categories represent 
different types of health- and medical-oriented organizations and organized interests that 
might play a significant role in influencing prescription drug news, along with some basic 
information about their resources and goals, what is known about the types of subsidies 
they produce, and how they have collaborated with other organizations in the past to 
produce information related to prescription drugs. Some categories have examples of 
specific organizations to be illustrative, but this does not mean that many other relevant 
organizations do not exist within these categories.  
Industry. Manufacturers of prescription drugs engage in research and 
development to bring new products to market and engage in substantial public relations 
and marketing activities to promote new products, maintain loyalty for existing products, 
ensure a favorable regulatory environment, and inspire shareholder and investor 
confidence. Prescription drug spending is one of the fastest growing components of total 
national health care spending. In the United States in 2008, $234.1 billion was spent on 
prescription drugs compared to $40.3 billion in 1990 (Kaiser Family Foundation, 2010). 
As large corporate entities, pharmaceutical manufacturers have considerable public 
relations resources including internal public relations teams, contracts with outside public 





claims (Fugh-Berman, 2005; Manning, 2001; Nelkin, 1995). In addition to direct 
attempts to influence news media, pharmaceutical companies may engage in third-party 
techniques through their funding of many other organizations, such as universities and 
academic medical centers, medical professional societies and associations, and a variety 
of nonprofit patient- and disease-advocacy groups.   
The pharmaceutical industry is the largest producer of medical information about 
prescription drugs; it exerts considerable control over information about the scientific 
evidence base through its financial control of clinical research. Industry funds 
approximately 57% to 61% of all biomedical research in the United States, and 70% of 
all clinical drug trials (Moses & Martin, 2001, as cited in DeAngelis, Fontanarosa, & 
Flanagin, 2001; IOM, 2009). About 70% of pharmaceutical support goes to contract 
research organizations (CROs) that manage clinical trials for their clients; the other 30% 
goes to academic researchers (Sismondo, 2007).  
This economic advantage provides pharmaceutical companies with substantial 
control over what studies get funded, and if, and how, the findings are published in the 
scientific literature. Publications in prestigious, peer-reviewed scientific and medical 
professional journals are a “valuable commodity” for pharmaceutical companies (Wilkes, 
1997, p. 14). Biomedical journals are top sources of information for journalists and are 
the primary way that scientists, health care providers, and the public learn about new 
medical research findings (Fugh-Berman, 2005; Wilkes, 1997; Wilkes & Kravitz, 1995). 
Journal articles are used in sales visits to physicians and to convince regulators of drug 
efficacy and safety (Entwistle, 1995; Fugh-Berman, 2005; Nelkin, 1995; Sismondo, 





amendment and may also serve as a valuable, non-FDA regulated marketing tool (Sweet, 
2003). 
Concerns about the integrity of the medical professional literature have been 
raised by many concerned about industry control of the scientific literature and potential 
conflicts of interest between scientific investigators and industry sponsors (Collier & 
Iheanacho, 2002). Past research has found that manufacturer-sponsored studies are more 
likely to report favorable results about drug products and to publish studies with negative 
results later after prescribing patterns have been established (Bodenheimer 2000; Collier 
& Iheanacho, 2002; Healy & Cattell, 2003). One of the most controversial practices is the 
practice of ghostwriting. Ghostwriting is when an individual makes a substantial 
contribution to a manuscript, usually in the form of research and writing, without 
attribution or disclosure (Bodenheimer, 2000; Gøtzsche et al. 2007; Gøtzsche et al., 2009; 
Ross, Hill, Egilman, & Krumholz, 2008). Ghostwriters often work for contract research 
organizations (CROs) or medical education and communication companies (MECCs) 
hired by pharmaceutical companies to produce, place, and track journal articles. In the 
most extreme cases, ghostwriters produce manuscripts and high-profile academics are 
recruited after-the-fact to author the publications, sometimes collecting honoraria 
payments (Fugh-Berman, 2005; Healy & Cattell, 2003; Sismondo, 2007).   
Ghostwriting is difficult to detect and most knowledge about this practice has 
been made available through litigation. Cases of ghostwriting have been discovered 
through litigation for several high-profile drugs, including Wyeth’s hormone therapy 
drugs Premarin and Prempro, Merck’s anti-inflammatory Vioxx (Berenson, 2005; Ross et 





2003) and seizure-control drug Neurontin, also manufactured by Pfizer (Steinman, Bero, 
Chren, & Landefeld, 2006). 
Academic/medical institutions. A large portion of biomedical research and 
discoveries related to drug products happen at universities, particularly those with 
medical schools and affiliations with large teaching hospitals. Universities and medical 
centers benefit from positive publicity in the news media about faculty research, as 
publicity builds institutional reputation, which attracts high quality faculty, physicians, 
and students, and can bring more patients to medical centers (Gandy, 1982; Nelkin, 
1995). Academics rely on peer-reviewed publications for promotion and tenure, and news 
media attention can enhance their professional reputations and ability to secure grant 
funding (Wilkes, 1997). Although individual scientists will sometimes promote 
themselves, most often their institutions promote their work. Most major research 
institutions have public relations departments with substantial resources (Nelkin, 1995). 
 Public support of science has been declining, making academics and research 
institutions more reliant on industry sources of support (IOM, 2009). A 2006 national 
survey of department chairs in medical schools and teaching hospitals found that 67% of 
departments had financial relationships with industry (Campbell et al., 2007, as cited in 
IOM, 2009). In terms of individual-level arrangements, 60% of department chairs had 
relationships with industry, which ranged from paid consultancies and speaking 
opportunities to service on scientific advisory boards (Bero, 2008, as cited in IOM, 
2009).  
Links between academia and industry have often been controversial due to 





control their research programs and projects (IOM, 2009; Martinson, Anderson, & 
deVries, 2005). Through grant and contract funding opportunities, industry exerts a 
powerful role by deciding what studies are worthy of funding and hand-selecting 
investigators. Although university-industry contracts vary, academics sometimes must 
allow industry sponsors to be involved in designing study protocols and analyzing and 
interpreting data, and in some cases, investigators are not given full access to study data 
and statistical analyses are performed by company statisticians (Fugh-Berman, 2005; 
Healy & Cattell, 2003; IOM, 2009; Sismondo, 2007; Wager, 2007). Investigators are also 
sometimes forced to delay publication of important results when the information reported 
would result in the release of trade secrets on pending industry patents (IOM, 2009). 
Government agencies. Several agencies within the U.S. Public Health Service are 
engaged in medical research, health policymaking, and education and outreach efforts. 
Government agencies may enjoy a distinct advantage in the communication marketplace 
of ideas related to prescription drug efficacy and safety, as research has found that 
journalists perceive government officials and scientists as credible sources and rely on 
them heavily for health and medical news (Gandy, 1982; Manning, 2001; Nelkin, 1995). 
Two government agencies heavily involved in prescription drug science, regulation, and 
education are the National Institutes of Health (NIH) and the Food & Drug 
Administration (FDA).  
As institutions supported by tax dollars, the NIH and FDA use media relations to 
fulfill their missions of service to the public, manage their reputations, and demonstrate 
value and visibility to maintain public funding (Gandy, 1982). The NIH has an extensive 





and centers, and the FDA positions public affairs staff throughout the country to provide 
information at the local level. Both agencies engage in a wide range of public relations 
activities, including releasing medical research findings to the public, issuing safety alerts 
to consumers and health care professionals as necessary, and initiating a variety of health 
education and community outreach campaigns. In addition to internal staff, these federal 
agencies often contract with public relations agencies and consultancies for education and 
outreach efforts (U.S. Department of Health & Human Services, National Institutes of 
Health [USDHHS, NIH], 2010c).  
National Institutes of Health. The National Institutes of Health (NIH) is a federal, 
medical research agency. Part of the United States Public Health Service, it is comprised 
of 27 institutes and centers in different disease areas. The “NIH’s mission is to seek 
fundamental knowledge about the nature and behavior of living systems and the 
application of that knowledge to enhance health, lengthen life, and reduce the burdens of 
illness and disability” (USDHHS NIH, 2010a). The NIH, funded by tax dollars through 
appropriations authorized by Congress, spends more than $31.2 billion annually on 
medical research, making it the second largest funder of biomedical research, after the 
pharmaceutical industry, which invests more than twice that amount (Moses & Martin, 
2001, as cited in DeAngelis et al. 2001, p. 90). About 80% of NIH funding goes to 
universities, academic medical centers, and other research institutions in the United 
States and around the world in the form of extramural grants. Another 10% goes to NIH 
employee scientists, often called intramural scientists, at the NIH clinical center campus 





As a tax-supported agency, NIH is answerable to the public for its research 
programs and actions. Historically, a range of consumer groups have launched initiatives 
to pressure the agency to alter its funding priorities. Due to growing concerns about the 
potential for government-funded investigators to have financial ties to industry, the U.S. 
Public Health Service (PHS) began requiring all research institutions that receive PHS 
funding to disclose financial conflicts of interests between investigators and industry 
when applying for grants and to develop conflict of interest policies. The IOM panel on 
conflict of interest in medicine concluded, however, that these requirements are often not 
properly overseen or enforced (IOM, 2009). For example, in 2004, national newspapers 
publicized an account of scientists in NIH’s own intramural research program that failed 
to disclose financial relationships with industry, which triggered an NIH investigation 
(IOM, 2009). 
Food & Drug Administration. The Food & Drug Administration (FDA) is a 
regulatory consumer protection agency with authority over food and drug products. The 
agency works to ensure the safety and efficacy of all prescription and over-the-counter 
drugs by reviewing clinical data and approving drugs for market, inspecting 
manufacturing facilities, monitoring drugs on the market for adverse events, and 
reviewing all product labeling and advertising for truthfulness and accuracy. A range of 
educational and regulatory techniques are used by the agency when industry is in 
violation of the law, including issuing warning letters to manufacturers, requesting 
mandatory product labeling changes, issuing public health safety advisories to health care 





when they pose an immediate threat to public health or accumulating evidence suggests 
the risks of their use significantly outweigh the benefits (USDHHS FDA, 2011a). 
The fiscal year 2010 budget for the FDA was $3.2 billion, which included $2.35 
billion in Congressional tax dollar-funded appropriations, and $828 million in industry-
user fees for regulated products. Of these industry-user fees, $578 million came from 
manufactures of prescription drugs when submitting drug approval applications 
(USDHHS FDA, 2009). The FDA began collecting user fees from the pharmaceutical 
industry through the Prescription Drug User Fee Act of 1992, which allowed the agency 
to expand staff and approve drug applications more quickly (Meier, Garman, & Kaiser, 
2003). This arrangement, however, is controversial and critics worry about potential 
conflicts of interest in the drug approval process due to this substantial industry support 
(Kaufman, 2002).  
The FDA’s Division of Drug Marketing, Advertising, and Communications 
oversees all promotional labeling and advertising of prescription drugs to health care 
providers and consumers to ensure that “prescription drug information is truthful, 
balanced and accurately communicated” (USDHHS FDA, 2010). FDA guidelines require 
a “fair balance of efficacy and risk information in all communications” (Sheehan, 2003, 
p. 160). The FDA conducts the bulk of its review process when reviewing a new 
product’s labeling, and at times will require what is commonly referred to as a “black 
box” warning, which requires the manufacturer to highlight serious adverse side effects 
in text surrounded by a black box to get the attention of health care providers and 





FDA reviews claims made to make sure they conform to the FDA-approved product 
labeling (Calfee, 2002; Morris & Griffin, 1992).    
As a regulatory agency, FDA must manage relationships with a variety of publics, 
including but not limited to, industry, Congress, the President, the federal courts, state 
agencies, and a variety of trade associations, lobbyists, and scientific and consumer 
groups that seek to influence the agency, often through testimony on proposed 
regulations (Meier, Garman, & Kaiser, 2003).   
Professional societies and trade associations. Often active in the debate about 
prescription drugs and other medical treatments are numerous nonprofit medical 
professional societies and trade associations. There are many professional societies at the 
national and state levels that represent the interests of physicians, specific medical 
specialties, and other allied health professionals. For example, the American Medical 
Association (AMA) represents physicians across the nation, the American Congress of 
Obstetricians and Gynecologists represents obstetrics and gynecology specialists, and the 
Massachusetts Medical Society represents physicians practicing in the state of 
Massachusetts only. Other types of trade organizations typically represent industry. For 
example, The Pharmaceutical Research and Manufacturers of America (PhRMA) 
represents just about all the nation’s leading pharmaceutical and biotechnology 
companies. Professional societies and trade associations play a key role in advocating for 
legislation and public policies that are favorable to their memberships. Medical societies 
also tend to engage in a range of other activities, such as providing continuing education 
for their members, sponsoring medical conferences, publishing peer-reviewed medical 





Referred to as “business leagues” or 501c(6) organizations per the IRS 
classification system, professional societies and trade associations are nonprofit, tax-
exempt organizations. While exempt from federal taxes on revenues, they cannot receive 
tax-deductible contributions from individual or corporate donors as 501c(3) public 
charities can (Boris, & Steuerle, 2006). 501c(6) organizations are permitted to engage in 
unlimited lobbying to influence federal, state, and local legislation related to the 
organization’s common business interests without jeopardizing its tax-exempt status. 
Lobbying can include grassroots lobbying activities to influence public opinion and 
mobilize support or direct lobbying activities to influence legislation. They can also 
engage in political campaigns to support or oppose candidates for public office, but this 
cannot be the organization’s “primary activity,” or it risks losing tax-exempt status, and 
monies spent on political election activities may be taxed (U.S. Department of Treasury, 
IRS [USDT IRS], 2010b). A large portion of the budgets of professional societies and 
trade associations are paid by members in the form of dues. Medical societies typically 
earn additional revenue through sponsorship of continuing education and conferences and 
journal subscriptions and advertising fees (IOM, 2009).  
Some concerns have been raised about pharmaceutical support of medical 
professional societies. The pharmaceutical and medical products industries contribute 
substantially to these organizations’ operating budgets through continuing education and 
conference support, advertising in medical journals, and a variety of research and 
recognition awards (Beder et al., 2003; IOM, 2009). Overall, it is estimated that 
approximately 30% to 50% of medical society budgets come from industry sources 





clinical practice guidelines and editorial control of peer-reviewed journals. Clinical 
practice guidelines are often developed by medical societies and distributed to members 
to guide their treatment practices and approaches to various diseases and conditions 
(IOM, 2009), and more than one-third of leading medical journals are published by 
medical societies (Wilkes & Kravitz, 1995).  
Assessing the extent of potential conflicts of interest between industry and 
professional societies and trade organization is a difficult task. 501c(6) organizations are 
not required to report information about the actual sources of the funds they receive when 
they report financial information via IRS Form 990, the form required of all nonprofit, 
tax-exempt organizations (Boris, & Steuerle, 2006). While many organizations 
transparently list corporate donors in their annual report or other publications, or 
announce corporate support of specific activities, the actual amount of funding is often 
not reported (IOM, 2009). 
Health advocacy organizations. A large number of nonprofit patient and 
consumer advocacy groups play an active role in communication about health issues. 
Some represent constituencies, such as women, and others are disease-specific in 
orientation. These organizations are diverse in their nature, size, and resources, ranging 
from large, well-funded organizations like the American Heart Association to small 
community-level organizations with names rarely recognized outside of their respective 
communities. These organizations engage in a range of activities, including fundraising, 
patient counseling and support, education campaigns, and public policy advocacy (Batt, 
2005; Lofgran, 2004). Some well-funded organizations have public relations departments 





to-no resources. Many employ media advocacy techniques, such as holding press 
conferences, issuing press releases, and using celebrities, community events, and protests 
to build the news media agenda for their cause (Shoemaker & Reese, 1996; Wallack et 
al., 1993).  
Most patient and disease-specific advocacy groups are IRS-category 501c(3) 
organizations, which are commonly referred to as “public charities” or “charitable 
organizations,” and comprise the largest number of nonprofit organizations in the United 
States (Boris & Steuerle, 2006; USDT IRS, 2010a). To qualify as a public charity, an 
organization must be “engaged in educational, religious, scientific, or other forms of 
charitable behavior” (Boris & Steuerle, 2006, p. 67). Public charities have the most 
generous exemption rules. In addition to their revenues being tax exempt, 501c(3) 
organizations can receive tax-deductible donations from individuals and corporations. 
Unlike 501c(6) professional societies and trade organizations; however, the lobbying and 
political activities of public charities are more restricted. Although 501c(3) organizations 
cannot engage in any direct or indirect activity related to the election of political 
candidates for public office, they can engage in mission-related grassroots and direct 
lobbying, as long as these activities do not comprise a “substantial part” of the 
organization’s overall activities (USDT IRS, 2010a). 
 Pharmaceutical company-patient advocacy group partnerships are now common 
in the U.S., Canada, Europe, Australia, and New Zealand (Batt, 2005; Beder et al., 2003; 
Lofgran, 2004). Although pharmaceutical companies had long viewed consumer groups 
as antagonists, this began to change in the 1980s when pharmaceutical companies 





of drugs to treat HIV/AIDS and for federal money for AIDS research (Batt, 2005; Burton 
& Rowell, 2003a). Industry typically targets financial support to these organizations in 
areas of disease awareness campaigns, education, and advocacy, often providing funds 
for specific projects like outreach events and conferences or development of brochures 
and other materials (Batt, 2005; Moynihan et al., 2002). In addition, pharmaceutical 
company representatives sometimes serve on the boards of directors or other advisory 
boards of these organizations (Zones & Fugh-Berman, 1999). 
Tracing the amount of industry funding received by a nonprofit health advocacy 
group is difficult. Like 501c(6) organizations, 501c(3) organizations are not required to 
disclose the names of organizations or individuals that make contributions to their 
organizations to the IRS. While the Federal Lobbying Disclosure Act of 1995 requires 
501c(3) organizations to report sources of funding for federal lobbying activities, 
organizations are not required to do so unless lobbying is the “primary activity” of the 
organization (Fitzpatrick & Palenchar, 2006; USDT IRS, 2010a). As in the case of 
medical professional societies and trade organizations, many patient and consumer 
advocacy groups opt to disclose information in their annual reports and other materials in 
the interest of transparency. Often, however, it is difficult, and sometimes impossible, to 
ascertain the amount of funding received or to link funding sources back to specific 
initiatives.  
In a rare investigation of six patient-advocacy organizations in 2006—the 
American Diabetes Association, the National Alliance on Mental Illness (NAMI), 
Children and Adults with Attention Deficit/Hyperactivity Disorder (CHADD), the 





for Rare Disorders—the Philadelphia Inquirer reported that the groups received at least 
$29 million from major drug companies that marketed drugs to their constituencies, such 
as Eli Lilly, Merck, and Pfizer, but “disclosed limited or no details about the ties” when 
“commenting or lobbying about donors’ drugs” (Ginsberg, 2006, p. A01). Support from 
pharmaceutical companies also came in the form of management consulting 
arrangements; for example, an Eli Lilly & Company executive reportedly worked closely 
with the American Diabetes Association “to chart its growth strategy and write its 
slogan”(Ginsberg, 2006, p. A01). 
Substantial controversy exists over whether industry support of patient and 
consumer advocacy groups is a conflict of interest and should be disclosed, particularly 
within the nonprofit community itself. Some argue these partnerships violate the 
organization’s primary responsibility to its constituents; others argue that taking industry 
funding is a legitimate way for nonprofits to raise much-needed funds and for 
pharmaceutical companies to “give back” to their communities (see Batt, 2005; Beder et 
al., 2003; Burton & Rowell, 2003a; Ginsberg, 2006; Lofgran, 2004). Differences of 
opinion are evident in the varied funding policies of these groups: some accept no 
industry money; some will not accept money from companies that sell products directly 
to their constituencies; some will accept monies from those that target their 
constituencies, but will not publicize brand names; and some have no restrictions (Burton 
& Rowell, 2003b; Zones & Fugh-Berman, 1999).   
Coalitions. Coalitions are not actual organizations, but organized interests which 
are often made up of a variety of public- and private-sector organizations. “Coalitions are 





advocate for an intended purpose” and seek to influence public opinion and/or 
policymaking (Fitzpatrick & Palenchar, 2006, p. 205). Coalitions often produce joint 
media relations materials (Yoon, 2005) and once in place are often reactivated as areas of 
mutual interest continue to arise (Bridges, 2004; Crable & Vibbert, 1985). Coalitions are 
perhaps the most poorly understood type of organized interest that participates in the 
public policy process. 
Coalitions derive their credibility from the perception that they represent a large 
and diverse group of constituents typical of grassroots movements, but coalitions vary 
significantly in their funding bases, ranging from legitimate coalitions to illegitimate 
front groups (Batt, 2005). According to Fitzpatrick and Palenchar (2006), legitimate 
coalitions are transparent about their mission, sources of funding, and membership. Front 
groups are typically funded by a small number of individuals or an organization, and 
intentionally try to deceive publics by pretending they represent large constituencies. 
Front groups are often given “noble sounding” names, such as “Citizens for [Something 
Good]” (Fitzpatrick & Palenchar, 2006, p. 204). The front group phenomenon has often 
been called, “Astroturf lobbying,” in reference to grassroots lobbying that is false 
(Bodensteiner, 1997, p. 32). Often times the only way to distinguish a legitimate coalition 
from a front group is to analyze the group’s funding sources. Coalitions have multiple 
and numerous funding sources; front groups are often funded by a single source 
(Bodensteiner, 1997). Depending on how they are constructed, coalitions are often not 
subject to federal lobbying disclosure rules that require disclosure of their funding 





Little scholarly research overall has focused on front groups, and what does exist 
are typically case studies or anecdotal news media reports. The cases of front groups that 
have been uncovered are usually industry-driven efforts. For example, front groups have 
been used by the tobacco, gas, oil, utility, gaming, and pharmaceutical industries 
(Bodensteiner, 1997; Fitzpatrick & Palenchar, 2006). The tobacco industry used front 
groups to oppose federal anti-tobacco legislation in the name of smokers’ rights 
(Appollino & Bero, 2007), the health insurance industry used front group efforts to 
oppose Clinton-era health care reform (Bodensteiner, 1997), and an AARP investigation 
revealed that coalitions of senior citizen groups to oppose prescription drug policy 
changes were funded primarily by the pharmaceutical industry (Batt, 2005). 
Information subsidies and disclosure. Organizations produce a variety of 
information subsidies. Some information subsidies are provided in a more direct manner, 
in which the organization or organizations involved in their production are clear; others 
in a more indirect manner using a range of third-party techniques, with varying degrees 
of transparency.  
Understanding the organizations and interests that produce, fund, or disseminate a 
message is important, particularly in this health care climate in which conflicts of interest 
are common, making “the borders between research, education, and promotion more 
porous than is commonly recognized” (Steinman et al., 2006, p. 290). Some have claimed 
that the involvement of the pharmaceutical industry in the production and dissemination 
of health communication directly, and through financial relationships with a variety of 
other organizations, has led to a situation in which, “the social construction of disease is 





2002, p. 886). Critics argue that diseases are now created by organizations seeking to 
create a market for or increase demand for a drug through public relations campaigns that 
often involve multiple players (Burton & Rowell, 2003a; Moynihan, Heath, & Henry, 
2002; Sweet, 2003). For example, Moynihan, Heath, and Henry (2002) used the 
examples of irritable bowel syndrome, male baldness, social phobia, and hormone 
therapy to describe “disease awareness campaigns” sponsored by “informal alliances” of 
pharmaceutical companies, physicians, and consumer groups, stating: 
A key strategy of the alliances is to target the news media with stories designed to 
create fears about the condition or disease and draw attention to the latest 
treatment. Company sponsored advisory boards supply the ‘independent experts’ 
for these stories, consumer groups provide the ‘victims,’ and public relations 
companies provide media outlets with the positive spin about the latest 
‘breakthrough’ medications (Moynihan, Heath, & Henry, 2002, p. 886). 
While collaborations between industry, academia, government, and the nonprofit 
sector undoubtedly lead to positive scientific discoveries and public education initiatives, 
they can also bias the information available to publics for decision making in favor of the 
agendas of groups with more economic and political power. The medical and lay presses 
have no legal requirement to present fair and balanced information (Batt, 2005), and 
organizations may strategically use these outlets to build an agenda that promotes not 
only products, but the diseases or conditions those products are intended to treat. Because 
promotional messages are not always evident when delivered through third parties, 
individuals may process these messages less cautiously than messages delivered directly 





2006; Lofgran, 2004; Steinman et al., 2006), exerting a negative effect on informed 
decision making.  
Just about all entities that participate in the circle of prescription drug 
development and communication, including government, medical schools and 
universities, and a variety of professional societies and trade associations that represent 
medical professionals, medical writers, industry, and journalists have voluntary codes of 
conduct or conflict of interest policies to encourage their members to police themselves 
and avoid questionable practices, such as ghostwriting, off-label promotion, and front 
group-style advocacy efforts. These policies sometimes fail, however, because they lack 
adequate supervision and enforcement (IOM, 2009; Wager, 2007). 
A recurring theme in the scholarly work on conflict of interest in medicine is the 
need for full disclosure of all potential conflicts to maintain the integrity of and public 
confidence in medical science (Cook et al., 2007; Gøtzsche et al., 2007; Gøtzsche et al., 
2009; Hamilton & Royer, 2003; IOM, 2009; Woolley et al., 2006). Disclosures of 
conflicts of interest are made in the spirit of highlighting the potential for conflicts, but do 
not mean that actual conflicts actually exist, or that if conflicts do exist they can be 
eliminated through disclosure (DeAngelis et al., 2001). Public disclosure is primarily a 
deterrent and serves as a way to empower consumers with an understanding of the 
potential motivations of the organizations and individuals behind the information they 
receive (IOM, 2009).  
Some have argued that more responsibility should be placed on organizations to 
be more proactive about disclosing funding sources when working with news media 





journals, like JAMA, are moving toward publication policies that require more 
transparency about study financing and the role of study sponsors in study design, data 
collection, analysis, and manuscript preparation (DeAngelis et al., 2001; DeAngelis & 
Fontanarosa, 2008; Gøtzsche et al., 2009). In addition to JAMA, NEJM and The Lancet 
require authors to complete and sign detailed conflict of interest disclosure forms. A 
study of conflict of interest policies on the websites of 256 high-impact medical journals, 
found that while 89% of journals had conflict of interest policies requesting that authors 
submit information about any relevant conflicts, only 54% required authors to complete 
and sign disclosure statements (Blum, Freeman, Dart, & Cooper, 2009). 
There is a lack of literature to ascertain how proactive health and medical 
organizations are about their funding sources when issuing press releases and working 
with news media. Certainly, the use of front groups and other outward acts of deception 
clearly violate public relations codes of ethics as outlined by the Public Relations Society 
of America and the International Public Relations Association (Bodensteiner 1997; 
Fitzpatrick & Palenchar, 2006; Palenchar & Fitzpatrick, 2009). In the interest of 
transparency and reputation, organizations should proactively disclose information about 
potential financial conflicts of interest when a range of other strategies, such as third-
party techniques, are used as well.  
The literature on disclosure of pharmaceutical industry funding of other health 
and medical organizations generated the following research question, which was first 
posed separately for each body of text, press releases (RQ2d) and news stories (RQ3d) in 





generating univariate descriptions first in the Results chapter. For brevity, only the 
comparison question is listed below: 
RQ4d: How did press releases and news stories compare in terms of mentioning 
pharmaceutical industry-related financial conflicts of interest?  
The literature related to lack of disclosure in funding arrangements and third-party 
communication strategies indicated a need to trace funding relationships between 
organizations. For this reason, the most successful agenda builders that emerged from the 
study were identified and supplemental archival/document research was conducted to 
look for financial disclosures on materials produced by those organizations, such as 
scientific publications, websites, and annual reports. Additional qualitative analyses were 
also applied to the subset of press releases and news stories that mentioned these 
organizations to identify potential third-party communication strategies and 
collaborations and to provide a more nuanced and contextual understanding of how the 
organizations constructed and defined menopause and any proposed treatment 
recommendations. The research questions below were used to guide these inquiries: 
RQ5: What specific organizations emerged as successful agenda builders as 
evidenced by frequent mentions of these organizations in both press releases and 
news stories? 
RQ6a: What are the profiles of the most successful agenda-building organizations 
in terms of organization type, mission and goals, memberships, and financial 
support? Were any potential conflicts of interest evident through archival analysis 
of these organizations’ websites or materials, such as annual reports, or financial 





interest disclosed in press releases produced by these organizations or that 
mentioned these organizations or in news stories that mentioned these 
organizations? 
RQ6b: Did these organizations tend to collaborate with other organizations to 
produce joint press releases as evidenced by the press release source and contact 
fields? Did mentions of these organizations tend to frequently be associated with 
mentions of other organizations in the text of press releases? How did these 
patterns of organizational associations compare to the patterns of associations 
found in news stories that mentioned these same organizations? 
RQ6c: How did these organizations construct and define menopause, and how 
did these definitions relate to proposed treatment recommendations in press 
releases that were produced by these organizations or that mentioned these 
organizations? How did these definitions and treatment recommendations 
compare to those used in news stories that mentioned these same organizations? 
Health, Medicine, & Prescription Drug News 
A substantial literature has documented significant problems related to the 
accuracy and quality of science, health, and medical news (see for e.g., Friedman 1986a, 
1986b; Nelkin, 1995; PLOS Editors, 2008; Schwitzer, 2008; Seale, 2002). Traditional 
explanations for problematic news content have often focused solely on journalists and 
news organizations. For example, some have cited journalists’ lack of training in health 
and scientific methods (Friedman, 1986a; Nelkin, 1995; Schwitzer et al., 2005; Tanner, 
2004; Voss, 2002; Wilson et al., 2010) or reliance on routine storytelling frames that 





1972). Others have faulted the U.S. commercial media system, which results in the need 
for news organizations to please advertisers, considerable competition, and constant 
deadline pressures (Friedman, 1986b; Manning, 2001; PLOS Editors, 2008; Shoemaker 
& Reese, 1996).   
While insightful, the above explanations neglect the role organizations and other 
actors play in shaping the quality of news content (Gandy, 1982; Manning, 2001; Seale, 
2002; Shoemaker & Reese, 1996; Tankard, 2001). Exploring the role organizations and 
other organized interests play is particularly important given journalists’ heavy reliance 
on sources for health and medical news (Cho, 2006; Corbett & Mori, 1999; Gandy, 1982, 
Gans, 1979; Manning, 2001; Tanner, 2004; Wallington et al., 2007) and concerns about 
conflicts of interest in medicine, which involve organizations that produce, disseminate, 
and provide access to commonly used sources of information about health and medicine 
(IOM, 2009). Little research exists that systematically compares information subsidies to 
news content to see if problematic content originates from journalists themselves or the 
sources of information provided to journalists. This section reviews research on 
frequently cited problems associated with health and medical news, followed by the 
literature that is available on the quality of information subsidies produced by health and 
medical organizations. 
Quality of news. Although only a few content analyses have been conducted to 
assess the quality of prescription drug news, a substantial literature exists on the quality 
of science, health, and medical journalism more generally. Many scholars have written 
about problems related to the accuracy and quality of science, health, and medical news 





2008; Seale, 2002). The concerns highlighted in the literature that pertain to health and 
medical news are numerous, but for the purpose of this review will be collapsed into the 
following four major areas of concern: disease mongering or medicalization; 
sensationalism or lack of appropriate context; lack of balanced and accurate information 
related to benefits and risks; and limited sourcing and source disclosure.  
Disease mongering/medicalization. Medicalization refers to the application of 
biomedical diagnoses and definitions to states of health that some consider normal states 
of the human experience, rather than disease or illness (Brown, 1995). Disease 
mongering is a term used to refer to what are thought to be intentional attempts to 
medicalize natural states of health into diseases or conditions in need of treatment, or to 
exaggerate the true incidence of diseases or conditions to “expand markets for those who 
sell and deliver treatments” (Moynihan et al., 2002; p. 886; Schwitzer, 2008). Another 
element of what some refer to as disease mongering is treating “surrogate end points,” 
which are risk factors, not clinical manifestations of disease, as actual diseases, a problem 
that has become more common with the increased focus on preventive medicine 
(Schwitzer, 2008, p. e95).  
Claims about disease mongering have been made for many different health 
conditions. For example, some have argued that conditions, such as social phobia, male 
balding, and irritable bowel syndrome, represent normal states of physical and mental 
health rather than medical problems that require treatment (Moynihan et al., 2002). 
Historically, many women’s group have also claimed that normal biological changes 
experienced by women, such as childbirth, breast feeding, and menstruation, have been 





in these areas (Boston Women’s Health Book Collective, 2006; Chrisler & Levy, 1990; 
Kalbfleisch & Bonnell, 1996; Kalbfleisch, Bonnell & Harris, 1996; Seale, 2002).  
Despite these claims, only a few empirical studies have been conducted to 
document these problems in a systematic manner. In a content analysis of  500 news 
stories from the top-50 most widely circulated U.S. newspapers and AP Newswire; three 
weekly news magazines, Time, Newsweek, and U.S. News & World Report; and network 
newscasts on ABC, CBS, and NBC, Schwitzer (2008) found that almost one-third (30%) 
of articles that made claims about a healthcare product or procedure engaged in some 
type of disease mongering by medicalizing a natural state as disease, reporting benefits 
based only on surrogate end points, or exaggerating the prevalence of a health condition. 
News coverage may also inaccurately attribute symptoms to various conditions. For 
example, a content analysis of print media coverage of premenstrual syndrome found that 
a range of symptoms were attributed to the syndrome that had never been supported in 
the scientific literature (Chrisler & Levy, 1990). 
Sensationalism and lack of context. Sensationalism is a common criticism of 
news stories about scientific and medical developments that are often presented as 
miraculous breakthroughs, technological scare stories, or the latest controversy (Antilla, 
2005; Atkin et al. 2008; Nelkin, 1995; Seale, 2002). For example, Atkin et al. (2008) 
noted that breast cancer news stories tended to present news about new medical research 
findings or drugs as “breakthroughs” or potential “cures” (p. 15). Another common 
science story focuses on conflict by reporting opposing opinions and positions, as found 
by Nelkin (1995) in her case studies of news coverage of dioxin, artificial sweeteners, 





these types of conflict stories provide little in-depth analysis of the technical information 
required for informed decision making (Nelkin, 1995). For example, in the case of 
climate change, news coverage that focused on balancing news reports with the 
viewpoints of opposing sides provided a distorted picture of the underlying body of 
scientific evidence that clearly supported climate change (Antilla, 2005). 
Sensationalized news stories typically report new developments as isolated stories 
that are devoid of any context or in-depth reporting and analysis (Antilla, 2005; Nelkin, 
1995; Schwitzer et al., 2005; Seale, 2002). News reports often fail to contribute to 
effective decision making by reporting on individual study findings as opposed to the 
accumulation of findings in a specific area (Parrott & Condit, 1996), or analyses of how 
treatments compare to other available alternatives in terms of clinical benefits and risks 
(Schwitzer et al., 2008). A content analysis of top-circulating, U.S. news outlets also 
found that only 38% of stories about medical procedures and treatments discussed 
alternative options or financial costs of different treatments (Schwitzer, 2008). 
Balance and accuracy about benefits and risks. Concerns related to a lack of 
balanced or accurate benefit and risk information in news stories about medical 
treatments are common, with complaints related to presentations that directly omit critical 
benefit or risk information, attribute a benefit or risk inappropriately, fail in accurately 
conveying the magnitude or probability of a risk or benefit, or fail to mention the quality 
of the scientific evidence behind risk and benefit estimates (Roche & Muskavitch, 2003; 
Schwartz & Woloshin, 2004; Schwitzer, 2008; Wilson et al., 2010).  
Scholars have noted that news stories often present a distorted picture of the 





1995; Schwartz & Woloshin, 2002; Seale, 2002). For example, after findings about breast 
cancer drug tamoxifen were released from the Breast Cancer Control and Detection 
Program in 1998, almost all stories (91%) reported on the increased risk of uterine cancer 
and only 44% reported on the increased risk of pulmonary embolism, even though the 
risk of experiencing pulmonary embolism was much higher than uterine cancer and the 
cause of all deaths reported in the tamoxifen trials (Schwartz & Woloshin, 2002). Seale 
(2002) noted that coverage of the contraceptive implant, Norplant, was overwhelmingly 
favorable around the time of product launch and then became almost completely negative 
when the side effect of heavy menstrual bleeding became news in the mid-nineties. A 
similar pattern was observed for antidepressant Prozac, widely acclaimed as a wonder 
drug by the news media, until a period of negative news coverage that primarily focused 
on claims related to suicidal and violent behavior exhibited by some patients who took 
Prozac (Nelkin, 1995). News coverage of antidepressant Paxil also turned almost entirely 
negative after the FDA released safety advisories and product labeling changes to warn 
physicians and consumers about an increased risk of suicidality in children taking the 
drug; only 4% of 167 print, broadcast, and cable news stories published after the FDA 
action suggested that the benefits of Paxil may still outweigh the risks in some cases 
(Barry & Busch, 2010).  
According to risk communication experts, in addition to portraying a balanced 
portrayal of a treatment’s benefits and risks, how benefits and risks are communicated in 
terms of their magnitude is also important. A consistent finding in the risk 
communication literature is that individuals, including the general public and many who 





numerical information and particularly risk estimates that convey the probability of an 
outcome or event occurring (Rothman & Kiviniemi, 1999; Skubisz, Reimer, & Hoffrage, 
2009; Weinstein et al., 2004; Yamagishi, 1997). Current research suggests that benefit 
and risk information should be presented quantitatively in absolute terms whenever 
possible (Schwartz & Woloshin, 2004; Schwitzer, 2008), or through a combination of 
qualitative and quantitative information (Arkin, 1999; Ratzan, 1999), but not through 
qualitative information only because interpretations of words vary significantly 
(Holtgrave, Tinsley, & Kay, 1995; Weinstein et al., 2004). Quantitative information 
should always be reported with the most “contextual precision” possible by reporting 
both numerator and denominator information; where the numerator conveys the incidence 
or likely incidence of an event and the denominator conveys the population for which the 
effect is likely to occur (Roche & Muskavitch, 2003, p. 354), also called the “reference 
class” (Skubisz et al., 2009, p. 179). 
Medical research findings are often communicated in absolute and relative risk 
terms. “Absolute risk is simply the risk that an individual will get a certain disease over a 
defined time period. Relative risk is the ratio of the chance of disease in individuals 
exposed to a risk factor compared to the risk of disease in individuals without exposure” 
(Jeffery, 1989, p. 1196). Some representations, like relative risk, typically do not specify 
the reference class or supply base rate information regarding the reference class (Skubisz 
et al., 2009, p. 185). Relative risk figures are often reported in news stories and can make 
findings sound more dramatic (Boston Women’s Health Book Collective, 2006). For 
example, as described below for consumers in Our Bodies Ourselves: Menopause, if a 





getting a disease, actual disease reduction might be more limited than the 50 percent 
terminology suggests based on the absolute risk of getting the disease in the first place. 
If the relative risk for developing a disease is cut in half by taking a certain drug, 
but only one in 100,000 women who do not take the medicine develop the disease 
each year, only 1 in 200,000 women per year would avoid developing the disease 
if the whole group took the medicine—and all of the other women would be at 
risk of developing its unwanted ‘side’ effects (p. 27).   
Existing evidence indicates that news stories may convey the magnitude of 
benefits and risks poorly. Stories often include qualitative-only presentations of risks and 
benefits, and when quantitative information is reported, it often has a low degree of 
contextual precision (Moynihan et al., 2000; Roche & Muskavitch, 2003; Schwartz & 
Woloshin, 2002; Switzer, 2008). In Schwitzer’s (2008) content analysis of news coverage 
of medical products and treatments, only 28% of articles quantified benefits, 33% 
quantified harms, and 35% addressed the quality of the scientific evidence behind 
reported findings. Schwartz and Woloshin (2002) found that almost two-thirds (60%) of 
tamoxifen news stories that quantified the benefits of taking tamoxifen did so by 
reporting relative risk reduction figures without the base rate. For example, stories 
reported that the tamoxifen group had 49% fewer cases of breast cancer, but neglected to 
report that the breast cancer rate in the control group without tamoxifen was 67 annual 
cases per 10,000 women.  
Limited sourcing and disclosure. When citing sources of information within 
health and medical stories, journalists often do not identify financial conflicts of interest 





supplied the information. The financial conflicts of interest of individuals who serve as 
sources of information are rarely reported, and information on conflicts of interest at the 
level of the organization are reported even less frequently (Appollino & Bero, 2007; 
Barry & Busch, 2010; Cassels et al., 2003; Moynihan et al., 2000).  
In a content analysis of 1,152 top news stories published in national and regional 
U.S. newspapers and by wire services in 2004 and 2005 in areas of basic science, 
engineering, and clinical research, Cook, Boyd, Grossmann, and Bero (2007) found that 
38% of stories provided information on funding agencies or organizations, and only 11% 
included information about investigators’ financial ties, such as stock ownership, 
consulting fees, or honoraria. Moynihan et al. (2000) found that information available 
about financial ties in the scientific literature were disclosed only 39% of the time in 
corresponding news stories about three drugs in large-circulation national and regional 
newspapers, ABC, NBC, CBS, and CNN. A study of news coverage about the association 
between antidepressant use and suicidality found that none of the analyzed news stories 
included any information indicating whether reports asked the experts they interviewed if 
they had any pharmaceutical industry conflicts of interest (Barry & Busch, 2010). 
Quality of information subsidies provided to news media. Although substantial 
research has focused on inaccurate or exaggerated news media treatment of the benefits 
and risks of medical treatments, devices, and products, less research exists that goes one 
step back to see if these presentations come from the sources of information provided to 
journalists, or journalists themselves. Some studies have demonstrated patterns between 





studies, however, have compared news content to the actual information subsidies 
provided to news media. 
Several studies have demonstrated associations between the sources of 
information cited in health and medical news and the information or frames included in 
those stories or story tone (Kennedy & Bero, 1999; Moriarty et al., 2008; Wells, 
Marshall, Crawley, & Dickersin, 2001). For example, Moriarty et al. (2008) found that 
news stories about cancer clinical trials were mostly neutral to positive in nature, and 
positive stories were more likely to cite pharmaceutical companies and medical journals 
as sources of information. Kennedy and Bero (1999) found in their content analysis of 
newspaper and magazine coverage of passive smoking from 1981 to 1994 that articles 
were more likely to portray the risks of passive smoke as controversial when tobacco 
industry sources of information were cited, even after the danger of passive smoking had 
long been established in the scientific community.  
Studying 627 news stories about genetic research from major daily newspapers in 
the U.S., Canada, Britain, and Australia, as well as 111 studies in 24 scientific and 
medical journals, Bubela and Caulfield (2004) found that 11% of newspaper articles had 
“moderately to highly exaggerated” claims in comparison to the scientific articles. 
Almost all of the newspaper articles (97%) and scientific journal articles (98%) discussed 
the likelihood of the benefits of the research, and only 15% of the newspaper articles and 
5% of the scientific journal articles discussed any potential costs or risks. Woloshin and 
Schwartz (2002) found in a study of 127 press releases by nine top medical journals, 
obtained from journal websites and EurekAlert!, a wire service for medical and scientific 





differences between groups via relative risk or odds ratio information, and of those, only 
about half gave corresponding base rate or denominator information. Only 23% 
mentioned any study limitations, and although 23 studies were industry-funded, only 
22% of releases for those studies indicated that support. 
Based on the above studies, some recommendations have been made to improve 
the quality of information subsidies and make it easier to investigate the organizations 
that produce, fund, and disseminate information subsidies about health and medicine. 
Woloshin and Schwartz (2002) suggested that press releases should all contain common 
components, such as a section that displays all statistics in absolute terms, a section for 
study limitations, and disclosures of any potential conflicts of interest. Moriarty et al. 
(2008), surprised that their content analysis of cancer news found such infrequent explicit 
mentions of pharmaceutical companies, suggested that future researchers look not just at 
explicit references in news stories to pharmaceutical companies, but other ways 
pharmaceutical companies more subtly influence news content through grants to research 
institutions and other organizations, or by examining statements of disclosure on medical 
journal articles.  
The use of third-party strategies by organizations might make it difficult for 
journalists to uncover financial relationships, or less likely to investigate financial 
relationships when information subsidies are disseminated by government or other 
nonprofit organizations. Past research has indicated that news editors are more likely to 
accept subsidies from nonprofit organizations or organizations that they perceive to be 
working in the public interest than other organization types (Berkowitz & Adams, 1990; 





Investigating financial conflicts of interest is also difficult due to practices like 
ghostwriting and federal legislation and tax codes that do not require many organizations 
to report on their funding sources (see Bodenheimer, 2000; Bodensteiner, 1997; 
DeAngelis & Fontanarosa, 2008; Fitzpatrick & Palenchar, 2006). In the absence of 
common repositories for funding information, journalists must take considerable time to 
conduct investigative research if they want to “connect the dots” between messages and 
their funding sources (Batt, 2005; Fitzpatrick & Palenchar, 2006, p. 212; Schwitzer et al., 
2005).   
Because of the scientific and technical nature of health and medical information, 
it might be unrealistic in some cases to expect journalists to improve their reporting, if the 
sources of information they receive are biased and/or inaccurate. Placing the burden 
solely on journalists to uncover financial relationships that are not disclosed on source 
documents or to detect practices like ghostwriting through investigate reporting is 
impractical. Health and medical organizations that supply information to news media also 
need to take responsibility for the quality and transparency of the information 
disseminated. Research that compares the content of prescription drug news to the 
content of information subsidies produced by health and medical organizations about 
prescription drugs can yield new insights and recommendations to improve news 
coverage about health and medicine.   
Hormone Therapy (HT)  
 Literature specifically related to HT has indicated that women rely on a variety of 
sources for information about HT, including news (Barber et al., 2004; Bastian, Breslau, 





dramatically at times over the study period in response to new evidence about its benefits 
and risks (Austin et al. 2003; Haas et al., 2004: Hersh et al. 2004; Roumie et al., 2004). 
Although little systematic research has been conducted to examine the quality of HT 
news, some have claimed that news coverage about HT may have inaccurately portrayed 
or exaggerated the benefits and risks of HT (Fugh-Berman & Pearson, 2002; Katz, 2003; 
Moynihan et al., 2002; Pines, 2008; Sweet, 2003), and that health and medical 
organizations, particularly pharmaceutical companies and organizations funded by them, 
played a role in promoting misperceptions (Felgran & Hettinger, 2002; Fugh-Berman & 
Scialli, 2006; Zones & Fugh-Berman, 1999; Zuckerman, 2002).  
Women and HT. Menopause is clinically defined as the end of fertility, which is 
marked by the absence of menstrual period for 12 consecutive months (North American 
Menopause Society, 2010). The average age of menopause is 51, but the changes leading 
to menopause often begin gradually years before in the time period referred to as 
perimenopause. During the transition through perimenopause and into menopause, the 
ovaries shrink and produce less of the female reproductive hormones estrogen and 
progesterone. This reduced hormone production can lead to vasomotor symptoms, 
commonly referred to as “hot flashes” or “night sweats,” sleep disturbances, changes in 
mood, low libido, and vaginal dryness (USDHHS NHLBI, 2005). Women experience 
menopause differently, due to various factors related to socioeconomic status, health 
status, cultural factors, and social support, but evidence suggests that only about 15% of 
women experience problems severe enough to disrupt their daily lives (Boston Women’s 





For women who experience problems, there are various ways to control 
symptoms, including prescription medications now most commonly referred to as 
hormone therapy (HT), but once referred to as hormone replacement therapy (HRT) and 
estrogen replacement therapy (ERT). Two different types of therapies exist. Estrogen-
plus-progestin therapy is typically prescribed for women whose uterus in intact, and 
estrogen-only therapy for women whose uterus has been removed. Some women find 
non-prescription alternatives helpful in controlling symptoms, including a variety of 
vitamins and herbs, dietary changes and exercise, relaxation techniques, support groups, 
acupuncture and vaginal lubricants (Boston Women’s Health Book Collective, 2006; 
Kalbfleisch & Bonnell, 1996). 
Whatever decisions a women makes about relieving symptoms should be based 
on a thorough understanding of the benefits and risks of each approach so she can make a 
decision that best suits her unique circumstances. Because all interventions have benefits 
and risks, the optimal decision is often the one that maximizes benefits while keeping 
risks to a minimum (Parrott & Condit, 1996). Literature on shared decision-making has 
indicated that individuals experience more satisfaction and better outcomes when they are 
empowered to participate in decisions about their health (for e.g., see Frosch & Kaplan, 
1999; King, Eckman, & Moulton, 2011). To make informed decisions, consumers need 
information from a variety of sources and the skills to understand that information. “True 
empowerment comes from having independent information about diseases and their 
treatments, and tools to critically analyze a problem” (Batt, 2005, p. 12). Unfortunately, 
much of the information women often have access to is dominated by corporations 





Role of news in HT decision making. Previous research has found that the 
decision to take HT is highly complex, and a variety of factors play a role in women’s 
decision-making processes, including: internal beliefs, feelings, and values related to 
menopause; experience and perceptions of menopausal symptoms; expected 
consequences of taking HT; influence of family members, friends and physicians; 
information in a variety of media, including advertising, news, magazines, pamphlets, 
and books; and cultural factors, such as ageism, sexism, and associated stereotypes 
(Boston Women’s Health Book Collective, 2006; Buick et al., 2005; Fugh-Berman & 
Scialli, 2006; MacLennan, Taylor, & Wilson, 2004; Majumdar, Almasi, & Stafford, 
2004; Wathen, 2006).  
Although many external sources of information contribute to the complex 
decision of whether or not to take HT, news media are a significant source of 
information. More than 80% of middle-aged women have reported relying on mass media 
for health information (National Council on Aging Survey, as cited in Whiteman, Cui, 
Flaws, Langenberg, & Bush, 2001), and some women report relying on mass media more 
than medical professionals (Buick et al., 2005; MacLennan et al., 2004).  In a 1997 study, 
49% of women reported using magazines and newspapers as sources of information to 
help them decide about HT (Newton et al., 1997). Newspaper readership is high for 
women age 50 and older, particularly among women with high levels of education and 
income, who also happen to be more likely to use HT (Keating, Cleary, Rossi, Zaslavsky, 
& Ayanian, 1999). Substantial numbers of women who discontinued hormone therapy 
have also reported that news media coverage played an important role in their decision to 





Ettinger et al., 2003; Huston, Jackowski, & Kirking, 2009; MacLennan et al., 2004; 
McIntosh & Blalock, 2005).  
History and patterns of HT use. Estrogen was first approved to treat the 
symptoms associated with menopause in 1942 by the FDA (U.S. Department of Health & 
Human Services, Food and Drug Administration [USDHHS FDA], 2011b). Based on 
research to ascertain the ability of animal sex glands to maintain youth, Ayerst 
Laboratories manufactured the product from the urine of pregnant horses and named it 
Premarin, which was short for “PREgnant MARes’s urINE” (Rothenberg, 2005). 
Although it took a couple decades to catch on, the use of estrogen therapy increased 
significantly in the 1960s and 1970s, but then dropped off sharply in the late 1970s and 
early 1980s when it was linked to an increased risk of uterine cancer. In the mid-to-late 
1980s, sales began to increase again when it was discovered that adding progestin to 
estrogen could protect women from uterine cancer, leading to multi-pill regimens. 
Estrogen-only therapy continued to be prescribed for women without a uterus. In 1995, 
the FDA approved Prempro, the first one-pill-only formulation of estrogen-plus-
progestin, manufactured by Wyeth-Ayerst (Boston Women’s Health Book Collective, 
2006; Hersh, Stefanick, & Stafford, 2004; Katz, 2003). 
Women began taking hormone therapy in unprecedented numbers throughout the 
1990s, turning Premarin and Prempro into blockbuster drugs. An estimated 36 million 
annual prescriptions for hormones were filled in the United States in 1992, representing 
approximately 17% of women ages 50 to 74. By 2001, that number had jumped to 91 
million annual prescriptions, with an estimated 42% of women age 50 to 74 taking 





formulations had only been approved by the FDA for the indications of vasomotor 
symptoms (hot flashes), vulvar and vaginal atrophy, and postmenopausal osteoporosis 
(USDHHS FDA, 2011b), many women and their clinicians believed hormone therapy 
could prevent a host of other conditions, such as cardiovascular disease, memory loss, 
and aging of the skin (Fugh-Berman & Pearson, 2002). Prevention of cardiovascular 
disease was perhaps the most common, unproven belief (Utian & Schiff, 1994). In 1990, 
the FDA denied a request by Wyeth to add a cardiovascular disease prevention indication 
to estrogen due to conflicting scientific evidence. Despite this fact, many physicians 
routinely prescribed estrogen off label for this reason (Katz, 2003; Roussouw, 1996).   
In 1991, the Women’s Health Initiative (WHI), one of the largest controlled, 
clinical prevention trials ever conducted in the United States, was launched by the 
National Heart, Lung, and Blood Institute (NHLBI) in conjunction with other agencies 
within the National Institutes of Health (NIH), including the Office of Women’s Health. 
The trials, which involved 161,808 healthy, menopausal women between the ages of 50 
to 79 across the nation, tested the effects of estrogen-plus-progestin (Prempro) and 
estrogen-only (Premarin) hormone therapy, low-fat diet, calcium, and vitamin D 
supplements on the prevention of heart disease, bone fractures, breast and colorectal 
cancer (Katz, 2003; USDHHS NHLBI, 2005).  
On July 9, 2002, WHI investigators held a press conference to announce that the 
estrogen-plus progestin portion of the clinical trial had been stopped prematurely because 
the researchers found that women given Prempro experienced a higher risk of heart 
disease, blood clots, stroke, and breast cancer compared to those taking a placebo. In 





trial as well upon finding that women taking Premarin had an increased risk of stroke and 
venous thrombosis (deep vein blood clots) and had experienced no significant reductions 
in risk of coronary artery disease. Although Prempro and Premarin did result in 
reductions in vasomotor symptoms, atrophy-related symptoms of vaginal dryness, and 
osteoporotic bone fractures, investigators determined the risks outweighed these benefits 
(USDHHS NHLBI, 2005; WHI Investigators, 2002).   
Several studies have indicated that extensive news coverage of the WHI findings 
in 2002, which documented substantial harms associated with estrogen-plus-progestin 
combination therapy, resulted in dramatic drops in HT prescription use. Evidence of 
striking differences in temporal trends of HT prescription use before and after the release 
of the WHI findings have been documented, with HT use increasing steadily prior to the 
release and decreasing steadily after the release (Austin et al. 2003; Haas et al., 2004: 
Hersh et al. 2004; Roumie et al., 2004). For example, Haas et al.’s (2004) analysis of an 
observational cohort of women, ages 50 to 74, from the San Francisco Mammography 
Registry documented an 18% per quarter decrease in HT use after the WHI 
announcement. An analysis of the Breast Cancer Surveillance Consortium cohort of 
327,144 postmenopausal women across the U.S., ages 50 to 74, found that the prevalence 
of HT use declined from 45% to 27% among women who lived in areas where there was 
an average household exposure of at least three WHI-related newspaper articles 
compared to a decline of 43% to 31% among women who lived in areas exposed to one 
article or less (Haas et al., 2007). 
Claims about quality of HT news. Despite the substantial news coverage that 





about the benefits and risks of HT, raising questions about the quality of news coverage 
that was received. For example, although 95.7% of 185 postmenopausal hormone therapy 
users in Minnesota were aware of the WHI findings when surveyed from August 2002 to 
January 2003, they showed less understanding of the study’s specific results. Only 39.8% 
were aware of the reported breast cancer increase; 30% were aware of the increased risk 
for heart attack; and 26.7% were aware of multiple risks. Only 2.8% were aware that 
estrogen-plus-progestin was no longer thought to have overall health benefits or to 
prevent cardiovascular disease. Almost a third of women (31.8%) reported feeling 
“confused, scared, nervous, or worried about the results” (Barber et al., 2004, p. 978). 
Some studies also found that women taking estrogen-only were just as likely in some 
cases as women taking estrogen-plus-progestin to discontinue use after the 2002 WHI 
announcement, even though the 2002 announcement pertained only to the combination 
therapy (McIntosh & Blalock, 2005). It is likely, however, that some women understood 
the differences, but wanted to be cautious due to the estrogen in both products.  
The difficult decision many women face about whether or not to take HT has not 
gone away. Women continue to report frustration about HT information that seems 
contradictory (Wathen, 2006) and express a desire for better information to make 
decisions about HT (Buick et al., 2005). Despite the focus on the role HT news coverage 
may have played in reducing HT prescription rates immediately after the 2002 WHI 
announcement, little systematic research has been conducted to understand the actual 
quality of HT news coverage prior to the WHI announcement, during the WHI 
announcements, or after. Prior to the 2002 announcement, approximately 42% of all 





Analyses of the quantity and quality of news coverage in the run-up to the announcement 
might provide some insights as to why this was the case. It is also important to 
understand the current news environment surrounding HT, particularly with the more 
recent emergence of new, lower-dose HT formulations on the market (Global Data, 
2010). 
Although little systematic research has been conducted to examine the amount 
and quality of HT news, claims have been made in editorials and other articles in the 
medical literature about the quality of HT news coverage (see for e.g., Fugh-Berman & 
Pearson, 2002; Katz, 2003; MacLennan et al., 2004; Moynihan et al., 2002; Pines, 2008). 
These claims are sometimes backed by systematic research, but more often backed by 
anecdotal evidence, and are similar to the four major areas of concern that have been 
raised about health and medicine more generally that were reviewed earlier: disease 
mongering/medicalization, sensationalism and lack of context, balance and accuracy 
about benefits and risks, and limited sourcing and source disclosure.   
Media hype about menopause has been referred to as the “menoboom” in 
reference to the tendency of the media to try to exaggerate problems associated with 
menopause to appeal to aging women who are a large segment of the population 
(Kalbfleisch, Bonnell & Harris, 1996, p. p. 284), despite the fact that estimates suggest 
that only about 10 to 15 percent of women encounter menopausal symptoms that pose 
serious challenges to their everyday lives (Kalbfleisch et al., 1996). Menopause began to 
be understood within the medical establishment as an estrogen-deficiency disease 
beginning in the 1930s and 1940s. This view was further popularized in the 1960s when 





youthful, attractive, and sexually active (Boston Women’s Health Book Collective, 2006; 
Katz, 2003), and beginning in the 1980s, as a cure all, preventive measure that could 
prevent other diseases like osteoporosis and heart disease (Fugh-Berman & Pearson, 
2002; Katz, 2003).  
Popular media have often portrayed menopausal women as physically or mentally 
unwell and have rarely portrayed women experiencing menopause in positive ways 
(Kalbfleisch et al., 1996). This view of menopause as a medical condition in need of 
pharmacological treatment has been countered by some feminists and women’s health 
advocates who view menopause as a natural development stage or claim that women are 
not adequately informed of non-prescription alternatives and coping strategies outside of 
the dominant medical model (Boston Women’s Health Book Collective, 2006). Lack of 
communication about treatment options has been observed for other women’s health 
issues, particularly in the area of reproductive health. For example, despite concerns 
voiced by women’s health organizations that hysterectomy was an over-used procedure, 
particularly for uterine fibroids, U.S. newspaper stories that appeared from 1986 to 1992 
reported superficially on new technologies related to hysterectomy, rarely offered critical 
analysis as to whether or not hysterectomies were always needed, and failed to place the 
long-term benefits and risks of hysterectomy in the context of other surgical and non-
surgical alternative approaches (Sefcovic, 1996). 
In the wake of the WHI findings, several scholar-physicians in the medical 
community claimed that news media presented a distorted picture of HT by emphasizing 
its benefits and excluding or downplaying its potential risks (Fugh-Berman & Pearson, 





had inaccurately conveyed information about off-label uses of HT never approved by the 
FDA. Most controversial was the off-label use of HT for heart disease prevention, which 
was based entirely on associations found in observational studies or clinical trials that 
examined surrogate endpoints only rather than controlled clinical trials that assessed 
actual heart disease outcomes (Fugh-Berman & Pearson, 2002; Katz, 2003), with some 
alleging that this important fact was rarely communicated (Sweet, 2003). Moynihan et al. 
(2002) claimed that the perceptions of the osteoporosis prevention benefit of HT were 
often inflated through news reports that included relative risk reduction information only. 
Conversely, others have argued that news media coverage of the WHI findings 
was alarmist and overemphasized and dramatized the risks of HT (Pines, 2008). A 
content analysis that compared scientific journals and print news media coverage about 
the HT-breast cancer link from January, 1, 1995, to June 30, 2000, found that news media 
were more likely to report on scientific studies that found a positive link between HT and 
breast cancer than those with null or negative findings (Whiteman et al., 2001). 
MacLennan et al. (2004) argued that frequent, relative risk-only presentations 
exaggerated the risk of breast cancer for estrogen-plus-progestin therapy.  
Claims about sources of HT news. After the 2002 WHI findings, some accounts 
blamed journalists for not being critical enough of HT-related research and information 
due to aggressive pharmaceutical promotion and influence (Felgran & Hettinger, 2002; 
Zuckerman, 2002). Felgran and Hettinger (2002), two former editors of women’s 
magazines, recounted in a Columbia Journalism Review article that “a handful of 
sources” had regularly “fed” women’s magazines HT information that often promoted the 





that journalists need to better identify sources with financial ties to pharmaceutical 
companies that often use press conferences and other non-FDA regulated avenues to 
promote off-label indications for drugs.  
Documents that became public during litigation by women who developed breast 
cancer while taking HT highlighted the extent of pharmaceutical industry influence. An 
analysis of 1500 internal documents revealed that Wyeth Pharmaceuticals paid 
DesignWrite, a MECC, to produce more than 50 peer-reviewed articles in medical 
journals, including those reporting on clinical trials, and a variety of other materials, 
including journal supplements, scientific abstracts, and posters on Premarin and Prempro 
from 1996 to 2003. Numerous pieces of correspondence indicated that DesignWrite often 
wrote the publications and then recruited prestigious academic physicians, who played 
minimal roles, to author the publications with no attribution to DesignWrite writers. 
Comparisons of court documents to actual publications, found that Wyeth used 
ghostwriters to produce “dozens” of articles to “mitigate the perceived risks of breast 
cancer associated with HT, to defend the unsupported cardiovascular ‘benefits’ of HT, 
and to promote off-label, unproven uses of HT such as the prevention of dementia, 
Parkinson’s disease, vision problems, and wrinkles” (Fugh-Berman, 2010, p. 2).  
Although many claims have focused on potential pharmaceutical industry 
influence on HT information, other types of organizations were also involved in 
communicating about HT, particularly government organizations. The Women’s Health 
Initiative (WHI) study, which demonstrated the risks of HT, was an NIH-funded 
collaboration between several NIH institutes and centers, including NHLBI and the 





For example, in 1990, women’s health advocates successfully organized to prevent the 
FDA from approving Wyeth’s application to get heart disease prevention on the list of 
approved indications for HT due to insufficient evidence (National Women’s Health 
Network, 2006). In 2003, after the WHI study had documented the risks of HT, the FDA 
required that all labels on estrogen and estrogen-plus-progestin carry black-box warnings 
on possible adverse events and state clearly that the products are not approved for 
cardiovascular disease prevention (Katz, 2003). 
Professional societies and health advocacy organizations may have also played a 
key role in framing HT treatment. For example, the American Congress of Obstetricians 
and Gynecologists, a 501c(6) organization that represents more than 52,000 dues-paying 
physicians, residents, and medical students practicing in the area of obstetrics and 
gynecology, and its educational subsidiary, the American College of Obstetricians and 
Gynecologists, a 501c(3) organization that publishes the journal, Obstetrics & 
Gynecology (ACOG, 2011), released various technical publications and clinical 
recommendations to guide physician practice in the 1990s, suggesting HT was effective 
for prevention of cardiovascular disease and senile dementia (Fugh-Berman & Scialli, 
2006). The organization also became active in response to the WHI findings released in 
both 2002 and 2004, issuing public statements and creating its own Hormone Therapy 
Task Force to examine the WHI data. ACOG now recommends against the routine use of 
menopausal hormone products for chronic disease prevention, but supports its use for 
short-term treatment of the menopausal symptoms of hot flashes and vaginal dryness, and 





Various nonprofit health advocacy and consumer groups also played a role in HT 
controversies, particularly groups associated with the women’s health movement. Some 
have argued that industry funding might be related to the positions of various women’s 
health groups on HT-related policy and treatment (Batt, 2005; Zones & Fugh-Berman, 
1999). The women’s health movement is a diverse one, comprised of  “grassroots” 
organizations, which are run primarily by consumers and tend to challenge the status quo 
and offer women information on a range of treatment options, including complementary 
and alternative approaches, and “professionalized” organizations, which are run primarily 
by clinicians and researchers and tend to promote greater access for women to 
conventional treatments offered within the dominant medical model (Batt, 2005; Zones & 
Fugh-Berman, 1999). A study of 51 nonprofit women’s health groups, found that 
grassroots groups were less likely to accept industry funding than more professionalized 
groups, particularly funding from corporations that directly targeted their constituents as 
customers (Zones & Fugh-Berman, 1999).  
 The WHI study came about through the advocacy actions of a coalition of several 
women’s health groups. Spearheaded by the National Women’s Health Network, a 
501c(3) nonprofit organization that does not accept any support from pharmaceutical, 
medical device, or tobacco companies, the coalition pressured the NIH and Congress to 
conduct the large-scale trials (National Women’s Health Network, 2006). The coalition 
was brought about by concerns about the relationships between HT and heart disease and 
breast cancer, combined with an interest in how diet was related to a variety of women’s 
health outcomes, particularly the relationship between dietary fat and breast cancer 





National Women’s Health Network, recounted in the network’s newsletter that the 
coalition felt a need to fill what they perceived as a serious void in the research on the 
relationship between diet and women’s health, which she attributed to the pharmaceutical 
industry’s lack of interest in sponsoring trials that explored the efficacy of alternative 
interventions that do not make money (National Women’s Health Network, 2006).  
Other debates have also taken place with various women’s health groups taking 
different issue positions. For example, in 1990 several advocacy groups that received 
contributions from Wyeth-Ayerst, including the American Medical Women’s 
Association, the National Osteoporosis Foundation, and Business and Professional 
Women/USA, testified at an FDA hearing against allowing a generic form of estrogen on 
the market to compete with Premarin, claiming it contained an extra ingredient that 
might be dangerous even though the FDA initially considered the ingredient insignificant. 
The only group that supported the generic entry as a way of saving consumers money 
was the National Women’s Health Network (Zones & Fugh-Berman, 1999). In another 
example, the executive director of the Society for Women’s Health Research (SWHR), a 
501c(3) charitable organization, spoke out strongly against the WHI findings when they 
were released, arguing that the findings were premature and exaggerated. News media 
later reported that Wyeth-Ayerst had funded the organization’s black-tie gala in 2000 to 
celebrate “the coming of age” of midlife women, gave the society a $250,000 check to 
celebrate the 60
th
 anniversary of Premarin, and that individuals from Eli Lilly, Johnson & 
Johnson, Merck, Pfizer, and Wyeth served on the society’s corporate advisory board 







The following conceptual models, which are displayed as figures, were developed 
based on the theoretical and empirical literature reviewed in this chapter. These 
conceptual models were informed by the interactions and linkages between the literatures 
reviewed in the areas of mass communication, strategic communication, and critical 
scholarship. The interdisciplinary approach resulted in a set of research questions that 
was driven by multiple theoretical perspectives to understand how health and medical 
organizations use news media strategically to communicate about prescription drugs.  
Based on the lack of empirical literature specifically investigating how 
organizations use information subsidies to build and shape the news media agenda for 
prescription drugs, all inquiries in this study were stated as research questions rather than 
hypotheses. Although there was not enough empirical literature to justify the 
advancement of hypotheses, the literature related to agenda building, information 
subsidies, framing, and health and medical issues more generally, suggested some initial, 
tentative expectations that guided the conceptual models. Three models were created: one 
overall conceptual model outlining the focus and scope of the study, and two more 
specific models to elaborate some of the expectations regarding the production and 
framing of information subsidies. These models were used to guide the research 
questions summarized below and the data analysis procedures outlined in the Method 
chapter. 
Figure 1 below outlined the overall focus and scope of the study. This figure 
proposed that a variety of health and medical organizations would produce carefully-





furthered their strategic interests. These subsidies were conceptualized as having the 
potential to act like a form of prescription drug promotion, similar to DTCA, medical 
journal advertising, detailing and sampling, and medical/scientific journal articles. Based 
on agenda-building research, I expected the public relations agenda created by these 
organizations to influence the news media agenda through an interactive process of 
reciprocal, bi-directional influence. I assumed that the public relations agenda would 
influence the news media agenda through proactive information subsidies, and that the 
news media would sometimes influence the public relations agenda by stimulating 
reactive information subsidies in response to news coverage of issues with strategic value 
for health and medical organizations. 
The process of effects for press releases was envisioned as an indirect one, in 
which the content of press releases would be diffused to physicians and consumers 
through news media. This study only explored the red boxes and arrows in Figure 1. The 
purpose was to explore how information subsidy production and distribution by a variety 
of health and medical organizations shaped the quantity and quality of news coverage. 
The link from news coverage to potential outcomes, such as prescription drug use, was 
not explored in this study. Although the current study did not attempt to link the quantity 
and quality of news coverage to HT prescription rates, it did yield data that can be used in 
the future to examine patterns of concomitant variation between news content and 










































Figure 2 below proposed that some types of organizations would have more 
explicit influence and other types of organizations would have less explicit influence on 
the news media agenda. As demonstrated by the figure, I tentatively expected 
government and academic research organizations to have the most explicit influence on 
the news media agenda because they are perceived by many journalists as authoritative 
and credible sources. Because other nonprofit organizations perceived to be working in 
the public interest are also valued as sources of information by journalists, they were 
expected to have more success in explicitly building the news media agenda than 
industry/pharmaceutical companies, which were expected have less explicit influence. 





more success in terms of getting their organizations mentioned in news stories as a result 
of press releases. 



































The remainder of the figure, based on literature related to conflict of interest in 
medicine, suggested that pharmaceutical companies would influence the news media less 
explicitly by funding the efforts of U.S. government agencies, academic/medical 
institutions, and nonprofit organizations with the potential to further their strategic 
interests. These organizations would in turn influence the news media directly through 
press releases about these funded efforts. Specifically, it was proposed that 





production of a variety of information sources, such as scientific research and 
publications, the results of which would then be delivered to news organizations by 
experts and organizations perceived as more credible and less profit motive-oriented.  It 
was anticipated that collaborations between organizations through such funding 
mechanisms would be rarely disclosed in press releases and news stories.  
Figure 3 tentatively proposed a relationship between the funding base of 
organizations and how they framed menopause, its proposed treatments, and more 
specifically, HT, in terms of its substantive attributes. Pharmaceutical companies and 
organizations that received pharmaceutical industry funding were expected to be more 
likely to distribute press releases that framed menopause as a biomedical illness or 
deficiency in need of pharmacological treatment and to frame the attributes of HT in 
more promotionally-oriented ways by mentioning the brand names of HT products, 
promoting off-label indications for HT, and emphasizing the benefits of HT. 
Organizations that received less or no pharmaceutical support were expected to frame 
menopause as more of a natural life stage, to address alternative, non-pharmacologically-
based treatments, and to frame the attributes of HT in a less promotionally-oriented way 
by not mentioning brand names, sticking to FDA-approved indications for HT, and 
including more information about the potential risks of HT. If organizations were 
successful in their framing efforts, news content was expected to be similar to press 
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As discussed in the Method chapter to follow, quantitative content analysis, along 
with some supplemental qualitative content analysis procedures were required to test 
specific research questions generated from these conceptual models. A summary of the 






Summary of Research Questions   
(Note: RQ1-RQ5 questions were addressed with quantitative procedures, except RQ1d.)  
RQ1: What was the relationship between the quantity of press releases about hormone 
therapy (HT) distributed by organizations via PR Newswire and EurekAlert! and the 
quantity of news stories about HT in AP Newswire and four, top-circulating U.S. 
newspapers from 1995 – 2011? 
RQ1a:  How many press releases about HT appeared between 1995-2011? 
RQ1b: How many news stories about HT appeared between 1995-2011? 
RQ1c: Was the amount of press releases positively correlated with the amount of 
newspaper stories over time?   
RQ1d. What overall story frames or themes were associated with peaks in press 
release and news story activity? 
RQ2: What was the content of press releases about hormone therapy (HT) distributed by 
organizations via PR Newswire and EurekAlert! from 1995-2011? 
RQ2a: What types of organizations distributed press releases most often? What 
types of organizations were mentioned in press releases most often? What types 
of individuals were quoted most often? How did these factors vary by the types of 
organizations that produced press releases? 
RQ2b: What benefits and risks were associated with HT? How were benefits and 
risks presented (qualitative vs. quantitative; relative vs. absolute terms). How did 





RQ2c: How often were specific brand-name HT products mentioned in press 
releases? How did brand-name mentions vary by the types of organizations that 
produced press releases? 
RQ2d: How often were pharmaceutical industry-related financial conflicts of 
interest mentioned in press releases? How did identification of conflicts of interest 
vary by the types of organizations that produced press releases? 
RQ3: What was the content of news stories about HT in AP Newswire and four, top-
circulating U.S. newspapers from 1995 – 2011? 
RQ3a: What types of organizations were mentioned in news stories most often? 
What types of individuals were quoted most often? 
RQ3b: What benefits and risks were associated with HT? How were benefits and 
risks presented (qualitative vs. quantitative; relative vs. absolute terms).  
RQ3c: How often were specific brand-name HT products mentioned in news 
stories? 
RQ3d: How often were pharmaceutical industry-related financial conflicts of 
interest mentioned in news stories?  
RQ4: How did the press releases and news stories compare in terms of content from 
1995-2011?  
RQ4a: How did press releases and news stories compare in terms of the types of 
organizations mentioned and types of individuals quoted? 
RQ4b: How did press releases and news stories compare in terms of benefits and 
risks associated with HT and risk and benefit presentation (qualitative vs. 





RQ4c: How did press releases and news stories compare in terms of mentioning 
specific brand-name HT products? 
RQ4d: How did press releases and news stories compare in terms of mentioning 
pharmaceutical industry-related financial conflicts of interest?  
RQ5: What specific organizations emerged as successful agenda builders as evidenced by 
frequent mentions of these organizations in both press releases and news stories? 
(Note: RQ6 questions were answered with qualitative procedures.) 
RQ6: How, if at all, did organizations that emerged as key agenda builders via the 
quantitative content analysis procedures (as determined by RQ5 above) collaborate with 
other organizations to build and frame the news media agenda?  
RQ6a: What are the profiles of the most successful agenda-building organizations 
in terms of organization type, mission and goals, memberships, and financial 
support? Were any potential conflicts of interest evident through archival analysis 
of these organizations’ websites or materials, such as annual reports, or financial 
disclosures available on scientific articles or elsewhere? Were these conflicts of 
interest disclosed in press releases produced by these organizations or that 
mentioned these organizations or in news stories that mentioned these 
organizations? 
RQ6b: Did these organizations tend to collaborate with other organizations to 
produce joint press releases as evidenced by the press release source and contact 
fields? Did mentions of these organizations tend to frequently be associated with 





patterns of organizational associations compare to the patterns of associations 
found in news stories that mentioned these same organizations? 
RQ6c: How did these organizations construct and define menopause, and how 
did these definitions relate to proposed treatment recommendations in press 
releases that were produced by these organizations or that mentioned these 
organizations? How did these definitions and treatment recommendations 






Chapter III: Methodology 
This study used content analysis to examine the public relations and news media 
agendas for hormone therapy (HT) from 1995-2011. The public relations agenda refers to 
the amount and content of information subsidies about HT that were provided by 
organizations to news media during this time period. The news media agenda refers to the 
amount and content of HT news coverage about HT during the same time period. These 
conceptualizations are similar to those found in the public relations and mass 
communication literatures (for e.g., see, Dearing & Rogers, 1996; Kiousis et al., 2006, 
2007; Turk, 1985, 1986; McCombs & Shaw, 1972). The public relations agenda was 
measured through press releases about HT distributed through PR Newswire and 
EurekAlert!. The news media agenda was measured via HT news stories in the 
Associated Press (AP) Newswire and four, top-circulating, U.S. newspapers: The New 
York Times, The Washington Post, Los Angeles Times, and The Wall Street Journal. The 
rationale for these source selections are discussed in the sections to follow. 
Quantitative content analysis procedures were applied to the entire dataset to 
understand how a variety of health- and medical-oriented organizations actively built and 
framed the news media agenda for HT over the study period. These procedures were used 
to examine the over-time relationship between the public relations and news media 
agendas in terms of the quantity of HT coverage and the quality of HT coverage, as 
demonstrated by co-occurrences of constructs of interest within and between the two 
agendas. Supplemental qualitative content analysis procedures were applied to a subset of 
the data to provide a more nuanced and contextual understanding of the agenda-building 





successful agenda builders. Supplemental analyses included qualitative, thematic 
analyses of press releases and news stories that contained references to the most 
frequently mentioned organizations as documented by the quantitative content analysis, 
along with additional archival/document research to understand the financial 
relationships and collaborations that may have existed between these organizations. 
Content Analysis 
 Content analysis has been used extensively in mass communication research to 
analyze a variety of texts, such as news, advertising, entertainment programming, and 
political speeches (Krippendorff, 2004; Riffe, Lacy, & Fico, 2005). It has also been used 
in agenda-setting studies to determine the salience of various objects and frames in news 
stories (see Dearing & Rogers, 1996) and agenda-building studies to examine the 
transference of object salience and frames from press releases to news coverage 
(Andsager & Smiley, 1998; Dunn, 2009; Kiousis et al., 2006; Kiousis et al, 2007; Kiousis 
et al., 2009; Miller & Riechert 2001; Tedesco, 2001). Riffe et al. (2005) described news 
content as “the consequence of a variety of other antecedent conditions or processes that 
may have led to or shaped its construction" (p. 10), such as journalists’ interaction with 
sources (Riffe et al. 2005; Shoemaker & Reese, 1996). Content analysis is well suited to 
explore these interactions, as it is a nonobtrusive or nonreactive technique often used to 
study phenomena that are not easily observed by other means (Krippendorff, 2004; Riffe 
et al., 2005). 
 Many definitions of content analysis abound in the literature. Cartwright (1953) 
described content analysis as the “objective, systematic, and quantitative description of 





quantitative analyses, but to analyses of “manifest content” only (p. 18). Manifest content 
refers to the “surface meaning of the text” and latent content refers to “the deeper layers 
of meaning embedded in the document” (Holsti, 1969, p. 12). Holsti (1969) and 
Krippendorff (2004) have advocated for more open definitions of content analysis, 
arguing that content analysis does not need to be quantitative or restricted to manifest 
content only. Holsti (1969) defined content analysis as “the application of scientific 
methods to documentary evidence” (p. 5). Krippendorff (2004) defined content analysis 
as “a research technique for making replicable and valid inferences from texts (or other 
meaningful matter) to the contexts of their use” (p. 18).  
Holsti (1969) and Krippendorff (2004) argued that using quantitative versus 
qualitative distinctions to define content analysis results in a false dichotomy. All texts 
are inherently qualitative to begin with, and what differs between quantitative and 
qualitative approaches to content are merely differences in techniques for processing, 
reducing, and summarizing data. Restricting analyses to manifest content only is also 
rejected by these scholars because the notion of manifest content implies that meaning 
resides inside a text, but texts have no “reader-independent qualities;” humans give texts 
their meaning and texts can have multiple interpretations (Krippendorff, 2004, p. 22). 
Krippendorff (2004) identified the context for the meaning of a text for a content analysis 
study as the context that the researcher brings to the text based on research objectives that 
are grounded in theoretical and empirical literature. Holsti (1969) made a similar 
argument claiming that content analyses have “generality” in terms of having “theoretical 







 A longitudinal content analysis study was conducted because longitudinal, single-
issue studies are best suited to understanding the temporal dynamics of agenda-setting 
processes (Dearing & Rogers, 1996; Trumbo, 1995), as this study attempted to do by 
examining how the agenda building and framing efforts of organizations influenced the 
news media agenda over time. Quantitative content analysis procedures were chosen as 
the primary analytic method because these procedures are well-suited to analyzing large 
amounts of content, making reproducible generalizations about the presence or absence 
of manifest content, and yielding data that can be submitted to statistical analysis to test 
for relationships between items (Holsti, 1969; Krippendorff, 2004; Riffe, Lacy, & Fico, 
2005). Quantitative analysis procedures used alone do not allow for analysis of latent 
content or important nuances or context (Berg, 2006; Holsti, 1969; Krippendorff, 2004). 
For this reason, supplemental qualitative content analysis was performed on a subset of 
the data. The combination of these procedures strengthened the study by capitalizing on 
the strengths and mitigating the weaknesses of each.   
The methodological goal was to examine press releases and news stories that were 
primarily about HT in terms of the universe of appropriate content that would provide 
answers to the research questions. Therefore, the unit of analysis was each press release 
or/and news story that was primarily about HT. What qualified as a press release or news 
story that was primarily about HT is discussed in the following sections. 
Collecting a census of content.  This study used a census as opposed to a sample. 
Studies that use a census analyze all relevant content in the defined population of interest. 





content in those sources, rather than sampling from a wider set of sources. The approach 
of using a census over time from a more limited number of sources that have been found 
to set the agenda for news coverage at the national level has been used by other scholars 
for longitudinal studies (e.g., Corbett & Mori, 1999; Hester & Gibson, 2003; Rogers, 
Dearing & Chang, 1991; Trumbo, 1995; Yanovitzky, 2002). Of key interest to this study 
was the quantity of coverage and variation in that quantity over time and the relationship 
between the public relations and news media agendas. Although some studies have 
employed sampling procedures for media outlets with constructed-week sampling 
methods, these methods introduce error to estimates of coverage variation over time and 
are fairly complex (Connolly-Ahern, Ahern, & Bortree, 2009). Various scholars have 
used censuses of news stories from major news sources, such as The New York Times, 
The Washington Post, Los Angeles Times, USA Today, and AP Newswire, to predict 
various national-level outcomes, such as cocaine use, mammography screening rates, safe 
sex behaviors, federal funding for HIV/AIDS research, and drunk driving legislation over 
time (Fan, 2002; Fan & Holway, 1994; Rogers et al., 1991; Stryker, 2003; Trumbo, 1995; 
Yanovitzky, 2002; Yanovitzky & Blitz, 2000; Yanovitzky & Stryker, 2001).  
Selecting a census of appropriate content for this study required several steps. The 
following sections detail the steps taken and the rationale behind the choices made at 
each decision point. First, I describe the sources selected to measure the public relations 
and news media agendas, and the databases used to retrieve those sources. Second, I 
detail the iterative process used to arrive at a suitable search string for use on these 
databases. Third, I describe how I operationalized what qualified as a press release or 





Source selection and retrieval. The first step in collecting a census of appropriate 
content for this study involved selecting specific press releases distribution outlets and 
news sources to measure the public relations and news media agendas and establishing 
appropriate databases to retrieve the relevant content in these outlets.  
Measuring the public relations agenda. Press releases were selected as measures 
of the public relations agenda. Although organizations produce many different types of 
information subsidies for news outlets, the press release is the most common type of 
publicity release (Lattimore et al., 2007). Press releases have been analyzed by other 
scholars to discover how political candidates, organizations, and other groups frame 
issues, and how those frames translate to the news media agenda (Andsager & Smiley 
1998; Dunn, 2009; Kiousis et al., 2006; Kiousis et al., 2007; Kiousis et al., 2009; Miller 
& Riechert, 2001; Tedesco, 2001). Press releases are distributed by the types of 
organizations relevant to this study, including pharmaceutical companies, government 
agencies, universities, medical centers and hospitals, medical professional societies and 
trade organizations, medical journal publishers, foundations, and health advocacy groups.  
Press releases were retrieved from two major wire and press release distribution 
services: PR Newswire and EurekAlert!.  Previous content analysis studies have used PR 
Newswire and/or EurekAlert! to retrieve press releases distributed by organizations 
(Andsager & Smiley, 1998; Brechman et al., 2011; Brechman et al., 2009; Kiousis et al., 
2007; Woloshin & Schwartz, 2002). PR Newswire distributes press releases to about 
1,500 major media outlets (Lattimore et al., 2007). PR Newswire was chosen instead of a 
similar service, Business Wire, because PR Newswire has a more diverse clientele than 





related to financial management and earnings. PR Newswire’s clientele includes a variety 
of organization types in the private, public, and nonprofit sectors, and distributes more 
releases in the categories of “Medicine and Health” and “Diseases and Disorders” 
(Connelly-Ahern et al. 2009, p. 865). EurekAlert! is a press release distribution service 
for science and medical news operated by the American Association for the 
Advancement of Science (AAAS). Universities, medical centers, medical journals, 
government agencies, nonprofit organizations, and corporations worldwide use 
EurekAlert! to distribute news about research developments in the areas of science, 
medicine, and technology.  
 All press releases were retrieved in full-text format through electronic, searchable 
databases. PR Newswire was searched via the LexisNexis database, and press releases 
were available for the entire study period. Press releases distributed by EurekAlert! were 
retrieved through an online archive available on the EurekAlert! website. EurekAlert! 
releases were only available back to  January 1, 1996. For this reason, it was not possible 
to include press releases distributed through EurekAlert! for the first year of the study, 
1995. This distribution service was still used, however, because its omission would have 
substantially reduced the scope of press releases available for this study in systematic 
ways. It became clear through preliminary searches on both databases that EurekAlert! is 
the distribution vehicle of choice for many academic research institutions and medical 
journals that do not release information via PR Newswire. Omitting this resource would 
have eliminated most of the press releases distributed by these types of organizations. 
Measuring the news media agenda. The news media agenda was measured via 





circulating U.S. newspapers: The New York Times, The Washington Post, Los Angeles 
Times, and The Wall Street Journal.  Newswire and newspaper stories were selected as 
measures of the news media agenda for several reasons related to: audience 
characteristics; the role these particular news sources play in setting the agenda for other 
news media outlets throughout the U.S.; content and geographical diversity; and their 
full-text accessibility via electronic, searchable databases for the entire study period, 
which is an important feature for a longitudinal study of this scope. 
News media serve as major sources of health information for consumers, health 
care providers, and policymakers (Martinson & Hindman, 2005; Pew Project for 
Excellence in Journalism, 2010; Phillips et al, 1991; Schwartz & Woloshin, 2004; 
Viswanath et al., 2008). Women have cited news and other mass media as primary 
sources of health and medical information, with some women reporting relying more on 
newspapers and magazines than medical professionals (Buick et al., 2005; MacLennan et 
al., 2004; National Council on Aging Survey, as cited in Whiteman, Cui, Flaws, 
Langenberg, & Bush, 2001; Newton et al., 1997). Newspaper readership is high for 
women age 50 and older, particularly among women with high levels of education and 
income, who also happen to be more likely to use HT (Keating, Cleary, Rossi, Zaslavsky, 
& Ayanian, 1999).  
Even if consumers and health care providers did not actually read the specific 
newspapers selected for this content analysis, it is likely that they would have been 
exposed to similar content in other newspaper, broadcast, cable, and online news outlets. 
AP Newswire and similar, top-circulating  newspapers, such as The New York Times and 





studies to assess the quantity and quality of news coverage that occurred nationally for 
specific topics or issues because of the role they play in setting the news agenda for other 
media outlets across the U.S. (Corbett & Mori, 1999; Davidson & Wallack, 2004; 
Dearing & Rogers, 1996; Fan, 2002; Fan & Holway, 1994;  Gans, 1979; Rogers et al., 
1991; Seale, 2002; Shoemaker & Reese, 1996). Even though more and more Americans 
are going online to get their news, the information that appears in traditional newspapers 
still dominates online content (Hesse et al., 2005; Kovic, Lulic., & Brumini, 2008; Pew 
Project for Excellence in Journalism, 2010; Viswanath, et al., 2006). Eighty percent of 
online news traffic is concentrated on 7% of websites, which are dominated by traditional 
media outlets like The New York Times, USA Today, The Washington Post, ABC, NBC, 
CBS, Fox, CNN, and Time magazine, which offer online versions of news distributed 
through their traditional print, broadcast, and cable outlets. News aggregators, such as 
Yahoo News or Google News, also tend to pull content from large, traditional news media 
outlets (Pew Project for Excellence in Journalism, 2010).  
The mix of news sources selected for this study also provided substantial content 
and geographical diversity based on their foci and range. AP Newswire stories are printed 
as written by newspapers throughout the U.S., particularly by smaller, daily newspapers 
(Gandy, 1982; Nelkin, 1995; Walters & Walters, 1992; Wilson et al., 2010). The New 
York Times is a leading source of health and medical news, and The Washington Post 
serves as an important source of information about issues with potential public policy 
implications (Dearing & Rogers, 1996; Rogers et al., 1991; Stryker, 2003; Yanovitzky, 
2002: Yanovitzky & Bennett, 1999; Yanovitzky & Blitz, 2000). The Wall Street Journal 





suited to capturing pharmaceutical industry-oriented news about HT. The Los Angeles 
Times enhances the geographical diversity of the study with its West Coast location and 
has a reputation for high-quality science news (Boyle, 2001; Logan, Zengjun, & Wilson, 
2000). All these news sources employ specialist health reporters for a potentially more 
diverse measure of health and medical news (Gandy, 1982; Nelkin, 1995; Walters & 
Walters, 1992; Wilson et al., 2010).  
Print newspaper stories in electronic format were selected due to the longitudinal 
scope of the study. Unlike other sources, such as magazines, newspaper stories are 
electronically searchable and retrievable in full-text format for the entire study period, 
making data gathering tasks manageable. Although it should be noted that the daily 
format of newspaper stories is quite different from magazine features, which may have 
contained different information about HT. The LexisNexis database had full-text 
coverage back to the start date of this study in 1995 and was used to retrieve news stories 
from the following three sources: AP Newswire, The New York Times, and The 
Washington Post. Because LexisNexis only indexes abstracts for The Wall Street 
Journal, and the academic version of LexisNexis did not include full-text access for all 
study years for the Los Angeles Times, the ProQuest database was used to retrieve full-
text stories from the The Wall Street Journal and the Los Angeles Times for the entire 
study period. LexisNexis and ProQuest have similar capabilities in terms of the types of 
database searches that can be performed.  
Creation of search string. Online electronic databases like LexisNexis are 
commonly used to retrieve data for content analyses (Connelly-Ahern et al., 2009; 





the external validity of a content analysis study if the search string used does not 
represent the intended universe of content. Appropriately gathering the intended universe 
of content can be thought of in terms of a trade-off between recall and precision. A search 
string with high recall will come close to retrieving the entire universe of content by 
reducing errors of omission by including the maximum number of possible search terms. 
A search string with high precision will get close to retrieving the entire universe of 
content, but will significantly reduce errors of commission by excluding unnecessary 
search terms. Recall and precision tend to have an inverse relationship; as one improves, 
the other declines (Stryker et al., 2006).  
Stryker et al. (2006) suggested that researchers should consider the trade-offs 
between recall and precision within the context of their study goals and methods. For 
example, when human coders are used, recall might be more important than precision, as 
humans are able to recognize errors of commission and filter out irrelevant material 
during the coding process. For a computer content analysis, precision might be more 
important, as a computer can only code based on programmed rules and will code 
irrelevant content as long as the rules are satisfied, regardless of important contextual 
factors. Because this study employed human coding, a search string with high recall was 
favored over precision when trade-offs needed to be made.  
The LexisNexis and ProQuest databases were used to develop the search string 
for this study due to its flexibility. LexisNexis accommodates the use of Boolean 
operators, wildcard, and truncation terms and segment-specific keyword searching on 
defined areas of text. EurekAlert! was not used for the search string development process 





without Boolean operators, wildcard, or truncation terms, and does not offer options to 
search only specific segments of documents for keywords. For these reasons the more 
flexible databases were use to develop the search string. Once the search string was 
finalized manual searches for each term were conducted to retrieve the actual study 
sample from EurekAlert! 
Initial search strings were developed to retrieve relevant press releases and news 
stories. Initial strings combined search terms that reflected all phrases that have been used 
to refer to HT historically, along with associated acronyms (e.g., hormone replacement 
therapy “HRT,” hormone therapy “HT,” estrogen replacement therapy “ERT,” estrogen 
therapy, “ET”) and all brand-name HT products (e.g., Premarin, Prempro, Premphase, 
Menest, Cenestin, Enjuvia). A list of all brand-name HT products was derived from 
searching the following two FDA databases that contain information on FDA-approved 
drugs: Drugs@FDA and the Orange Book: Approved Drug Products with Therapeutic 
Equivalence Evaluations (See Appendix B).   
All acronyms were excluded after multiple trial searches and reviews of 
corresponding results indicated that acronyms like “HRT,” “HT,” and “ET” are rarely 
used in press releases or news stories without the terms being spelled out first at least 
once. The use of these acronyms also brought in hundreds of irrelevant texts because the 
acronyms often were used as other abbreviations. For example, HT resulted in a large 
number of sports stories that listed athletes’ heights (HT) and numerous stories about 
broadcast and other programs that used ET to refer to Eastern Standard Time. I also 
discovered that the truncation term, “!”, was needed in some cases. For example, 





therapies.” For this reason, I added truncation symbols to all terms when appropriate to 
make certain to retrieve their singular and plural forms. Due to my inclusion of estrogen 
as a truncated term, “estrogen!,” terms like “estrogen replacement therap!” and “estrogen 
therap!” could be eliminated, as all these instances were retrieved with more general 
truncated term, “estrogen!”. 
The following search string was finally arrived at for entry into LexisNexis and 
ProQuest to retrieve press releases and news stories after many trial searches and 
subsequent adjustments as described above. The search string below reflects what was 
entered into Lexis Nexis; minor, non-substantive alterations were made to the syntax to 
accommodate the ProQuest database. For example, the “!” was replaced with the 
ProQuest truncation term, “*”, for the ProQuest searches.   
“hormone therap! OR hormone replacement OR estrogen! OR Activell! OR Alora 
OR Angeliq OR Cenestin OR Climara OR CombiPatch OR Delestrogen OR 
Depo-Estradiol OR Divigel OR Elestrin OR Enjuvia OR Estrace OR Estraderm 
OR Estrasorb OR Estratab OR Estratest OR Estring OR Evamist OR Femhrt OR 
Femring OR Femtrace OR Menest OR Menostar OR Ogen OR Ortho-Est OR 
Prefest OR Premarin OR Premphase OR Prempro OR Prometrium OR Provera 







The numerical results of this search string are reported below: 
Table 1 
Results of First Search String 
Database Sources Results 
LexisNexis PR Newswire 5,801 documents 




ProQuest  Wall Street Journal, Los Angeles Times 1,581 documents 
 
As can be seen in the table above, the search string yielded a large number of 
press releases and news stories. Visual inspection of the retrieved texts indicated that the 
vast majority were irrelevant to the study, as they did not exemplify press releases or 
stories that were primarily about HT. For example, the strings retrieved press releases 
primarily about corporate earnings, corporate personnel changes, and sales forecasts and 
trends in which HT was just briefly mentioned far into the body text. Many press releases 
and news stories were also retrieved that were about estrogen or hormones, but 
completely unrelated to postmenopausal HT. For example, “estrogen!” returned stories 
on the use of estrogen to treat cancerous breast cancer tumors and stories on birth control 
pills, and “hormone therap!” retrieved stories on the use of hormones to treat prostate 
cancer in men. At the same time, however, visual inspection made it clear that 
eliminating these terms would significantly reduce recall, as these terms were also used in 
documents that were primarily about HT. 
 Selecting press releases/stories primarily about HT. Due to the unmanageable 
and unsatisfactory results reported above, I repeated the search using the LexisNexis and 





string elements in the headline only. The search string below reflects what was entered 
into Lexis Nexis; minor, non-substantive alterations were made to the syntax to 
accommodate the ProQuest database. For example, the “!” was replaced with the 
ProQuest truncation term, “*”, and “HEADLINE” was replaced with the ProQuest 
function “ti” (for title). 
“HEADLINE(hormone therap!) OR HEADLINE(hormone replacement) OR 
HEADLINE(estrogen!) OR HEADLINE(Activell!) OR HEADLINE(Alora) OR 
HEADLINE(Angeliq) OR HEADLINE(Cenestin) OR HEADLINE(Climara) OR 
HEADLINE(CombiPatch) OR HEADLINE(Delestrogen) OR HEADLINE(Depo-
Estradiol) OR HEADLINE(Divigel) OR HEADLINE(Elestrin) OR 
HEADLINE(Enjuvia) OR HEADLINE(Estrace) OR HEADLINE(Estraderm) OR 
HEADLINE(Estrasorb) OR HEADLINE(Estratab) OR HEADLINE(Estratest) 
OR HEADLINE(Estring) OR HEADLINE(Evamist) OR HEADLINE(Femhrt) 
OR HEADLINE(Femring) OR HEADLINE(Femtrace) OR HEADLINE(Menest) 
OR HEADLINE(Menostar) OR HEADLINE(Ogen) OR HEADLINE(Ortho-Est) 
OR HEADLINE(Prefest) OR HEADLINE(Premarin) OR 
HEADLINE(Premphase) OR HEADLINE(Prempro) OR 








The numerical results of this search string are reported below: 
Table 2 
Results of Second Search String 
Database Sources Results 
Lexis Nexis PR Newswire 728 documents 
Lexis Nexis AP Newswire, New York Times, 
Washington Post 
446 documents 
ProQuest Wall Street Journal, Los Angeles Times 208 documents 
 
Visual inspection of the results indicated that the headline/title functions did a 
better job of eliminating irrelevant documents as compared to the full text search results 
reported above. Using the headline/title functions was also a better theoretical match to 
agenda building theory because it ensured that the main focus of the article was about 
HT. Still, even when using the headline/title function, many irrelevant articles were 
retrieved that included the search terms in the headline, but were not referring to 
postmenopausal HT, but other therapeutic uses of hormones and estrogen. It was unclear 
that removing terms was a viable option because removal would result in loss of too 
many relevant texts. Because human rather than computer coding for this study was used, 
I decided it would be best to further refine the universe of content through manual coding 
procedures instead of trying to add proximity terms related to menopause. This decision 
was made to avoid unnecessary reductions in recall because the total number of 
documents retrieved with the use of the headline/title functions remained manageable for 
manual coding.  
 Once search strategy and terms were finalized, the relevant press releases were 





Boolean operators or proximity terms, searches needed to be conducted separately for 
each individual term in the search string above. All releases retrieved then needed to be 
manually reviewed to eliminate duplicates. This process resulted in a total of 334 
additional, unique press releases from EurekAlert! for the study.  
After all database searches were complete, a total of 1,062 press releases and 674 
news stories met the headline criteria for the study. It was also necessary to further code 
all press releases and news stories that had any of the search terms in the headline to 
make sure the terms indeed referred to postmenopausal hormone therapy. The coding 
instrument was used to accomplish this as described below. Press releases and news 
stories that did not meet this criterion as outlined in the coding protocol were filtered out 
of the study, and no more coding was performed on these documents.  
In addition, coding categories were created in the press release and news story 
codebooks to filter out documents retrieved that were not primarily about HT. The coding 
category in the press release instrument filtered out press releases about organizational 
news (e.g., corporate mergers, patent disputes, personnel changes, etc.), market 
predictions (e.g., reports prepared by industry forecasting/market research firms) 
entertainment products (e.g., books, films, television, theater, etc.), or studies conducted 
with animals only. The coding category in the news story instrument also filtered out 
stories with similar content, along with editorials, letters to the editor, and Q&A-style 
health advice columns. 
Quantitative content analysis procedures. The following procedures were 
followed to extract and analyze quantitative data to answer research questions RQ1 





of the intercoder reliability analyses were conducted with the Statistical Package for the 
Social Sciences (SPSS) version 20, a statistical software and data analytics package.  
Intercoder reliability analyses were calculated with the Program for Reliability 
Assessment with Multiple Coders, often known as PRAM, by Skymeg Software. 
Codebook construction. The purpose of a codebook is to operationalize the 
theoretical context of a study into “analytical constructs” (Krippendorff, 2004, p. 3). Each 
abstract construct is translated to a concrete measure (Riffe et al., 2005). Each measure 
must be derived from a single classification principle and be constructed as mutually 
exclusive and exhaustive (Neuendorf, 2002; Riffe et al., 2005). Mutually exclusive means 
that only one code is appropriate for the measured construct. If multiple codes are 
possible, they should all be constructed as separate measures. Exhaustive means that 
there must be a viable code for every measured construct. This is often accomplished by 
including “other” or “unable to determine” categories (Neuendorf, 2002, p. 118).    
The codebooks for press releases and news stories consisted of a coding protocol 
with explicit decision rules for identifying the proper coding categories for all measures 
and a coding sheet that coders used to record data (Riffe et al., 2005) (see Appendices C 
& D). A separate codebook, each with its own coding protocol and codesheet, was 
created for press releases and news stories. Major constructs coded for included: press 
release or publication date and source; variables to ascertain that the press release or news 
story was primarily about postmenopausal HT; type of organization that produced 
release; HT brand name mentions; HT benefits and risks mentioned; whether HT risks or 
benefits were quantified or not and in relative or absolute terms; types of organizations 





news story; and whether any individual-level or organizational-level conflicts of interest 
were disclosed.  
The press release and news story were the units of analysis for all coding. 
Although this was necessary due to the volume of texts analyzed in this study, it did not 
allow for content variables to be associated with specific sources cited within the body of 
the texts. For example, if a press release or news story contained a claim that HT 
prevented heart disease, the press release or news story was coded as mentioning this 
benefit. The coding scheme used was not sensitive enough to detect whether a claim was 
attributed to a specific organization or individual cited within the text of the press release 
or news story.  
To develop the codebook, I drew on the theoretical and empirical literature to 
construct coding categories to answer the research questions. Detailed information, such 
as the list of brand-name HT products and some of the potential risks and benefits of HT 
were derived from searching Drugs@FDA and the Orange Book: Approved Drug 
Products with Therapeutic Equivalence Evaluations, two FDA databases which 
contained listings of FDA-approved drugs along with their product labels (USDHHS, 
FDA, 2011b; USDHHS FDA, 2011c). In addition, I carefully reviewed press releases and 
news stories about HT and other prescription drugs outside the sources that I used for my 
study census to refine the draft codebooks and coding sheets. Using material outside of 
my study boundaries retained the integrity of the data for analysis.  
Coding procedures and training. I recruited two undergraduate students in 
addition to myself, resulting in three total coders, to assess the reliability of the coding 





one studied Communications and the other studied Computer Security & Information 
Assurance. Both coders conducted the work during their summer breaks and were 
compensated for their time. I used relevant content outside the study census parameters 
for coder training and practice (Riffe et al., 2005), referred to as pilot coding (Neuendorf, 
2002). The student coders were thoroughly instructed in use of the codebook and 
categories, but remained blind to the specific study research questions to reduce the 
potential for coder bias (Neuendorf, 2002).  During pilot coding sessions, coders were 
provided with the same sample of press releases and articles to code individually without 
discussion. After the coding was complete, disagreements were discussed and the 
codebook’s protocol of instructions and decision rules and the coding sheets were 
updated as necessary. Several iterations of this process were required to arrive at final 
codebooks for intercoder reliability testing. 
Establishing intercoder reliability. Theoretically, establishing reliability between 
coders’ use of coding categories makes quantitative content analysis procedures 
reproducible (Krippendorff, 2004; Neuendorf, 2002; Riffe et al., 2005). Neuendorf more 
realistically described obtaining reliability as a way of ensuring “intersubjective 
agreement” between coders (p. 141), rather than objectivity as past scholars have claimed 
(Berelson, 1952; Cartwright, 1953). Reliability is a consistency measure that measures 
the extent to which different coders apply the same classification rules and arrive at the 
same category decisions for the same content. Reliability is a necessary, but insufficient, 
condition for validity. If reliability is achieved it does not mean the categories accurately 
operationalize the abstract construct intended; only that coders assigned categories 





After pilot coding tests indicated high levels of agreement, I drew a random 
sample of 10% of the total 1,062 press releases and 674 news stories that comprised the 
actual, final study data for reliability testing. This resulted in 106 press releases and 65 
news stories for the intercoder reliability test. Sub-samples of 10% to 20% of the data to 
be coded for reliability analyses are typical for content analysis studies (Riffe et al., 
1995). Reliability analyses were conducted on all measured variables in the codebook, 
including the criteria used to determine the relevance of each press release or news story 
for full coding and analysis. 
A variety of reliability coefficients exist, ranging from simple percent agreement 
between coders (Holsti, 1969) to more rigorous formulas that account for chance 
agreement (see Krippendorff, 2004; Neuendorf, 2002, for reviews). Fleiss’ kappa 
coefficient for multiple coders was used to establish reliability because it is a 
conservative measure that accounts for chance agreement; is appropriate for nominal-
level data; and accommodates more than two coders (Fleiss, 1971; Neuendorf, 2002). 
Fleiss’ kappa coefficient is an adaption of Cohen’s kappa for two coders, the most widely 
used reliability statistic at this time (Neuendorf, 2012). The generalized formula for 
Fleiss’ kappa coefficient (Fleiss, 1971) appears below: 
  
 ̅   ̅ 
   ̅ 
 
Where     ̅ measures the amount possible, non-chance agreement and 
  ̅     ̅ measures the amount of non-chance agreement that was actually 
obtained.  
The kappa coefficient ranges from .00 when coders agree by chance to 1.00 when coders 





no exact threshold for what constitutes acceptable reliability exists, many scholars 
generally agree that kappa coefficients of values of .70 or more indicate strong agreement 
with values of .80 or more indicating excellent agreement (see Neuendorf, 2002).  For 
this reason, a kappa of at least .70 was set as the necessary threshold for a variable to be 
included in the study. 
The free, academic version of PRAM (version 0.4.7), a Program for Reliability 
Assessment with Multiple Coders, by Skymeg Software, Inc., was used to calculate the 
Fleiss kappa coefficients. PRAM (version 0.4.7) was used because it is one of the few 
programs that runs the Fleiss adaptation of Cohen’s kappa for multiple coders, and the 
results have been statistically validated by Dr. Kimberly Neuendorf and her research 
team at Cleveland State University (Neuendorf, 2012).  
When conducting the intercoder reliability tests, data for variables that were 
exactly the same in news stories and press releases were combined. All codebook 
variables reached the predetermined threshold of .70 or higher with the exception of 
variables for which the kappa coefficient was indeterminate because the variable never 
took on the value of being present in the sample. When a variable has only one value (in 
these cases all zeros for “absent”), a reliability coefficient cannot be determined. It can be 
argued, however, that all coders reliably agreed that the construct was never present. The 
40 variables for which the coefficient was indeterminate were kept in the study to see if 
they emerged in the full study dataset. The most common instances of indeterminate 
coefficients occurred for less well-known brand name HT products, many of which also 
never appeared in the full study data. Several variables that measured whether a risk or 





reports the results of the intercoder reliability tests for all study variables; variables for 
which a coefficient could not be determined are noted. 
Coding and data entry procedures. After the reliability of the coding instruments 
was established, I coded the full dataset myself. This process took approximately six 
months. Due to the labor intensive nature of the work, I hired ORI, a market research 
firm located in Herndon, Virginia, to enter all the data from the coding sheets. I provided 
ORI with the data file structures, and I periodically mailed them sets of completed 
codesheets for data entry. When entry was complete, all paper coding sheets were 
returned to me along with two electronic data files, one for the press releases and one for 
the news stories. To check on the quality of the data entry, I randomly selected 10% of 
the cases in the press release data file and compared them with the paper coding sheets; I 
did the same for the news story data file. No errors were found beyond occasional minor 
spelling or typographical errors for fields in which verbatim text was entered. Before 
proceeding to data analysis, I also ran many checks to ensure the internal consistency of 
the data through cross tabulation procedures. For example, I ran checks to make sure that 
if an organization was written in a text field, at least one organization type was also 
marked as present, or if a risk or benefit was marked as quantified, that risk or benefit 
was also marked as first appearing in the text. No errors were found.   
Data analysis. The following data analysis procedures were used to answer 
research questions addressed through the quantitative content analysis.   
Relationships between quantities of press releases and news stories. The first set 
of research questions (RQ1 series of sub-questions) concerned the relationship between 





these questions, the number of press releases and newspaper articles were calculated 
separately and displayed quarterly from 1995 to 2011, resulting in 68 data points for each 
of the two sequences (16 years * 4 quarters-per-year). Both sequences were presented 
visually on a line graph to observe concomitant variation between them. In addition, the 
Pearson product-moment correlation coefficient was used to test for the magnitude and 
statistical significance of the correlation over time between the two sequences. Because 
the relationship between the public relations agenda and news media agenda was 
conceptualized in this study to be a reciprocal back-and-forth interaction between and 
among organizations and the news media, and the public relations agenda likely 
influences the news media agenda fairly immediately at very small time lags, making 
computation of useful lags unrealistic, no attempt was made to examine cross-lagged 
correlations between the series to determine the direction of effects or to employ any 
other time series analysis procedures.  
The line graph was then visually inspected for meaningful peaks in public 
relations activities and news coverage. Previous scholars that have conducted 
longitudinal studies of news coverage have found that the results are more insightful 
when data analyses are conducted on the entire time series and on “unique sub-sets of the 
series” (Trumbo 1995, p. 8; Rogers et al., 1991). For this reason, the dates of key 
historical events, such as the WHI findings, other important study findings, and FDA 
approvals and labeling actions were superimposed on the line graph. For example, 
because quantities of press release and news coverage differed significantly between the 
pre- and post-WHI time period, and the WHI study findings sparked a major public 





presentation were conducted for the overall time period and broken out by the pre- and 
post-WHI time periods.  
In addition to superimposing key dates on the line graph, the line graph was 
accompanied by a brief, historical narrative of the evolution of HT over the study period 
to provide important context. Trumbo (1995) argued that, “An empirical analysis of the 
agenda-setting process should be accompanied by a qualitatively-based historical 
consideration of the issue under study” to provide an “important contextual framework 
for the analysis” (p. 8).  This historical narrative was written after all quantitative coding 
for the study was conducted, as the process of engaging with and coding all texts across 
the study time period lent considerable insight to the narrative. Particular attention was 
paid to describing any major debates or issues that might have driven organizations’ 
public relations activities and subsequent news coverage during peak periods of press 
release and news coverage activity.  
Describing patterns within each series. The next sections of the results chapter 
(RQ2 and RQ3) describe the content of press releases and news stories, first treated 
separately as two data series. While some research questions posed of each series were 
descriptive in nature, others looked to discover patterns between variables. For example, 
analyses were conducted to determine if the type of organization that produced a press 
release was associated with the quantity and quality of benefit and risk information 
provided in that release.  
Two of the most commonly used techniques for content analyses are simple 
tabulations and cross-tabulations (Krippendorff, 2004). Tabulated data can be used to 





represented as relative frequencies in relation to some whole, as in reporting the 
percentage of a category that occurred within some meaningful total. Cross-tabulations 
can be used to examine co-occurrences between coding categories within a body of text 
or across multiple bodies of texts. In addition to reporting frequencies and percentages of 
co-occurrences, these co-occurrences can be statistically tested to see if the observed 
patterns of co-occurrences in the columns and rows of a cross-tabulation table differ from 
the co-occurrences expected by chance based on the table’s marginal frequencies.  
A tabulation and cross-tabulation strategy was used for most analyses. Because 
codebook variables were all measured at the nominal level, the chi-square statistic was 
used to test for statistical significance for the majority of statistical analyses. Tabulation-
only analyses that reported data for a single variable employed the chi-square goodness-
of-fit test to test whether the distributions across categories of a variable were 
significantly different from distributions expected under the null hypothesis, otherwise 
known as chance differences. In all cases, the chi-square goodness-of-fit test was 
conducted using an alpha of .05. Before conducting each analysis, I examined the data to 
make sure the assumption that each cell had an expected value of five or more cases was 
met (Agresti, 2007; Lomax & Hahs-Vaughn, 2012). In just a few cases this assumption 
was not met. In these cases, I omitted categories too small for testing, collapsed the data 
when possible to create larger categories, or flagged relevant results as possibly unstable 
and to be interpreted with caution in the results section.  
While a significant chi-square goodness-of-fit test indicates a statistically 
significant pattern of results, it does not indicate exactly which categories were 





these cases, follow-up tests were conducted by examining the standardized residuals as 
recommended by Agresti (2007) and Lomax and Hahs-Vaughn (2012) to see which 
categories contributed significantly to the chi-square statistic as evidenced by 
standardized residuals greater than an absolute value of two. 
The chi-square test of independence was used to test for associations between two 
variables (e.g., type of organization that produced a press release and whether or not heart 
disease was identified as a potential risk of HT). While the chi-square test of 
independence can be usefully interpreted with two variables or factors, interpretation 
becomes more difficult for larger tables (Krippendorff, 2004). When larger tables were 
tested, post-hoc z-tests for column percentages using the Bonferroni adjustment method 
were used to examine each pair of percentages to see exactly which percentages were 
statistically different from one another. The Bonferroni adjustment method holds alpha at 
.05 for the entire group of comparisons by splitting alpha up equally among each pair-
wise comparison to avoid inappropriate inflation of Type I error (Lomax & Hahs-
Vaughn, 2012). 
In a few cases, it was possible to transform the original nominal-level data to 
continuous measures to facilitate analyses of group means. For example, the data on 
whether each coded benefit or risk was absent or not in a press release or news story was 
summed to arrive at a total number of benefits and risks identified in each document. This 
facilitated analyses such as comparisons for the average number of benefits and risks 
prior to and after the first WHI announcement. In cases such as this, when only two group 





homogeneity of variance was examined to determine if the t-test for equal or unequal 
variances should be used (Lomax & Hahs-Vaughn, 2012). 
Sometimes more than two-group analyses were called for. For example, some 
analyses examined the average number of benefits and risks contained in press releases 
by the type of organization that produced the release. When more than two group means 
were compared, one-way analysis of variance techniques (ANOVA) were employed. 
When the omnibus ANOVA test was significant, follow-up post-hoc, t-tests were used to 
determine which specific group means differed from one another while holding Type I 
error at .05 (Lomax, 2001). Prior to conducting post-hoc tests, Levene’s test for 
homogeneity of variance was examined. Based on those results, appropriate formulas 
were run that assumed equal or unequal variances. When variances were equal, the 
Tukey-Kramer multiple comparison procedure was selected, which adjusts for unequal ns  
per group and assumes equal variances. When variances were unequal, the Games-
Howell post-hoc multiple comparison test was used, which also adjusts for unequal ns but 
assumes unequal variances (Lomax, 2001). 
Content comparisons between PR and news media agendas. Remaining sub-
questions for RQ4 asked about how press releases and news stories differed from one 
another in terms of content. For these questions, chi-square tests of independence were 
used to test for statistically significant differences between nominal-level variables. T-
tests were used for comparisons of group means between the two series. The same 
procedures identified earlier to meet the statistical assumptions of both tests (minimum 





 Identifying successful agenda-building organizations. RQ5 asked what 
organizations emerged as successful agenda builders, as evidenced by frequent mentions 
in press releases and news stories. Coding instructions required that all specific 
organization names that appeared in press releases and news stories be keyed to a 
database. Frequencies were run on these database fields to identify organizations that 
were most frequently mentioned in both data series.  
Qualitative content analysis procedures. The following procedures were 
followed to collect and analyze qualitative data from the relevant texts to answer research 
questions RQ6 and its associated sub-questions. The supplemental qualitative content 
analysis procedures in this section were applied only to press releases and news articles 
that were produced by or that mentioned specific organizations that emerged as key 
agenda builders, as determined by the quantitative analysis described in the section 
immediately above this one on identifying key agenda builders. Therefore, all qualitative 
content analyses were conducted after the quantitative content analyses were complete. 
Qualitative content analysis was chosen for these research questions because the 
types of frames of interest were more likely to involve latent content and less likely to be 
amenable to strict coding decision rules that might lead to invalid interpretations. 
Focusing on a key set of organizations for these analyses provided me with a manageable 
amount of data to thoroughly analyze in an in-depth, qualitative manner. Qualitative data 
analyses also provided a more detailed and nuanced account of collaborations between 






While many qualitative approaches to data extraction and analysis exist, I used 
the approach outlined by Miles and Huberman (1994), which involves working iteratively 
and systematically between three processes: “data reduction,” “data display,” and 
“conclusion drawing and verification” (pp. 10-11). Data reduction was achieved by 
isolating the press releases and news coverage pertinent to the specific organizations of 
interest by examining the database fields that organization names were entered to. I then 
made a list of all the unique press release and news story identification numbers. The 
identification number were then used to extract the documents of interest into two sets of 
texts, one for press releases and one for news stories, that contained only the relevant 
documents. The files were then examined and coded as necessary for recurring themes 
related to the research questions and to make contrasts and comparisons between 
organizations and between press releases and news stories.  
Thematic analyses of frames and collaborations. Relevant press releases and 
news stories were coded for themes relevant to the research questions. Themes of interest 
related to three major conceptual areas: 1) overall story frames or angles; 2) constructions 
and definitions of menopause and HT, and how those definitions related to proposed 
treatment recommendations; and 3) potential collaborations between organizations. 
Coded themes were displayed in data display matrices using Excel. Data displays 
enhance the validity of qualitative research by facilitating processing and interpretation of 
large amounts of text in an attempt to guard against researcher biases and false 
assumptions (Miles & Huberman, 1994). During this process I also remained open to 
discovering important themes, not specifically related to the predetermined, specific 





During the conclusion drawing and verification process, themes were collapsed, 
expanded, and reorganized as necessary to best describe meaningful patterns found in the 
data. Actively searching for variant cases was employed to reduce the temptation to over-
categorize results. These safeguards are important because the reliability and validity of 
qualitative research rests primarily on the skills of the researcher (Miles & Huberman, 
1994). Major themes were reported through narrative text, supported by example 
quotations or passages of text for evidence of those themes. 
Background profiles of successful agenda-building organizations. This study 
also employed some supplemental archival research as necessary to shed further light on 
the organizations that emerged as successful agenda builders over the time period studied 
(as indicated in RQ6a). Specifically, I explored organizations’ websites and annual 
reports to describe organizations’ mission and goals, memberships, and sources of 
financial support. Original scientific studies that were the subject of substantial publicity 
by these organizations were also reviewed for any financial conflict of interest disclosure 
statements. This allowed me to compare how frequently news releases and news articles 
provided conflict of interest information that was readily available.  
Although this procedure was able to provide some preliminary insights about the 
extent of conflicts of interest between study investigators and research sponsors, it likely 
yielded conservative estimates in light of the literature on ghostwriting and lack of 
disclosure in scientific journal articles. Fugh-Berman’s (2010) article published in PLOS 
Medicine, included a table of 28 scientific articles for which substantial evidence of 
Wyeth publication planning and ghostwriting occurred in collaboration with the 





supplemental information allowed me to combine contextual background profiles of the 
organizations with the results of the qualitative analyses on how they attempted to build 






Chapter IV: Results 
This chapter presents the data that answer the research questions. The first section 
of the chapter presents the results to research question one (RQ1) and its associated sub-
questions, which examined the over-time relationship between press releases and news 
stories. The second section presents the results of research questions that were posed 
about the content of press releases and news stories and answered with quantitative 
procedures (RQ2 – RQ5). The third section presents the results of research questions that 
were posed about the content of a sub-set of press releases and news stories that were 
answered with qualitative procedures (RQ6). The six major organizing research questions 
for the study, along with their respective sub-questions, are used as headings to organize 
the results in each section. This results chapter is based on a total of 675 press releases 
and 429 news stories. 
Over Time Relationship Between Press Releases and News Stories  
This section presents the results to research question one: What was the 
relationship between the quantity of press releases about hormone therapy (HT) 
distributed by organizations via PR Newswire and EurekAlert! and the quantity of news 
stories about HT in AP Newswire and four, top-circulating U.S. newspapers from 1995 – 
2011? 
RQ1a:  How many press releases about HT appeared between 1995-2011?  
A total of 1,062 press releases were originally retrieved from PR Newswire and 
EurekAlert! via the search terms for the entire study period. All the releases were coded 
using the coding instrument for press releases (see Appendix C). A total of 387 press 





instrument because they did not meet the study criteria. More specifically, 172 releases 
were removed via variable PV4 because the search terms in the headline referred to 
something other than menopausal hormone therapy (for e.g., hormone therapy for 
prostate cancer or breast cancer treatment), and 215 releases were removed via variable 
PV5 because they were primarily about an organization rather than HT, such as 
announcements about personnel changes or new licensing or marketing agreements 
between firms (n=107); market forecasts by market research firms; publicity for a book, 
film, movie, theater or other entertainment product (n=57), or reports of research studies 
conducted with animals only (n=28).  
This left a total number of 675 press releases that were fully analyzed for the 
study; 392 of these press releases were retrieved from PR Newswire, and 283 were 
retrieved from EurekAlert!. All analyses to follow in this results section are based on 
these 675 releases.  
RQ1b: How many news stories about HT appeared between 1995-2011? 
A total of 654 news stories were originally retrieved from AP Newswire, The New 
York Times, The Washington Post, The Wall Street Journal, and the Los Angeles Times 
via the search terms for the entire study period. All the news stories were coded using the 
coding instrument for news stories (see Appendix D). A total of 225 news stories were 
removed from the study early via variables NV4 or NV5 on the coding instrument 
because they did not meet the study criteria. More specifically, 171 news stories coded 
out of the study on variable NV4 because the search terms in the headline were referring 
to something other than menopausal hormone therapy, and 54 coded out on the next 





(n=9), letters to the editor/editorials (n=35), entertainment product reviews (n=3), Q&A 
style health advice columns (n=4), or stories about research studies conducted with 
animals only (n=3).  
This left a total number of 429 news stories that were fully analyzed for the study. 
In terms of sources, 176 of the news stories were from AP Newswire; 85 were from The 
New York Times, 78 were from the Los Angeles Times, 46 were from The Washington 
Post, and 44 were from The Wall Street Journal. All analyses to follow in this results 
section are based on these 429 news stories.  
RQ1c: Was the amount of press releases positively correlated with the amount of 
newspaper stories over time? 
Before the numbers of press releases and news stories were correlated with one 
another, a correlation matrix was produced to see how the quantity of press releases 
correlated with the quantity of news stories in each individual news source and to 
examine the intercorrelations between each news source. As can be seen in Table 3, the 
number of press releases was positively correlated with all news sources except, The 
Washington Post. Although the correlation between the number of press releases and 
news stories in The Washington Post was in the right direction in terms of being positive, 
the coefficient was not statistically significant. The Washington Post was positively and 
significantly correlated with all other news sources with the exception of The Wall Street 
Journal. The lack of positive correlation may have been due to the different foci of these 
newspapers. The Washington Post tends to report more on stories with significant public 
policy-oriented implications, and the Wall Street Journal focuses more on financial news. 






To determine if the total number of press releases was positively correlated with 
the total number of newspaper stories over time, the number of press releases and news 
stories were totaled separately on a quarterly basis in three-month increments from 1995 
to 2011, resulting in 68 data points for each of the two sequences (17 years * 4 quarters 
per year). A Pearson correlation coefficient indicated a moderately strong, positive, and 
statistically significant relationship between the press releases and news stories over time,  
r = .55, p<.001.  
RQ1d. What overall story frames or themes were associated with peaks in press 
release and news story activity?   
After a statistically significant correlation was obtained between press releases 
and news stories, the two sequences were plotted together on an area graph to observe 
patterns of concomitant variation between them (see Figure 4). Individual press releases 
and news stories were then reviewed within peak periods of press release and/or news 
activity to arrive at a descriptive set of themes about major issues and events that drove 











































































*p<.05, two-tailed; **p<.01 two-tailed.





superimposed on the graph. Together the descriptive themes and key dates provide 
historical context to better understand the study’s more detailed findings. 
Figure 4 is intended to help readers visualize some of the major turning points in 
the history of HT. The sheer volume of research studies published over the study time 
period, the shifting and conflicting nature of the findings, and the responses of 
organizations to those findings, makes anywhere near a full accounting of all major 
events impossible. Although far from exhaustive, this visual aid provides examples of the 
types of activities that occurred within different time periods. 
 Data showed consistently more press releases than news stories over the entire 
time period (see Figure 4). The average number of press releases per quarter was 9.9. The 
average number of news stories per quarter was 6.3. A visual inspection of the over-time 
graph of the quantities of press releases and news stories over the study time period 
supported a highly interactive agenda-building process. The graph demonstrated a 
continual, up-and-down pattern of spikes and valleys for press releases and news stories; 
sometimes the two sequences appeared to rise together and other times one sequence 
peaked before the other and vice versa.  
Examination of press releases and news stories in terms of their major foci, 
particularly in terms of peak periods, revealed more similarities than differences in terms 
of the type of content that drove activity on the part of health and medical organizations 
and news media. The next section describes the following major content themes seen 
across the press releases and/or news stories: research findings, regulatory actions and 





Research findings. New research findings about HT were the primary driver of 
peaks in activity for both press releases and news stories.  The vast majority of research 
studies related to the potential benefits and risks of HT in the areas of heart disease, 
breast cancer, and osteoporosis, and to a lesser extent, Alzheimer’s disease, dementia, 
and stroke. The press releases and news stories that focused on research findings and 
some of the corresponding studies published in medical and scientific journals are best 
characterized within four time periods. These time periods are noted in gray boxes in 
Figure 4 and described below.  
1995 to 1997: Disease-prevention benefits outweigh risks. From early 1995 
through late 1997, studies were published suggesting that HT had multiple disease-
prevention benefits, including prevention of heart disease, osteoporosis, Alzheimer’s 
disease, and dementia. Studies focused on HT risks centered around the potential breast 
cancer risk associated with HT use, a topic which continued to generated substantial 
controversy due to conflicting patterns of findings that began well before 1995 (Brown, 
1995). Other studies attempted to place the potential breast cancer risk of HT in the 
context of its supposed disease-prevention benefits, and concluded that the heart disease-
prevention benefits of HT generally outweighed any increased risk of breast cancer.   
A few large, highly publicized studies serve as examples of the disease 
prevention-related evidence that began to emerge during this time period. Results of the 
Postmenopausal Estrogen/Progestins Interventions (PEPI), a large, randomized clinical 
trial were reported in the Journal of the American Medical Association (JAMA) on 
January 18, 1995, and November 6, 1996, indicating that estrogen-only and estrogen-






















































































































































Figure 4. Number of press releases and news stories by quarter.  
PR Agenda News Agenda
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well-established risk factor for heart disease, and increased bone mineral density of the 
spine and hip (Writing Group for the PEPI Trial, 1995, 1996). On August 15, 1996, The 
New England Journal of Medicine (NEJM) reported data from the Nurse's Health Study, 
a longitudinal, observational study of female nurses, which concluded that estrogen-only 
and estrogen-plus-progestin were equally effective at reducing heart disease (Grodstein et 
al., 1996). Another longitudinal, observational study, the Baltimore Longitudinal Study 
of Aging (BLSA), published in the June 1997 issue of Neurology, found that HT use was 
associated with reduced risk of Alzheimer’s disease (Kawas et al., 1997). 
Breast cancer risk-related studies also continued to attract attention during this 
period of time. On June 15, 1995, the NEJM published a study based on data from the 
Nurse's Health Study, indicating that use of estrogen-only and estrogen-plus-progestin for 
more than five years was associated with an increased risk of breast cancer (Colditz et al., 
1995). A decision analysis model based on previous literature published in JAMA, 
however, on April, 4, 1997, concluded that HT’s ability to increase life expectancy due to 
decreases in cardiovascular disease outweighed the risk of breast cancer for “nearly all 
women” and recommended “broader use of hormone replacement therapy” (Col et al., 
1997, p. 1140). Similarly, more data from The Nurses’ Health study published in NEJM 
on June 19, 1997, concluded that HT users had lower mortality rates than non-users due 
to lower rates of cardiovascular disease, and that these mortality reduction benefits did 
not disappear due to increased breast cancer deaths until ten or more continuous years of 






1998 to mid-2002: Conflicting information about benefits and risks increases. 
From early 1998 to mid-2002, conflicting information about the benefits and risks 
of HT continued to increase. Studies began to unexpectedly show that the positive impact 
HT had on heart disease risk factors and biomarkers, like cholesterol and lipoprotein(a), 
did not translate into actual heart disease outcomes, and in addition to breast cancer, HT 
increased risks for blood clots and gallbladder disease. Another study also showed no 
positive effect of HT on stroke risk. 
Although the early months of 1998 continued to demonstrate potential benefits of 
HT, the tide began to turn by the middle of the year. On April 17, 1998, additional results 
from the (PEPI) trial were reported in Circulation, demonstrating that estrogen-only and 
estrogen-plus-progestin reduced plasma Lp(a) concentrations, an important biomarker for 
increased coronary heart disease risk. The results of the Heart Estrogen Replacement 
Study (HERS I), a randomized, clinical trial to assess the relationship between estrogen-
plus-progestin use and actual heart disease outcomes, however, brought disappointing 
results. Published in JAMA on August 19, 1998, HERS I reported that after 4.1 years of 
follow-up, despite improvements in lipid (cholesterol) profiles, estrogen-plus-progestin 
did not decrease heart attacks for women with existing heart disease and increased the 
risk of blood clots and gallbladder disease (Hulley et al., 1998).  
More negative findings emerged in the following years. For example, the 
Estrogen Replacement and Atherosclerosis (ERA) trial published in NEJM on August, 
24, 2000, found that despite improvements in lipid profiles, women with coronary disease 
given estrogen-only or estrogen-plus-progestin showed no reduction in the progression of 





I, published in Circulation on February 6, 2001, reported that estrogen plus progestin had 
no significant effect on stroke risk as hoped for postmenopausal women with heart 
disease (Simon et al., 2001). Finally, the results from the HERS II study, which followed 
HERS I participants for an additional 2.7 years, were published in JAMA on July 3, 2002, 
concluding that study participants still experienced no reduction in heart disease events 
and continued to experience increased risks for blood clots and gallbladder disease 
(Grady, 2002, p. 49). 
Meanwhile, in addition to the blood clot and gallbladder disease risks being 
associated with HT, studies continued to demonstrate breast cancer risk. For example, on 
January 26, 2000, data from the national, longitudinal Breast Cancer Detection 
Demonstration Project were reported in JAMA, indicating that estrogen-plus-progestin 
increased breast cancer risk more than estrogen alone, and breast cancer risk increased 
with duration of use for both types of therapy (Schairer, 2000).  
July 2002 – 2004: The WHI Studies: HT risks outweigh benefits. The results of 
the National Institute of Health’s (NIH) Women’s Health Initiative (WHI) trial marked a 
major turning point in the history of HT by changing the perception that the benefits of 
HT outweighed its risks to the perception that the risks of HT outweighed its benefits. 
The WHI, was a large, randomized clinical trial, which involved 161,808 healthy, 
menopausal women between the ages of 50 to 79 across the nation to test the effects of 
estrogen-only and estrogen-plus-progestin hormone therapy, low-fat diet, calcium, and 
vitamin D supplements on the prevention of heart disease, bone fractures, breast and 
colorectal cancer. The trial began enrolling participants in 1993 and was not expected to 





Women’s Health Initiative Investigators, 2002). Much to the surprise of scientists, health 
care professionals, and the public, the estrogen-plus-progestin and the estrogen-only arms 
of the trial were stopped prematurely when it became clear that the risks to participants 
taking HT outweighed any potential benefits. 
The NIH held a press conference on July 9, 2002, to announce that the WHI 
estrogen-plus-progestin trial arm was being stopped. Figure 4 shows that press release 
and news story activity reached its highest point during the time immediately surrounding 
this announcement. In addition to the announcement, study investigators published their 
findings in the July 17, 2002, issue of JAMA. Results demonstrated that after 5.2 years of 
follow-up, estrogen-plus-progestin users had increased risks for invasive breast cancer, 
coronary heart disease, stroke, and pulmonary embolism, and decreased risks for hip and 
other bone fractures and colorectal cancer. The trial was stopped because the WHI data 
and safety monitoring board determined that the overall health risks for participants 
exceeded any benefits. Investigators concluded in the JAMA article that estrogen-plus-
progestin therapy “should not be initiated or continued for primary prevention of CHD 
[coronary heart disease]” (Writing Group for the Women’s Health Initiative, 2002, p. 
321).  
On March 2, 2004, the NIH held another press conference to announce that the 
estrogen-only arm of the WHI trial was also being stopped. This date is also indicated in 
Figure 4. Again, in addition to the announcement, study results were published in JAMA 
on April 14, 2004. Results demonstrated that after 6.8 years of follow-up, estrogen-only 
use increased the risk of stroke and deep vein thrombosis (blood clots), had no effect on 





Because no overall benefit was found for participants and data indicated no heart disease 
benefit, which was a key question of the trial and unlikely to change with additional 
follow-up, the trial was halted. Investigators concluded in JAMA that estrogen-only 
therapy “should not be recommended for chronic disease prevention in postmenopausal 
women” (Women’s Health Initiative Steering Committee, 2004, p. 1701). 
During this time period, WHI investigators also released disappointing findings 
from the Women’s Health Initiative Memory Study (WHIMS), a sub-study of the WHI to 
assess the ability of HT to prevent mild cognitive impairment and dementia. On May 28, 
2003, WHIMS investigators reported in JAMA that estrogen plus progestin afforded 
women 65 years of age and older no protection against mild cognitive impairment and 
increased rates of probable dementia (Shumaker et al., 2003). On June 23, 2004, a JAMA 
article by WHIMS investigators also reported that women 65 years of age and older who 
took estrogen-only had increased rates of mild cognitive impairment and probable 
dementia (Shumaker et al., 2004). 
2005 – 2011: WHI re-analyses, the “timing hypothesis,” and breast cancer-
related outcomes. By late 2004, many organized interests were beginning to claim that 
the WHI results had been blown out of proportion, that HT still played a valuable role in 
women’s health, and that the women in the WHI trials were not representative of the 
typical HT user due their advanced age (for e.g., see Berger, 2004; Boodman, 2005; 
Neergaard, 2004). It was in this context that re-analyses of the WHI data and additional 
studies began to appear in the 2005 to 2011 period that were designed to test what 
became known as the “timing hypothesis,” which proposed that HT could have heart 





2007). Other studies in this time period continued to track the breast cancer-related 
outcomes of HT. 
Studies that supported the timing hypothesis during this period came primarily 
from the Nurses’ Health Study and re-analyses of the WHI data. For example, on January 
24, 2006, the Journal of Women’s Health published an analysis from the Nurses’ Health 
Study, which found lower rates of coronary heart disease (CHD) for women who began 
taking estrogen-only or estrogen-plus-progestin close to menopause and no relationship 
between HT and CHD for older women or women who started HT ten years or more after 
menopause” (Grodstein, Manson, & Stampfer, 2006, p. 35). The following year, a 
secondary analysis of the WHI data, published in JAMA on April 4, 2007, found that 
women who started hormone therapy within 10 years of menopause showed a non-
statistically significant trend toward less CHD risk and total mortality than women who 
started later, although the risk of stroke was increased regardless of time since menopause 
(Rossouw, 2007, p. 1465). The New England Journal of Medicine published an ancillary 
substudy of the estrogen-only arm of the WHI on June 21, 2007, finding that women who 
were age 50 to 59 at trial enrollment had less calcified coronary artery plaque after trial 
completion, leading the authors to conclude that their data lent “support for the 
hypothesis that estrogen therapy may have cardioprotective effects in younger women” 
(Manson et al., 2007, p. 2599). 
 Breast cancer also received continued focus during this time period. For example, 
JAMA published a study on April 12, 2006, based on WHI participants, which found that  
women, ages 50-79 with a prior hysterectomy who were given estrogen-only for 7.1 





increased risk of breast cancer (Stefanick et al., 2006). On April 19, 2007, a secondary 
data analysis of the National Cancer Institute’s (NCI) Surveillance, Epidemiology, and 
End Results Registries (SEER) was published in NEJM, showing that substantial declines 
seen in estrogen-receptive-positive breast cancer rates among women 50 years of age and 
older appeared related to national declines in HT prescription use that occurred after the 
WHI report in 2003 (Ravdin et al., 2007). 
Regulatory actions and disputes.  A few actions and disputes related to regulation 
of prescription HT products also stimulated press release and/or news reporting activity 
over the study time period. The action that attracted attention by both press releases and 
news stories and had the most repercussions in terms of stimulating additional actions by 
other organizations was the U.S. Food and Drug Administration’s (FDA) change to the 
product labeling for HT products in response to the WHI findings.  
During the entire time period for this study, HT was only FDA-approved for the 
treatment of vasomotor symptoms (hot flashes and/or night sweats), symptoms of vaginal 
atrophy, such as vaginal dryness or painful intercourse, and osteoporosis prevention 
(USDHHS FDA, 2011b). On January 8, 2003, the FDA issued new labeling requirements 
for all HT products based on the risks that emerged from the WHI estrogen-plus- 
progestin trial. Although up until that point the WHI study had only tested one dosage 
and formulation of estrogen-plus-progestin in the form of Prempro, the FDA ruled that 
until proven otherwise, the same risks needed to be assumed for all HT dosages and 
formulations, including estrogen-only products and HT products with different delivery 





The new FDA-approved label included black-box warnings about the potential 
risks for heart disease, heart attack, stroke, and breast cancer, along with a warning 
statement that HT products are not approved for the prevention of heart disease 
(Superville, 2003). The postmenopausal osteoporosis indication was also changed to 
encourage consideration of alternative treatments if used “solely for the prevention of 
postmenopausal osteoporosis.” An additional statement warned that “estrogens with or 
without progestins should be prescribed at the lowest effective doses and for the shortest 
duration consistent with treatment goals and risks for the individual woman” (USDHHS 
FDA, 2011b). The risk of developing “probable dementia in postmenopausal women 65 
years of age or older” was also added to the label later on in 2003 after the WHIMS 
results were reported (USDHHS FDA, 2011b). In addition to the labeling changes, the 
FDA launched a Congressionally-mandated, nationwide menopausal hormone therapy 
information campaign about the benefits and risks of HT on September 9, 2003 
(Kaufman, 2003; Wyeth Pharmaceuticals, 2003c). 
Other regulatory disputes appearing in press releases and news stories related not 
to labeling, but to issues of access. The first revolved around a new drug application for a 
generic formulation of Premarin submitted to the FDA for approval by Duramed 
Pharmaceuticals in the mid-1990s. Wyeth had submitted a Citizen petition in 1994, along 
with several medical and consumer-oriented organizations active in women’s health, to 
block the FDA approval, alleging that the generic formulation did not meet the 
requirement of having active ingredients identical to Premarin, and therefore, posed 
unknown risks to women (Wyeth-Ayerst Laboratories, 1996). Despite substantial 





of Wyeth on May 5, 1997 (Wyeth-Ayerst Laboratories, 1997). Another issue, which was 
the focus of more press releases than news stories began to emerge in 2006 and continued 
sporadically throughout the remainder of the study period about the legality of custom, 
HT prescriptions written for women by their physicians and compounded from approved 
ingredients by pharmacists into new formulations, a practice deemed by some 
pharmaceutical companies as unlawful manufacturing and selling of unapproved drugs 
(Wyeth Pharmaceuticals, 2006).  
Clinical practice recommendations and guidelines. Disappointing results from 
cardiovascular-oriented trials in the 1998 to 2002 period and the release of the WHI 
findings also prompted action on the part of medical professional societies and nonprofit 
health-advocacy organizations that issue clinical practice guidelines for women’s health 
care. For example, primarily in response to the HERS I results, the American Heart 
Association (AHA) published revised guidelines in its journal, Circulation, on July 23, 
2001, advising physicians not to prescribe HT for the “sole purpose of preventing heart 
attacks and strokes in woman who already have cardiovascular disease” (American Heart 
Association, 2001). After the WHI findings were released, the American College of 
Obstetricians (ACOG) convened a Hormone Therapy Task Force to review the body of 
research on HT, which resulted in a report published in its October 1, 2004, issue of the 
Journal of Obstetrics & Gynecology. The report concluded that while “the risks of HT 
exceed the benefits for the prevention of chronic diseases” HT is the “most effective” 
treatment for vasomotor symptoms and vaginal atrophy and “healthy symptomatic 
women” should not be “denied this option based on available data regarding health risks” 





Another example of shifting guidelines and associated controversies occurred in 
2007. In a position statement released on January 1, 2007, and later published in its 
March 2007 issue of Menopause, the North American Menopause Society (NAMS) 
asserted that the evidence base supported the use of estrogen-only and estrogen-plus- 
progestin therapy for “menopause-related symptoms and disease prevention in 
appropriate populations of peri- and postmenopausal women,” citing  FDA approval of 
HT for the prevention of postmenopausal osteoporosis, “strong evidence” of HT’s 
efficacy in reducing fractures, and research studies indicating that younger women who 
start therapy early and close to menopause may realize coronary heart disease reduction 
benefits (NAMS, 2007, p. 168, p. 171; Parker-Pope, 2007). Conversely, in its updated 
cardiovascular disease prevention guidelines for women published in its journal, 
Circulation, on February 20, 2007, AHA stated that menopausal hormone therapies 
should not be used to prevent heart disease “because they have been shown to be 
ineffective in protecting the heart and may increase the risk of stroke” (American Heart 
Association, 2007). 
Product promotion. There was a steady drumbeat of press releases throughout the 
entire study time period that were strictly marketing-oriented in nature. Common topics 
of these press releases included the granting of FDA-approval for new products, 
announcements for new product launches, and competitive-oriented releases that 
presented the advantages of one product over another. Most releases were produced by 
pharmaceutical companies that manufactured prescription HT products. Over the entire 
study time period, the FDA approved a total of 23 new, brand-name HT products, which 





transdermal patches, gels, and sprays (see Appendix B). Most brand-name products were 
also available in different dosages, with each dosage requiring a separate FDA approval.  
Pharmaceutical companies often attempted to publicize not just the launch of 
entirely new products, but the availability of new dosages of existing products as they 
became available, particularly in the post-WHI period when a trend toward lower-dose 
HT therapies developed. For example, Wyeth Pharmaceuticals announced FDA-approval 
for its first low-dose versions of Prempro on March 13, 2003, and Premarin on April 25, 
2003 (Wyeth Pharmaceuticals 2003a, 2003b). After the WHI findings, manufacturers 
and/or distributors of alternative, non-prescription products also ramped up their efforts 
to position a variety of products to treat menopausal symptoms, such as herbal 
formulations to fight hot flashes and lubricants to ease vaginal dryness, as safer 
alternatives to HT. 
Primarily product-oriented news stories, however, were rare. Most news stories 
tended to refer to HT in general terms, such as hormone therapy, estrogen therapy, 
estrogen-plus-progestin therapy, or combination therapy rather than by brand name. 
Market leaders, Premarin, introduced to the market in 1942, and Prempro introduced to 
the market in 1995, were exceptions. These drugs were mentioned frequently across the 
entire study time period because of the large number of news stories about major clinical 
trials that happened to use them as study drugs, such as HERS and WHI, or for other non-
promotional reasons, such as being the subject of lawsuits waged by women against 
Wyeth in the post-WHI period. In the immediate period of time surrounding the two 
major WHI announcements (the halting of the estrogen-plus-progestin study arm on July 





focused more on the decision-making processes of women as a result of WHI addressed 
the range of prescription and/or non-prescription options for menopausal women.  
Legal actions. The last major theme that generated substantial press release and 
news story activity after the WHI findings was related to lawsuits waged against Wyeth 
by women who claimed they got breast cancer as a result of taking Prempro. In total, 
more than 4,500 lawsuits were filed against Wyeth after the WHI findings were released, 
and a few of these suits came to trial and attracted substantial publicity beginning in mid-
2006 and continuing throughout 2011(Agovino, 2006).  
The first trial took place in Federal Court in Little Rock, Arkansas, on August 21, 
2006. The plaintiff and her defense team argued that the plaintiff’s breast cancer was 
caused by her eight years of Prempro use, and that Wyeth engaged in inappropriate 
practices by failing to conduct long-term studies on breast cancer risk and marketing 
Prempro in a way that downplayed its risks and promoted unproven benefits (Agovino, 
2006). Wyeth’s defense focused on the inability to make a causal link between the 
plaintiff’s Prempro use and her subsequent breast cancer, the plaintiff’s failure to read the 
patient information included with her prescription that warned of a potential breast cancer 
risk, and the fact that Wyeth’s HT drugs are FDA-approved, and therefore, are considered 
safe (DeMillo, 2006). This first trial resolved in favor of Wyeth, but others focused on 
similar claims occurred throughout the remainder of the study period, some resolving in 
favor of the plaintiffs and others in Wyeth’s favor (for e.g., see Dale, 2006, 2007, 2009; 






Content of Press Releases and News Stories 
This quantitative results section addresses research questions two (R2) through 
five (RQ5). The first section (RQ2) describes the content of press releases; the second 
section (RQ3) describes the content of news releases; and the third section (RQ4) 
compares the body of press releases to news stories in terms of their content. The fourth 
section (RQ5) identifies key organizations that emerged as successful agenda builders as 
evidenced by frequent mentions of these organizations in both press releases and news 
stories.  
Content of press releases. This section presents the results from the series of 
questions related to research question two: What was the content of press releases about 
hormone therapy (HT) distributed by organizations via PR Newswire and EurekAlert! 
from 1995-2011? The analyses reported in this section are based on these 675 press 
releases.  
RQ2a: What types of organizations distributed press releases most often? What 
types of organizations were mentioned in press releases most often? What types of 
individuals were quoted most often? How did these factors vary by the types of 
organizations that produced press releases? 
Distributing organizations. Six different types of health and medical 
organizations produced information subsidies in the form of press releases about HT. 
These organization types are rank-ordered in terms of their prominence from highest to 







Pharmaceutical companies and academic/medical institutions, such as 
universities, hospitals, and clinical centers were responsible for almost two-thirds (60%) 
of all press release activity. Nonprofit organizations (14.2%) and medical journal 
publishers (11.6%) distributed substantially less, but not insignificantly. Notably, the 
majority of press releases in the nonprofit category were distributed by 501c3 health-
advocacy organizations. Only a few press releases in the nonprofit category were 
distributed by 501c6 medical professional societies/trade associations or coalitions.   
The most inactive organization types were those classified as miscellaneous for-
profit organizations, which included a range of non-pharmaceutical companies, including 




Pharmaceutical Companies 239 
(14.52)
35.4






              Health Advocacy Organizations (501c3)
a 76 11.3
             Professional/Trade Associations (501c6)
a 16 2.4
             Coalitions
a 4 0.6
Medical/Scientific Journal Publishers 78 
(-1.87)
11.6
Miscellaneous For-Profit Organizations 51 
(-4.62)
7.6









 These 3 categories are sub-categories of the larger nonprofit organization category 
above. Only the total nonprofit category was used for the chi-square goodness-of-fit 
test.






relations agencies. Surprisingly, given their central role in matters of public health, less 
than five percent of press releases were distributed by U.S. government agencies. 
Organizations that could not be classified into any coherent category were placed in a 
seventh category, labeled other.   
To determine if the observed pattern of results in Table 4 differed from the pattern 
expected under the null hypothesis, a chi-square goodness-of-fit test was conducted at an 
alpha level of .05. The assumptions of independence and expected frequencies of at least 
five cases per cell were met. Results indicated that the overall pattern of differences 
across the seven types of organizations was statistically significant, χ
2
=399.90, df=6, 
p<.001. Follow-up tests were conducted by examining the standardized residuals to see 
which categories contributed significantly to the chi-square statistic, as evidenced by 
standardized residuals greater than an absolute value of two (Agresti, 2007; Lomax & 
Hahs-Vaughn, 2012). The pharmaceutical and academic/medical institution categories 
had large, positive residuals, indicating that these organizations distributed proportionally 
more releases than would be expected by chance. Miscellaneous for-profit organizations, 
U.S. government agencies, and the other category all had large, negative residuals, 
indicating that these organizations distributed proportionally less releases than expected 
by chance (residuals reported in Table 4).   
 Organizations mentioned in text.  Multiple organizations were mentioned in the 
body text of each press release. The average number of organizations mentioned per 
release was approximately three (M=3.19, SD =1.86). Press releases also included 
multiple types of organizations. The average number of organization types mentioned 





As can be seen in Table 5, more than half of all press releases mentioned an 
academic/medical institution (59.3%) or a U.S. government agency (53.6%).  
Pharmaceutical companies (47.1%) and nonprofit organizations (31.7%) were mentioned 
by less than half of all releases. Miscellaneous for-profit organizations (11.3%) and those 
classified as other (9.9%) were rarely mentioned.  
 
 
To determine if the observed pattern of results in Table 5 differed from the pattern 
expected under the null hypothesis, a chi-square goodness-of-fit test was conducted at an 
alpha level of .05. The assumptions of independence and expected frequencies of at least 
five cases per cell were met. The results indicated that the overall pattern of differences 
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5 0.7








Note . Percentages do not total 100% because the body text of each press release could 
contain multiple organization types.
a
 These 3 categories are sub-categories of the larger nonprofit organization category 
above. Only the total nonprofit category was used for the chi-square goodness-of-fit 
test.
Table 5





p<.001. Examination of the residuals indicated that academic/medical institutions, U.S. 
government agencies, and pharmaceutical companies (all with large, positive residuals 
greater than two) were more likely to be mentioned in press releases than other types of 
organizations (see Table 5.)   
Although medical/scientific journal publishers were included in the coding for 
organizations distributing press releases, they were not included in the coding for what 
organizations were mentioned in the body text. This decision was made because 
preliminary coding had clearly demonstrated that publishers rarely appeared in the body 
text; instead the name of the actual journal appeared in the text. More than 50.4% 
(n=340) of all press releases mentioned a medical or scientific journal.  
 Differences by type of organization. To determine whether the types of 
organizations mentioned in a press release varied by what type of organization produced 
the release, five chi-square tests of independence were conducted at an alpha level of .05. 
These analyses tested whether the probability of an organization type being mentioned in 
the body text of a press release was significantly associated with the type of organization 
that distributed the release. As can be seen in Table 6, all five tests were statistically 
significant. Only one analysis contained a cell with an expected frequency of less than 
five, the test to determine if mentions of miscellaneous for-profit organizations varied by 
the type of organization distributing the release. Although the chi-square value was 






Post hoc z-tests for column proportions using the Bonferroni adjustment method 
were then used to follow-up all significant chi-square results to determine which specific 
column proportions differed from one another. The Bonferroni adjustment method holds 
alpha at .05 for the entire group of comparisons by splitting alpha up equally among each 
pair-wise comparison to avoid inappropriate inflation of Type I error (Lomax & Hahs-
Vaughn, 2012). The results of these post hoc tests are also presented in Table 6 with the 
use of lettered subscripts. Only patterns that met this stringent threshold are commented 
on below. 
Unsurprisingly, organizations that distributed a press release were more likely to 
mention their own organization type in the release than any other organization type; 
likely because they included their own name in the body text of the release. Almost all of 
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Note.  Cells sharing the same subscript are not significantly different from one another using a z-test for 
column proportions with the Bonferroni adjustment method.
*This cell had an expected frequency of less than 5.
Table 6





company (97.9%); 98.8% of academic/medical institutions mentioned an 
academic/medical institution; 89.6% of nonprofits mentioned a nonprofit; 74.5% of 
miscellaneous for-profit organizations mentioned a for-profit organization, and 100% of 
government agency releases mentioned a government agency. More than three quarters 
(76.9%) of releases distributed by medical/scientific journal publishers mentioned 
academic/medical institutions, likely due to their dissemination of studies conducted by 
these institutions. 
Some organization types also tended to appear frequently in releases distributed 
by other types of organizations, particularly academic/medical institutions and 
government agencies. More than half of the releases distributed by nonprofit 
organizations (61.5%), medical/scientific journal publishers (76.9%), and U.S. 
government agencies (57.1%) mentioned an academic/medical institution in the body 
text. Almost three quarters (74.1%) of pharmaceutical company releases mentioned a 
U.S. government agency. 
 The chi-square test of independence procedure was used to see if the proportion 
of medical/scientific journal articles mentioned in press releases varied by the type of 
organization that distributed the release at an alpha level of .05. The assumptions of 
independence and expected frequencies of at least five cases per cell were met. A 
significant chi-square value resulted, χ
2
=232.62, df=5, p<.001, indicating an association 
between organization type and mentions of medical/scientific journals. This procedure 
was followed-up with post hoc z-tests for column proportions using the Bonferroni 
adjustment method. Results indicated that medical journal publishers (97.4%, n=76), U.S. 





were more likely than all other organization types to mention a medical/scientific journal.  
Half of nonprofit organizations (51.0%, n=49) and almost one-third of miscellaneous for- 
profit organizations (31.4%, n=16) mentioned a medical/scientific journal.  
Pharmaceutical companies were less likely than all other organization types to mention a 
medical/scientific journal, with only 17.6% (n=42) citing a journal article in the body text 
of a release.  
Types of individuals quoted. Table 7 shows that physicians and/or scientists were 
by far the most frequently quoted individuals. Almost two-thirds (62.4%) of all press 
releases over the study time period included a direct quote from a physician and/or 
scientist.  A substantial number of press releases (39.7%) quoted official spokespersons 
for an organization, such as chief executive officers (CEOs), directors of research, or 








































Note . Percentages do not total 100% because the body text of 
each press release could contain quotes from multiple types of 
individuals.
Table 7





To determine if the observed pattern of results in Table 7 differed from the pattern 
expected under the null hypothesis, a chi-square goodness-of-fit test was conducted at an 
alpha level of .05. The assumptions of independence and expected frequencies of at least 
five cases per cell were met. Results indicated that the observed pattern of differences 
across the eight categories was statistically significant, χ
2
=2049.96, df=7, p<.001. 
Follow-up tests were conducted by examining the standardized residuals to see which 
categories contributed significantly to the chi-square statistic as evidenced by 
standardized residuals greater than an absolute value of two. The large, positive 
standardized residuals for the physician and/or scientist and official spokesperson 
categories indicated that press releases quoted these types of individuals more than any 
other types of individuals, which all had large, negative standardized residuals (see Table 
7).  
Differences by type of organization. To determine whether the top two categories 
of quoted individuals varied by the type of organization that produced the release, two 
chi-square tests of independence were conducted at an alpha level of .05. These analyses 
tested whether the probability of a physician and/or scientist or official spokesperson 
being quoted in the body text of a press release was significantly associated with the type 
of organization that distributed the release. The assumptions of independence and 
expected frequencies of at least five cases per cell were met. As can be seen in Table 8, 
both chi-square tests of independence were statistically significant. Post hoc z-tests for 
column proportions using the Bonferroni adjustment method were used to follow-up the 





from one another. The results of these tests are reported in the table with subscripts. Only 
differences that met these stringent tests are described below. 
 
Academic/medical institutions (91%) were more likely than all other groups, 
besides U.S. government agencies (82.1%), to quote physicians and/or scientists. 
Medical/scientific journal publishers (12.8%) were the least likely to feature quotes from 
physicians and/or scientists. Pharmaceutical companies were more likely (75.7%) than all 
other groups, besides U.S. government agencies (60.7%), to quote official spokespersons.  
Medical/scientific journal publishers (1.3%) and academic/medical institutions (3.6%) 
were least likely to feature quotes from CEOs or official spokespersons. 
RQ2b: What benefits and risks were associated with HT? How were benefits 
and risks presented (qualitative vs. quantitative; relative vs. absolute terms). How did 
these factors vary by the types of organizations that produced press releases? 
Whenever possible, results related to benefits and risks of HT are provided for the 
entire study period and broken out by the “pre-WHI period,” from January 1, 1995, to 
July 8, 2002, and “post-WHI period,” from July 9, 2002 to December 31, 2011. The date 























































Types of Individuals Quoted by Type of Organization that Distributed Release(1995-2011)
Note . Cells sharing the same subscript are not significantly different from one another using a z -test for 





the day that NIH announced that it was stopping the estrogen-plus-progestin trial. It was 
deemed necessary to break the data related to benefits and risks into two time periods 
because the WHI study findings provided new evidence and sparked a major public 
reevaluation of the benefits and risks of HT.  
Amount of information about benefits and risks. Across the entire time period 
studied, two-thirds of press releases (66.4%, n=448) mentioned at least one potential 
benefit of HT, and a little less than two-thirds of press releases mentioned at least one 
potential risk (60.7%, n=410). Although these numbers seem fairly high, only 38.2% 
(n=258) of press releases contained a benefit and a risk together in the same release.  
More than one-quarter (28.1%, n=190) of releases mentioned a benefit with no risk, 
22.5% (n=152) mentioned a risk with no benefit, and 11.1% (n=75) of releases 
mentioned no information about benefits or risks. 
The mean number of benefits per press release was 1.27 (SD=1.37). To determine 
if the mean number of benefits differed prior to and after the initial WHI announcement, 
a two-tailed, t-test for independent samples assuming equal variances was conducted at 
an alpha level of .05. The equal variances formula was used because Levine’s test for 
equality of variances returned an insignificant result (F=1.79, p=.18). Results indicated 
that press releases were significantly more likely to contain more benefits per press 
release in the pre-WHI period (M=1.45, SD=1.31) than the post-WHI period (M=1.16, 
SD=1.40), t(673)=2.73, p=.01. 
The mean number of risks per press release was 1.52 (SD=1.89). When compared 
by time period, the reverse pattern occurred. Press releases contained significantly less 





period (M=2.17, SD=2.10), according to a two-tailed, t-test for independent samples 
assuming unequal variances conducted at an alpha level of .05, t(570)=14.24, p<.001. 
The unequal variance formula was used after Levine’s test for equality of variances 
returned a statistically significant result (F=272.06, p<.001). Figure 6 visualizes the 
trends for mean number of benefits and risks per press release across the two time 
periods.  
 
Figure 6: Mean benefits and risks by pre- vs. post-WHI period. 
 
Differences by type of organization. To test whether the mean number of benefits 
and risks per press release differed by the type of organization that distributed the release, 
two, one-way ANOVAs were conducted. For benefits, a one-way ANOVA indicated that 
the mean number of benefits differed significantly by organization type, F(5, 652) = 5.80, 
p<.001. Post hoc Tukey-Kramer tests were then used to determine which group means 
differed significantly from one another. The Tukey-Kramer multiple comparison 
procedure was selected because it adjusts for unequal ns and assumes equal variances, 
which was appropriate given that Levene’s test for homogeneity of variance was not 





the use of lettered subscripts. As can be seen in Table 9, pharmaceutical companies, 
academic/medical institutions, and U.S. government agencies included significantly more 
benefits per release than medical/scientific journal publishers and miscellaneous for-
profit organizations.  
 
For risks, a one-way ANOVA indicated that the mean number of risks differed 
significantly by organization type, F(5, 652)=10.78, p<.001. Games-Howell post hoc 
multiple comparison tests were then used to determine which group means differed 
significantly from one another. The Games-Howell procedure was used because it adjusts 
for unequal ns and unequal variances, which was appropriate given that Levene’s test for 
homogeneity of variance was rejected (F=30.47, p<.001). As can be seen in Table 9, U.S. 
government agencies reported significantly more risks per release than any other 



























































Mean Benefits and Risks by Type of Organization that Distributed Release (1995-2011)
Note. For benefits, means sharing a common subscript are not statistically different via the Tukey-
Kramer posthoc test, which adjusts for unequal n s.
Note: For risks, means sharing a common subscript are not statistically different via the Games-






Specific benefits. Table 10 reports the most frequently identified potential benefits 
of HT in press releases by total time period and by the pre- and post-WHI time periods. 
The total column shows that two of the three FDA-approved indications ranked in the 
first and second spots: reduction of hot flashes and osteoporosis prevention. Ranking in 
the third spot was heart disease prevention, an unapproved indication, which was 
identified more often as a potential benefit of HT than the FDA-approved indication for 
treatment of vaginal problems, such as vaginal atrophy and dryness, which ranked fourth. 
















































































Benefits for Total Time Period and by Pre- vs. Post-WHI Period
Table 10






The remaining two categories, “other disease/illness-reduction benefits” and 
“other overall health/well-being benefits” contained infrequent mentions of a variety of 
purported benefits that were sometimes the subject of miscellaneous research studies, but 
never developed into any focused research agenda. For example, the other disease/illness-
reduction benefits category included mentions of potential benefits like reductions in all 
cause-mortality, breast cancer, and periodontal disease, and improvements in blood sugar 
for diabetes patients. The other overall health/well-being category contained references to 
potential benefits such as improved mood, energy, and sleep, and less skin aging and 
weight gain.  
To determine whether mentioned benefits varied by the pre- and post-WHI period 
eight chi-square tests of independence were conducted at an alpha level of .05. The 
assumptions of independence and expected frequencies of at least five cases per cell were 
met for all tests. These analyses tested whether each potential benefit was more or less 
likely to appear in press releases before or after the WHI announcement. As can be seen 
in Table 10, five of these tests returned statistically significant results: osteoporosis 
prevention, heart disease prevention, treatment of vaginal atrophy, colon cancer 
prevention, and prevention of cognitive decline.  
A closer look at the directionality of these changes, suggests that patterns may 
have shifted in response to new evidence generated by the WHI, ongoing research to 
better understand the WHI findings, and FDA product-labeling actions.  Mentions of the 
unapproved indication of heart disease prevention went down dramatically between the 
two time periods (from 31.3% to 10.7%) and mentions of the approved indication for 





Other shifts in the texts of press releases can also be seen from the pre- to post-WHI 
period. Mentions of osteoporosis prevention (35.5% to 23.2%) and prevention of 
cognitive decline (8.7% to 2.9%) went down significantly, and mentions of colon cancer 
prevention (2.6% to 8.0%) increased significantly. 
Differences by type of organization. To determine whether the identification of 
specific, potential benefits varied by the type of organization distributing the press 
release, chi-square tests of independence were conducted at an alpha level of .05. The 
assumption of independence was met, and analyses were only conducted for the top four 
benefits for the entire time period rather than within the pre- and post-WHI period to 
avoid expected cell counts less than five. As can be seen in Table 11 all chi-square tests 
indicated highly significant associations between the type of organization distributing the 
release and the identification of each of the four benefits. Follow-up z-tests for column 
proportions using the Bonferroni adjustment method were used to examine differences 
between specific column percentages. Only those differences that met this stringent test 
are described below. It should be noted that for the vaginal atrophy row, one cell in the 
U.S. government column had an expected value of less than five. While the chi-square 
value was highly significant for this test, interpretation of differences in this row should 






Pharmaceutical companies (64.4%) were far more likely than any other 
organization type to identify the FDA-approved indication of hot flash reduction as a 
potential benefit of HT. U.S. government agencies (57.1%) were more likely than all 
other organization types, besides pharmaceutical companies (33.5%), to mention the 
FDA-approved indication of osteoporosis prevention. Academic/medical institutions 
(31.9%) and nonprofit organizations (31.2%) were more likely than pharmaceutical 
companies (7.5%) to mention a potential heart disease benefit, a controversial, non-FDA 
approved indication. Conversely, pharmaceutical companies (26.4%) were more likely 
than academic/medical institutions (6.0%), nonprofit organizations (8.3%), and 
medical/scientific journal publishers (6.4%) to mention the FDA-approved treatment of 
vaginal atrophy-related problems as a benefit.   
Specific risks. Table 12 reports the most frequently identified potential risks of 































































































Benefits by Organization Type that Distributed Release (1995-2011) 
Table 11
Note . Cells sharing the same subscript are not significantly different from one another using a z -test for 
column proportions with the Bonferroni adjustment method.





for total time period, breast cancer was the clear leader being mentioned in 40.9% of all 
press releases; heart disease (27.1%) and stroke (23.4%) took the second and third slots, 
with each being mentioned in about a quarter of all releases. The uterine cancer category, 
which primarily contained mentions of endometrial cancer, a cancer of the lining of the 
uterus, a long-known, well-documented risk of HT ranked fourth (21.3%) and was neck-
and-neck with blood clots (21.2%), which ranked in the fifth spot overall. Cognitive 
decline, gallbladder disease, and the other category, which included more sporadically 
mentioned potential risks, such as increased lung cancer risk, hearing loss, and asthma 




















































































Risks for Total Time Period and by Pre- vs. Post-WHI Period






To determine whether mentioned risks varied by the pre- and post-WHI period 
eight chi-square tests of independence were conducted at an alpha level of .05. The 
assumptions of independence and expected frequencies of at least five cases per cell were 
met for all tests. These analyses tested whether each potential risk was more or less likely 
to appear in press releases before or after the WHI announcement. As can be seen in 
Table 12, six of the tests returned significant results: breast cancer, heart disease, stroke, 
blood clots, cognitive decline, and other.   
When analyzed by time period, it is clear that during the pre-WHI period 
mentions of the potential risks of HT were quite low. Only the uterine cancer category 
rose above the 20% threshold, being mentioned in 23.4% of press releases in the pre-
WHI period. While this category remained stable from the pre- to post-WHI period, 
mentions of other potential risks increased significantly and dramatically in response to 
the WHI findings. Breast cancer risk increased from 15.5% to 57.3%; heart disease 
increased from 4.5% to 41.7%; stroke increased from 1.5% to 37.6%; blood clots 
increased from 5.7% to 31.2%; cognitive decline increased from 0% to 14.1%, and the 
other category increased from less than 1% (0.8%) to 10%.   
Differences by type of organization. To determine whether the identification of 
specific risks varied by the type of organization distributing the press release, chi-square 
tests of independence were conducted at an alpha level of .05 . The assumption of 
independence was met, and analyses were only conducted for the top five risks for the 
entire time period rather than within the pre- and post-WHI period to avoid expected cell 
counts less than five. As can be seen in Table 13 all chi-square tests indicated highly 





identification of each of the five risks. Follow-up z-tests for column proportions using the 
Bonferroni adjustment method were used to look at differences between specific column 
percentages. Only those differences that met this stringent test are described below.  
 
U.S. government agencies (75.0%) were more likely than pharmaceutical 
companies (33.5%), academic/medical institutions (43.4%), and nonprofit organizations 
(29.2%) to identify breast cancer as a potential risk. U.S. government agencies were more 
likely than any other organization type to mention heart disease (71.4%), stroke (67.9%) 
and blood clots (64.3%). Pharmaceutical companies (41.0%) were more likely than all 
other organization types, with the exception of U.S. government agencies (28.6%), to 






































































































Risks by Type of Organization that Distributed Release (1995-2011)
Note.  Cells sharing the same subscript are not significantly different from one another using a z -test for 





Benefit and risk presentation. In terms of presentation, quantification of benefits 
and risks was fairly infrequent. Of the 448 press releases that included information about 
at least one benefit, only 26.6% (f=119) quantified a benefit in any way. Most of the 
releases that quantified a benefit did so in relative terms only (19.4%, f=87); 0.9% (f=4) 
contained absolute and relative information; 0.7% (f=3) provided absolute information 
only; and 5.6% (f=25) provided some other type of quantitative information. Of the 410 
press releases that included information about at least one risk, only 31.5% (f=129) 
quantified a risk in any way. Most of the releases that quantified a risk did so in relative 
terms only (19.5%, f=80); 5.6% (f=23) contained absolute and relative information; 2.7% 
(f=11) provided absolute information only; and 3.7% (f=15) provided some other type of 
quantitative information.   
Differences by type of organization. To determine whether the appearance of 
quantitative information about a benefit in a press release varied by the type of 
organization that produced the release, a chi-square test of independence was conducted 
at an alpha level of .05. The assumptions of independence and expected frequencies of at 
least five cases per cell were met. Results indicated a statistically significant association 
between organization type and whether releases that contained at least one benefit 
presented any quantitative information about a benefit, χ
2
=22.25, df=5, p<.001. As can be 
seen in Table 14, follow-up z-tests for column percentages using the Bonferroni 
adjustment method indicated that academic and/or medical institutions (36.4%) and 
nonprofit organizations (39.7%) were more likely to produce press releases that 







To determine whether the appearance of quantitative information about a risk in a 
press release varied by the type of organization that produced the release, a chi-square 
test of independence was conducted at an alpha level of .05. The assumptions of 
independence and expected frequencies of at least five cases per cell were met. Results 
indicated that there was a statistically significant association between organization type 
and whether releases that contained at least one risk presented any quantitative 
information about a risk, χ
2
=81.04, df=5, p<.001. As can be seen in Table 15, follow-up 
z-tests for column percentages using the Bonferroni adjustment method indicated that 
pharmaceutical companies (3.1%) were less likely than any other type of organization to 
contain a risk that was quantified in any way.  
Table 14
# of Press Releases that Included at Least One Benefit n %
Pharmaceutical Companies (n =186) 31 16.7a
Academic & Medical Institutions (n =121) 44 36.4b
Nonprofit Organizations (n =58) 23 39.7b
Medical/Scientific Journal Publishers (n =32) 10 31.2a,b
Miscellaneous For-Profit Organizations (n =20) 3 15.0a,b
U.S. Government (n =21) 5 23.8a,b
Note.  Cells sharing the same subscript are not significantly different from one another 
using a z-test for column proportions with the Bonferroni adjustment method.









RQ2c: How often were specific brand-name HT products mentioned in press 
releases? How did brand-name mentions vary by the types of organizations that 
produced press releases? 
Brand name drugs were mentioned in 39.7% (n=268) of all press releases. In total, 
thirty-eight different brand names appeared across the press releases. Most of these 
brands were sporadically mentioned with concentrations of mentions based on relatively 
few brands. Table 16 presents a rank-ordered list of the most frequently occurring ten 
brands. To determine if the observed pattern of results in Table 16 differed from the 
pattern expected under the null hypothesis, a chi-square goodness-of-fit test was 
conducted at an alpha level of .05. The assumptions of independence and expected 
frequencies of at least five cases per cell were met. Results indicated that brand name 
mentions differed significantly from one another, χ
2
=356.04, df=9, p<.001. Analysis of 
the standardized residuals indicated that Premarin and Prempro clearly stuck out from 
the pack, as evidenced by large, positive standardized residuals well in excess of two, 
compared to other brands with negative residuals. Prempro and Premarin were both 
# of Press Releases that Included at Least One Risk f %
Pharmaceutical Companies (n =128) 4 3.1a
Academic & Medical Institutions (n =106) 45 42.5b
Nonprofit Organizations (n =49) 16 32.7b
Medical/Scientific Journal Publishers (n =62) 37 59.7b
Miscellaneous For-Profit Organizations (n =27) 8 29.6b




NOTE: Cells sharing the same subscript are not significantly different from one 
another using a z-test for column proportions with the Bonferroni adjustment 
method.





mentioned in more than 10% of all press releases; all other brands were mentioned in less 
than 5% of releases. 
 
 
Differences by type of organization. To determine if whether a brand-name HT 
product was mentioned varied by the type of organization that produced the release, a 
chi-square test of independence was conducted at an alpha level of .05. The assumptions 
of independence and expected frequencies of at least five cases per cell were met. Results 
indicated a significant association between type of organization and brand-name 
mentions, χ
2
=356.04, df=9, p<.001. As can be seen in Table 17, post hoc z-tests for 
Table 16
Top-10 Mentioned Brand Names (1995-2011)
Frequencies
(stand. resid.)
% of Total 
Press Releases 
(N =675)



































column proportions using the Bonferroni adjustment method indicated that 
pharmaceutical companies were more likely to mention a brand name in their press 
releases than any other organization type. Almost all 84.9% of pharmaceutical company 
releases mentioned a brand name. All other organizations were about equally likely to 
mention brand names. Medical journal publishers (2.6%), however, were less likely than 
miscellaneous for-profit organizations (31.4%) and government agencies (28.6%) to 
mention brand names in their releases. 
 
RQ2d: How often were pharmaceutical industry-related financial conflicts of 
interest mentioned in press releases? How did identification of conflicts of interest vary 
by the types of organizations that produced press releases?  
This study measured three potential types of financial conflicts of interest (COI) 
between organizations and the pharmaceutical industry: research study-level conflicts, 
organizational-level conflicts, and individual-level conflicts. Disclosure of financial 
conflicts in press releases was rare. Only 12.7% (n=86) of press releases mentioned any 
type of COI during the study time period. In terms of type of COI, research funding 
conflicts were the most often identified.  Approximately 10% (11.3%, n=76) of press 
Type of Organization n %
Pharmaceutical Companies (n =239) 203 84.9a
Academic & Medical Institutions (n =166) 25 15.1bc
Nonprofit Organizations (n =96) 13 13.5bc
Medical/Scientific Journal Publishers (n =78) 2 2.6c
Misc. For-Profit Organizations (n =51) 16 31.4b
U.S. Government (n =28) 8 28.6b
Table 17
Brand Name Mentions by Type of Organization that Distributed Release (1995-2011)
Brand Name Mentioned
Note . Cells sharing the same subscript are not significantly different from one another 





releases disclosed a financial conflict related to a research study. Only 1.5% (n=10) 
mentioned organizational-level conflicts, and less than 1% (0.7%, n=5) mentioned 
individual-level conflicts.   
Differences by organization type. To determine if whether a financial conflict of 
interested was identified varied by the type of organization that produced the release, a 
chi-square test of independence was conducted at an alpha level of .05. The assumption 
of independence was met, and the assumption of expected frequencies of at least five 
cases per cell was violated for only one category, the U.S. government category. Results 
indicated a significant association between type of organization and identification of a 
financial COIs, χ
2
=38.07, df=5, p<.001. As can be seen in Table 18, post hoc z-tests for 
column proportions using the Bonferroni adjustment method indicated that U.S. 
government agencies (32.1%) and academic/medical institutions (23.5%) were more 
likely than other organization types to disclose a COI. This claim should be interpreted 
with a bit of caution, however, as the expected cell count in the government category was 
less than five.  
 
n %
Pharmaceutical Companies (n =239) 22 9.2a
Academic & Medical Institutions (n =166) 39 23.5b
Nonprofit Organizations (n =96) 11 11.5ab
Medical/Scientific Journal Publishers (n =78) 4 5.1a
Misc. For-Profit Organizations (n =51) 1 2.0a
U.S. Government (n =28) 9* 32.1b
*This cell had an expected frequency of less than five.
Table 18
COI Disclosures by Type of Organization that Distributed Release (1995-2011)
Included Any COI
Disclosures
Note.  Cells sharing the same subscript are not significantly different from one 






Content of news stories. This section presents the results from the series of 
questions related to research question three: What was the content of news stories about 
HT in AP Newswire and four, top-circulating U.S. newspapers from 1995 – 2011? As 
reported earlier, there were a total of 429 news stories from January 1, 1995 to December 
31, 2011, which include 176 news stories from AP Newswire; 85 from The New York 
Times, 78 from the Los Angeles Times, 46 from The Washington Post, and 44 from The 
Wall Street Journal. All analyses to follow in this results section are based on these 429 
news stories.  
RQ3a: What types of organizations were mentioned in news stories most often? 
What types of individuals were quoted most often? 
Organizations mentioned in text.  Multiple organizations were mentioned in the 
text of each news story. The average number of organizations mentioned per news story 
was between three and four (M=3.55, SD =2.03). News stories also included multiple 
types of organizations. The average number of organization types mentioned was 
approximately two (M=2.14, SD=1.10).   
As can be seen in Table 19, almost two-thirds of all news stories mentioned an 
academic/medical institution (65.3%) and half mentioned a U.S. government agency 
(50.8%). Pharmaceutical companies (43.8%) and nonprofit organizations (35.7%) were 
mentioned by less than half of all releases. Miscellaneous for-profit organizations (7.5%) 







To determine if the observed pattern of results in Table 19 differed from the 
pattern expected under the null hypothesis, a chi-square goodness-of-fit test was 
conducted at an alpha level of .05. The assumptions of independence and expected 
frequencies of at least five cases per cell were met. Results indicated that the observed 
pattern of results across the six major categories differed significantly from what would 
be expected by chance, χ
2
=311.90, df=5, p<.001. 
Follow-up tests were conducted by examining the standardized residuals to see 
which categories contributed significantly to the chi-square statistic, as evidenced by 
standardized residuals with an absolute value greater than two. Academic/medical 
Table 19
Types of Organizations Mentioned in News Stories
Type of Organization n %
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a 1 0.2








Note. Percentages do not total 100% because the body text of each press 
release could contain multiple organization types.
a
 These 3 categories are sub-categories of the larger nonprofit organization 






institutions, U.S. government agencies, and pharmaceutical companies were mentioned in 
news stories more than expected by chance based on their large, positive standardized 
residuals. Miscellaneous for-profit organizations and those classified into the other 
category were mentioned less than expected by chance based on their large, negative 
standardized residuals. 
Medical/scientific journal publishers were not included in the coding for what 
types of organizations were mentioned in news stories. This decision was made because 
preliminary coding had clearly demonstrated that publishers rarely appeared in the body 
text; instead the name of the actual journal appeared in the text. Slightly more than half 
(51.7%, n=222) of all news stories cited a medical or scientific journal or publication.   
Types of individuals quoted. Table 20 shows that physicians and/or scientists and 
official spokespersons, such as CEOs, research and marketing directors, and public 
affairs personnel were by far the most frequently quoted individuals in news stories. 
Almost two thirds (62.9%) of all direct quotes across the news stories for the entire time 
period came from physicians/scientists, and a third (32.9%) came from official 







To determine if the observed pattern of results in Table 20 differed from the 
pattern expected under the null hypothesis, a chi-square goodness-of-fit test was 
conducted at an alpha level of .05. The assumptions of independence and expected 
frequencies of at least five cases per cell were met. Results indicated that the pattern of 
differences across the eight categories was statistically significant, χ
2
=1050.89, df=7, 
p<.001. Follow-up tests were conducted by examining the standardized residuals to see 
which categories contributed significantly to the chi-square statistic as evidenced by 
standardized residuals greater than an absolute value of two. The large, positive 
standardized residuals for the physician and/or scientist and official spokesperson 
categories indicated that news stories quoted these types of individuals more than any 
Table 20






























Note . Percentages do not total 100% because the body text of each 





other types of individuals, which all had large, negative standardized residuals (see Table 
20).  
RQ3b: What benefits and risks were associated with HT? How were benefits 
and risks presented (qualitative vs. quantitative; relative vs. absolute terms).  
Amount of information about benefits and risks. News stories frequently reported 
on both the potential benefits and risks of HT. Across the study time period, 80.7% 
(n=346) of news stories included at least one potential benefit, and 86.5% of news stories 
(n=371) included at least one potential risk. More than two-thirds of news stories (68.5%, 
n=294) contained a benefit and a risk together in the same release; 12.1% (n=52) of news 
stories mentioned a benefit with no risk, 17.9% (n=77) reported a risk with no benefit, 
and only 1.3% (n=6) of news stories provided no information about benefits or risks. 
The average number of benefits per news story was 2.25 (SD=1.85). To determine 
if the mean number of benefits differed prior to and after the initial WHI announcement, 
a two-tailed, t-test for independent samples assuming equal variances was conducted at 
an alpha level of .05. The equal variances formula was used because Levine’s test for 
equality of variances returned an insignificant result (F=.776, p=.38). News stories were 
significantly more likely to contain more benefits per story in the pre-WHI period 
(M=2.80; SD=1.65) than the post-WHI period (M=1.78; SD=1.88), t(427)=5.93, p<.001. 
The average number of risks per news story was 2.25 (SD=1.68). When compared 
by time period, the reverse pattern occurred. News stories contained significantly less 
risks per story in the pre-WHI period (M=1.47, SD=1.27) than in the post-WHI period 
(M=2.93, SD=1.69) according to a two-tailed, t-test for independent samples assuming 





variance formula was used after Levine’s test for equality of variances returned a 
significant result (F=28.64, p<.001). Figure 7 visualizes the trends for mean number of 
benefits and risks per news story across the two time periods.  
 
Figure 7: Mean benefits and risks by pre- vs. post-WHI period.  
Specific benefits. Table 21 reports the most frequently identified potential benefits 
of HT in news stories by total time period and by the pre- and post-WHI time periods. 
The total column shows that two of the three FDA-approved indications ranked in the 
first and second spots: osteoporosis prevention and reduction of hot flashes. More than 
half of news stories identified osteoporosis prevention (54.3%) and hot flash reduction 
(51.3%) as potential benefits of HT. More than two-thirds of news stories identified heart 
disease prevention (38.9%), a non-FDA approved indication. The FDA-approved 
indication of treatment for vaginal atrophy-related problems received about the same 
amount of mentions as less established benefits that attracted substantial attention in the 
research world, such as prevention of cognitive decline (15.6%) and colon cancer 





disease/illness-reduction benefits (13.3%) and other overall health/well-being benefits 
(12.8%) categories. 
 
To determine whether mentioned benefits varied by the pre- and post-WHI period 
eight chi-square tests of independence were conducted at an alpha level of .05. The 
assumptions of independence and expected frequencies of at least five cases per cell were 
met for all tests. These analyses tested whether each potential benefit was more or less 
likely to appear in news stories before or after the WHI announcement.  As can be seen in 
Table 21, five of these tests returned statistically significant results: osteoporosis 
prevention, hot flashes, heart disease prevention, prevention of cognitive decline, and 





















































































Benefits for Total Time Period and by Pre- vs. Post-WHI Periods






Four of the five significant tests demonstrated a downward trend from the pre- to 
post-WHI period. All these benefits were disease-prevention oriented in nature. Heart 
disease prevention mentions decreased dramatically; 66.2% of news stories identified 
heart disease prevention as a possible benefit in the pre-WHI period compared to only 
14.9% in the post-WHI period. Osteoporosis prevention followed a similar pattern, 
dropping from being identified in 77.6% of news stories to 33.8%. Cognitive decline and 
other less, well-supported disease and illness reduction claims also went down. The only 
category that increased was the FDA-approved indication for hot flashes. Less than half 
of news stories (44.8%) identified hot flash reduction as a benefit of HT in the pre-WHI 
period compared to well over half (57.0%) in the post-WHI period. 
Specific risks. Table 22 reports the most frequently identified potential risks of 
HT in news stories by total time period and by the pre- and post-WHI time periods. For 
risks for total time period, breast cancer was the most frequently identified risk, with 
almost three-quarters (72.5%) all news stories mentioning a potential breast cancer risk 
associated with HT. Heart disease (41.5%) followed. Stroke (34.5%), uterine cancer 
(30.5%), and blood clots (25.4%) were all mentioned by more than a quarter of news 
stories. Cognitive decline, gallbladder disease, and the other category, which included 
more sporadically mentioned potential risks, such as increased lung cancer, hearing loss, 






To determine whether mentioned risks varied by the pre- and post-WHI period 
eight chi-square tests of independence were conducted at an alpha level of .05. The 
assumptions of independence and expected frequencies of at least five cases per cell were 
met for all tests. These analyses tested whether each potential risk was more or less likely 
to appear in news stories before or after the WHI announcement. As can be seen in Table 
22, all eight of the tests returned statistically significant results.  
News stories identified each risk more in the post-WHI period with the exceptions 
of uterine cancer risk and gallbladder disease, which both decreased slightly. Perhaps 
most notable in the pre-WHI period was the high frequency of reporting on the potential 


















































































Risks for Total Time Period and by Pre- vs. Post-WHI Period
Table 22






potential risk in the pre-WHI period, a percentage that increased to 84.6% in the post-
WHI period. The most dramatic increases in risk were for heart disease and stroke; 
mentions of a potential heart disease risk increased from 13.9% in the pre-WHI period to 
65.8% in the post-WHI period, and mentions of stroke increased from 8.0% to 57.9%. 
Benefit and risk presentation. In terms of benefit presentation, less than one-third 
of news stories (30.3%, f=105) that identified at least one benefit of HT (n=346) 
contained any quantitative information about a benefit. When benefits were quantified 
they were most often presented in relative terms. Almost a quarter of news stories that 
quantified a benefit contained relative information only (22.0%, f=76); 2.6% (f=9) 
contained absolute and relative information; 2.6% (f=9) provided absolute information 
only; and 3.2% (f=11) provided some other type of quantitative information. Of the 371 
news articles that included information about at least one risk, 37.7% (f=140) quantified a 
risk is some way. About one-fifth (19.7%, f=73) contained relative information only; 
10.0% (n=37) contained absolute and relative information; 5.9% (f=22) provided absolute 
information only, and 2.2% (f=8) provided some other type of quantitative information. 
RQ3c: How often were specific brand-name HT products mentioned in news 
stories? 
Brand-name drugs were mentioned in almost half 46.6% (n=200) of all news 
stories. In total, thirty-four different brand names appeared across the news stories, 
however, only a few brands were mentioned with any frequency. Table 23 below presents 
a rank-ordered list for the ten most frequently mentioned brands. A chi-square goodness- 
of-fit test was conducted at an alpha level of .05 to determine if the pattern of frequencies 





expected under the null hypothesis.  The assumptions of independence and expected 
frequencies of at least five cases per cell were met. Results indicated that the pattern of 
differences was statistically significant, χ
2
=765.66, df=9, p<.001.  Analysis of the 
residuals indicated that Premarin and Prempro were clearly mentioned more often than 
any other brands, as evidenced by large, positive standardized residuals greater than an 













































RQ3d: How often were pharmaceutical industry-related financial conflicts of 
interest mentioned in news stories?  
Disclosure of potential pharmaceutical industry-related financial conflicts of 
interest (COI) was fairly uncommon. Only 9.6% (n=41) of news stories mentioned any 
type of COI, which included research study-level financial conflicts, organizational-level 
conflicts, and individual-level conflicts.  In terms of the specific types of COI, research 
funding conflicts were the most often mentioned. Still, only 5.4% (n=23) of news stories 
disclosed a conflict related to a research study. Only 0.5% (n=3) mentioned 
organizational-level conflicts, and 4.0% (n=17) mentioned individual-level conflicts.   
 Content comparisons between press releases and news stories. This section 
presents the results from the series of questions related to research question four: How 
did the press releases and news stories compare in terms of content from 1995-2011?  
RQ4a: How did press releases and news stories compare in terms of the types of 
organizations mentioned and types of individuals quoted? 
Organizations mentioned. The organizations found in the body text of press 
releases mirrored the organizations mentioned in news stories closely. Press releases and 
news stories mentioned similar types of organizations with the same approximate 
frequency. As can be seen in Table 24, the organizations mentioned in both sequences 
ranked in the same exact order from highest to lowest. Five separate chi-square tests of 
independence were conducted at an alpha level of .05 to determine if each organization 
type was more or less likely to appear in press releases or news stories. The assumptions 
of independence and expected frequencies of at least five cases per cell were met for all 





to appear in news stories than press releases (65.3% vs. 59.3%). No other differences 
were statistically significant.   
 
Medical and scientific journals were also cited at roughly the same rate. Just about 
half of all press releases (50.4%, n=340) and news stories (51.7%, n=222) cited a medical 
or scientific journal article. A chi-square test of independence conducted at alpha .05 
determined that these percentages did not differ beyond what would be expected by 
chance, χ
2
=0.20, df=1, p=.66.  
 Individuals quoted in text. To determine if press releases and news stories differed 
in terms of the types of individuals they quoted, five chi-square tests of independence 
were conducted at an alpha level of .05. The assumptions of independence and expected 
frequencies of at least five cases per cell were met for all tests (the everyday family 
members and celebrity categories were eliminated from this analysis because they were 
rarely mentioned and resulted in cell size instability problems). As can be seen in Table 












































Organization Types in Body Text: PR Releases vs. News Stories (1995-2011)
Table 24






types of individuals quoted. While medical experts, such as physicians and nurses or 
other clinicians were quoted with the same frequency, other types of individuals were 
quoted differentially. Press releases were more likely to contain quotes from CEOs and 
other official organizational spokespersons than news stories (39.7% vs. 32.9%).  
Conversely, news stories were more likely to contain quotes from attorneys than press 
releases (7.0% vs. 1.2%). News stories were also more likely to quote everyday women 
about their experiences with menopause or HT than press releases (7.5% vs. 0.6%). 
 
RQ4b: How did press releases and news stories compare in terms of benefits 
and risks associated with HT and risk and benefit presentation (qualitative vs. 
quantitative; relative vs. absolute terms)?   
 Amount of information about benefits and risks. To test whether the amount of 
benefits and risks differed for press releases and news stories across the total study time 
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Types of Individuals Quoted in Press Releases vs. News Stories (1995-2011)






compare the mean number of benefits per press release and news story and the mean 
number of risks per press release and news story. For benefits, a two-tailed, t-test for 
unequal variance was used because Levene’s test for homogeneity of variance was 
rejected (F=50.64, p<.001). For risks, a two-tailed t-test for equal variances was used 
because Levene’s test for homogeneity of variance was not rejected (F=2.015, p=.16). As 
can be seen in Table 26, news stories contained more benefits per story and risks per 
story than press releases.   
 
 
Differences by pre- and post-WHI period. Because significant differences were 
found for press releases and news stories in terms of the reporting of specific benefits and 
risks by the pre- and post-WHI time periods in previous analyses, the mean number of 
benefits and risks was also compared within each time period. Again t-tests for 
independent samples were conducted to test for significant differences at an alpha level 
of 05. Levene’s test for homogeneity of variance was rejected for benefits in the pre-WHI 
period (F=15.52, p<.001), risks in the pre-WHI period (F=34.01, p<.001), benefits in the 
post-WHI period (F=16.16, p<.001), and risks in the post-WHI period (F=19.46, p<.001). 
For this reason a two-tailed, independent t-test assuming unequal variances was used for 
all comparisons. As can be seen in Table 27, when broken out by time period, news 
t df p
M SD M SD
Benefits 1.27 1.37 2.25 1.85 9.49 723 <.001
Risks 1.52 1.89 2.25 1.68 6.47 1102 <.001




Total News Stories 
(N =429)









 Specific benefits. To determine whether press releases and news stories were more 
or less likely to report on specific, potential benefits, six chi-square tests of independence 
at an alpha level of .05 were conducted to compare the percentages for each benefit 
across the two datasets. The assumptions of independence and expected frequencies of at 
least five cases per cell were met for all tests. Table 28 shows that news stories were 
significantly more likely than press releases to report on all potential benefits with the 
exception of vaginal atrophy; news stories and press release were equally likely to 
identify treatment of vaginal atrophy-related symptoms as a benefit of HT. In the case of 
heart disease prevention, colon cancer prevention, and prevention of cognitive decline, 
the percent of news stories that identified each benefit was approximately double the 










































Note . For all t-tests the unequal variance formula was used (adjusted dfs) because Levene's test was rejected.
Pre-WHI Post-WHI
Table 27






Differences by pre- and post-WHI period.  To further analyze differences between 
the identification of specific benefits in press releases and news stories, comparisons 
were made within the pre and post-WHI periods. Again, chi-square tests for 
independence at an alpha level of .05 were conducted to compare the percentages for 
each potential benefit across press releases and news stories, but this time separately 
within each time period. The assumptions of independence and expected frequencies of at 
least five cases per cell were met for all tests. Table 29 shows that in the pre-WHI period 
news stories were more likely to identify all benefits besides vaginal atrophy-related 
problems, conforming to the same pattern that was revealed for the total time period. A 
slightly different pattern emerged, however, in the post-WHI period for the case of heart 
disease prevention. News stories were no more likely than press releases to identify heart 
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other benefit with the exception of vaginal atrophy, but the differences were much less 
pronounced than in the pre-WHI period.  
 
Specific risks. To determine if press releases and news stories were more or less 
likely to identify specific risks, six chi-square tests of independence were conducted at an 
alpha level of .05 between press releases and news stories to see if the percentages across 
press releases and news stories differed significantly for each risk. The assumptions of 
independence and expected frequencies of at least five cases per cell were met for all 
tests.  
Table 30 shows that news stories were significantly more likely to identify breast 
cancer, heart disease, stroke, and uterine cancer risks. The difference in identification of 
breast cancer risk was the most striking; 40.9% of press releases identified breast cancer 
as a risk compared to 72.5% of news stories. Press releases and news stories were equally 
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Differences by pre- and post-WHI period. To further analyze differences between 
the identification of specific risks across press releases and news stories, comparisons 
were made within the pre and post-WHI periods. Again, chi-square tests for 
independence at an alpha level of .05 were conducted to compare the percentages for 
each potential risk across press releases and news stories, but this time separately within 
each time period. The assumptions of independence and expected frequencies of at least 
five cases per cell were met for all tests. The cognitive decline and gallbladder disease 
categories were eliminated from this analysis due to small cell counts. 
As can be seen in Table 31, when broken down by time period, similar patterns 
emerged. News stories were more likely than press releases in both time periods to 
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cancer in the total time period table was also notable within both time periods, but more 
so in the pre-WHI period. News stories in the pre-WHI period were almost four times 
more likely than press releases to identify breast cancer as a potential risk (58.7% vs. 
15.5%). While news stories were more likely to mention uterine cancer and blood clots in 
the pre-WHI period, this difference was not sustained in the post-WHI period.  
 
 Benefit and risk presentation. To determine if press releases or news stories were 
more or less likely to quantify benefits and to present them in relative or absolute terms, 
three chi-square tests of independence were conducted at an alpha level of .05. The 
assumptions of independence and expected frequencies of at least five cases per cell were 
met for all tests. Press releases and news stories did not differ in their propensity to 
quantify benefits; 26.6% (f=119) of press releases that included at least one benefit 
(n=448), quantified a benefit in some way compared to 31.5% (f=105) of news stories 
that included at least one benefit (n=346), χ
2




















































































Risks: Press Releases vs. News Stories by Pre- vs. Post-WHI Period
Pre-WHI Post-WHI
Press Releases vs. 
News Comparisons






quantitative presentation, Table 32 shows that press releases and news stories were 
equally likely to present information in relative terms. Although the small cell sizes 
warrant some caution, it appears that news stories were significantly more likely than 
press releases to quantify a benefit in absolute terms (5.2% compared to 1.6%).  
 
 To determine if press releases or news stories were more or less likely to quantify 
risks and to present them in relative or absolute terms, three chi-square tests of 
independence were conducted at an alpha level of .05. The assumptions of independence 
and expected frequencies of at least five cases per cell were met for all tests.  Press 
releases and news stories did not differ in terms of the frequency of providing 
quantitative information. About one-third (31.5%, f=129) of press releases that identified 
a risk (n=410) quantified it in some way as did 37.7% (f=140) of news stories that 
identified a risk (n=371), a difference that was no greater than what would be expected by 
chance, χ
2
=3.39, df=1, p=.07.  Table 33 shows that press releases and news stories also 
tended to provide quantitative information in relative terms at about the same frequency. 
News stories, however, were more likely than press releases to provide risk information 
Type of Quantitative Information
Press Releases that 
Identified at Least 
One Benefit 
(n =448)
News Stories that 






Any relative benefit information in 






Any absolute benefit information in 






Note.  Each document could include both types of information, one type of information only, or
neither.
Table 32





in absolute terms; 15.9% of news stories that contained risk information provided an 
absolute presentation format compared to only 8.3% of press releases. 
 
RQ4c: How did press releases and news stories compare in terms of mentioning 
specific brand-name HT products? 
To determine if press releases and news stories differed in terms of their 
likelihood of mentioning brand-name HT products, a chi-square test of independence was 
conducted at an alpha level of .05. The assumptions of independence and expected 
frequencies of at least five cases per cell were met. Results indicated that news stories 
were more likely than press releases to use brand names. Almost half (46.6%, n=200) of 
news stories mentioned at least one brand-name HT product compared to 39.7% (n=268) 
of press releases, χ
2
=5.14, df=1, p=.02. Table 34 lists the top-ten mentioned brands in 
press releases and news stories side-by-side in rank order from the most to least 
frequently mentioned. The pattern of brand names across the two datasets was similar. 
Six of the brands in the top-ten for press releases were also in the top-ten for news stories. 
Premarin and Prempro were by far the most mentioned brands in both press releases and 
news stories. 
Type of Quantitative Information
Press Releases that 
Identified at Least 
One Risk
(n =410)
News Stories that 






Any relative risk information in 






Any absolute risk information in 






Note.  Each document could include both types of information, one type of information only, or
neither.
Table 33






RQ4d: How did press releases and news stories compare in terms of mentioning 
pharmaceutical industry-related financial conflicts of interest?  
To determine if press releases or news stories were more or less likely to include 
information about financial conflicts of interest a chi-square test of independence 
conducted at an alpha level of .05. The assumptions of independence and expected 
frequencies of at least five cases per cell were met. Only 12.7% (n=86) of press releases 
and only 9.6% (n=41) of news stories mentioned any type of COI (individual, 
organizational, or research study) during the whole time period, a difference that was not 
statistically significant, χ
2
=2.61, df=1, p=.11. As discussed previously, research study-
related conflict of interest disclosures accounted for the vast majority of COI information. 
Press releases 11.3% (n=76) were about twice as likely as news stories 5.4% (n=23) to 
mention pharmaceutical industry funding of research studies, χ
2
=11.18, df=1, p<.001. 
Table 34
Brand %  (n ) Brand %  (n )
Premarin 17.3 (117) Premarin 29.8 (128)
Prempro 11.1 (75) Prempro 29.4 (126)
Cenestin 4.3 (29) Estratab 2.6 (11)
Estrasorb 3.6 (24) Provera 2.6 (11)
Estratest 2.5 (17) Vivelle/Vivelle-dot 1.9 (8)
Prometrium 2.2 (15) Estrace 1.2 (5)
Climara/Pro 1.8 (12) Cenestin 0.9 (4)
Premphase 1.8 (12) Elestrin 0.9 (4)
Provera 1.5 (10) Estratest 0.9 (4)
Enjuvia 1.5 (10) Prometrium 0.9 (4)









Other forms of COI (organizational-level and individual-level) were too infrequent to 
statistically test.   
RQ5: What specific organizations emerged as successful agenda builders as 
evidenced by frequent mentions of these organizations in both press releases and news 
stories? 
To determine the successful agenda builders, I ran frequencies on the database 
fields that contained the verbatim text for organization names that appeared in press 
releases and news stories. Next, I rank-ordered the organizations from the most to least 
mentioned. This ranking was conducted separately for the series of press releases and 
news stories. To arrive at a cut-off point for each series, I calculated the mean number of 
times each organization was mentioned across each dataset. For press releases, there were 
a total of 522 different organizations mentioned; each organization was mentioned in an 
average of 3.98 press releases (SD=14.39). For news stories there were a total of 285 
different organizations mentioned; each organization was mentioned in an average of 
5.25 news stories (SD=15.37). Adding one standard deviation to the mean for press 
releases resulted in 18.37 (3.98 + 14.39); adding one standard deviation to the mean for 
news stories resulted in 20.62 (5.25 + 15.37). This information combined with my 
examination of the rank-ordered frequency distributions for each series prompted me to 
eliminate organizations for consideration that were mentioned in 19 or fewer press 
releases or news stories. By putting the initial threshold for inclusion at 20 or more press 






Next, I listed the organizations that made the cutoff point in both sequences side 
by side in Table 35, which lists the organizations for each series in rank order. I then 
defined the top agenda builders as the organizations that appeared in both the press 
release and news sequences. These organizations are highlighted in bold type in Table 35.  
 
 This left ten organizations that represented the different types of organizations of 
interest to this study. Wyeth Pharmaceuticals was included for the pharmaceutical 
industry. Four academic/medical institutions were included: Wake Forest University, 
University of California-San Francisco (UCSF), University of California-Los Angeles 
(UCLA) and Harvard University. Three organizations in the nonprofit, health advocacy 
n n
Food & Drug Administration (FDA) 208 Wyeth (or formerly Wyeth-Ayerst) 164
National Institutes of Health (NIH)* 184 National Institutes of Health (NIH)* 135
Wyeth (or formerly Wyeth-Ayerst) 148 Food & Drug Administration (FDA) 99
Duramed Pharmaceuticals 43
Harvard University (includes Brigham & 
Women's Hospital)
85
North American Menopause Society (NAMS) 41 North American Menopause Society (NAMS) 44
Wake Forest Univeristy (includes Wake Forest 
Baptist Medical Center) 
31
Univ. of California, Los Angeles (UCLA) 
(includes UCLA's Harbor & Olive View Medical 
Centers)
41
Univ. of California, San Francisco (USCF) 29 American Heart Association (AHA) 33
Solvay Pharmaceuticals 27 University of California, San Francisco (USCF) 32
American College of Obsetricians & 
Gynecologists (ACOG)
25
Columbia University (also includes Columbia-
Presbyterian Medical Center)
26
Univ. of California, Los Angeles (UCLA) 
(includes UCLA's Harbor & Olive View Medical 
Centers)
25
American College of Obsetricians & 
Gynecologists (ACOG)
25
American Heart Association (AHA) 24
Wake Forest University (includes Wake Forest 
Baptist Medical Center) 
21
Novavax, Inc. 24
Harvard University (includes Brigham & 
Women's Hospital)
23
Yale University (includes Yale Medical Center & 
New Haven Hospital)
22
Stanford University (includes Stanford Medical 
Center)
20
*Includes global references to NIH and to specific
institutes, NHLBI, NCI, and NIA
Table 35
Organizations Mentioned in At Least 20 Press Releases and News Stories: 1995 - 2011
Press Releases (N =675) News Stories (N =429)
*Includes global references to NIH and to specific institutes, 





category were also represented: the North American Menopause Society (NAMS), the 
American College of Obstetricians & Gynecologists (ACOG), and the American Heart 
Association (AHA). Finally, two U.S. government agencies were also included: the Food 
& Drug Administration (FDA) and the National Institutes of Health (NIH). The 
qualitative content analyses in the following section focused on press releases and news 
stories that mentioned these ten organizations. 
Qualitative Analyses of Successful Agenda-Building Organizations 
This qualitative results section addresses research question six (RQ6). The first 
section (RQ6a) used supplementary document analysis to describe successful agenda-
building organizations in terms of their mission and goals, memberships, financial 
support, and any potential financial conflicts of interest in relation to the pharmaceutical 
industry. This information was then used to see if any financial conflicts found were 
disclosed in press releases and reported in news stories. The second section (RQ6b) 
explored potential collaborations between successful agenda-building organizations by 
examining whether any joint efforts were evident in the source or contact fields of press 
releases, or if common co-occurrences and associations between organizations emerged 
in the body text of the press releases. News stories that mentioned these organizations 
were also analyzed for common or divergent themes in these areas. Section RQ6c 
examined how these organizations constructed and defined menopause, and how those 
constructions related to proposed treatment recommendations. News stories that 
mentioned these organizations were also analyzed for common or divergent themes in 





 Collaborations between organizations. This section addresses research 
question six (RQ6) which asked: How, if at all, did organizations that emerged as key 
agenda builders via the quantitative content analysis procedures (as determined by RQ5 
above) collaborate with other organizations to build the news media agenda? 
RQ6a: What are the profiles of the most successful agenda-building 
organizations in terms of organization type, mission and goals, memberships, and 
financial support? Were any potential pharmaceutical industry-related financial 
conflicts of interest evident through archival analysis of these organizations’ websites 
or materials, such as annual reports, or financial disclosures available on scientific 
articles or elsewhere? Were pharmaceutical industry-related financial conflicts of 
interest disclosed in press releases produced by these organizations or that mentioned 
these organizations or in news stories that mentioned these organizations?  
The previous section identified ten organizations that were the most successful 
agenda builders as defined by their frequent mentions in press releases and news stories. 
This section briefly describes the financial interrelationships between these organizations 
with a focus on pharmaceutical industry support. General patterns of disclosure of 
pharmaceutical industry support that were found in press releases and news stories are 
also described.   
Wyeth Pharmacueticals. Wyeth Pharmaceuticals, formerly called Wyeth-Ayerst 
Research, and now a wholly-owned subsidiary of Pfizer, is the manufacturer of leading 
HT brands Premarin and Prempro (Pfizer, 2009). Wyeth funded large, randomized trials 
to assess the efficacy of HT for chronic disease prevention, including the Heart Estrogen 





women with heart disease, and the Women’s Health Initiative Memory Study (WHIMS) 
designed to assess HT’s ability to prevent Alzheimer’s disease (Kolata & Petersen, 2002). 
Wyeth also donated the study drugs for other NIH-funded clinical trials that assessed the 
relationship between HT use and prevention of heart disease, colon cancer, and 
osteoporosis, including the Postmenopausal Estrogen/Progestin Interventions trial (PEPI), 
the Estrogen Replacement and Atherosclerosis (ERA) trial, and the entire WHI study. 
The National Institutes of Health (NIH). The NIH is a federal, publicly-funded, 
medical research agency. Three institutes funded HT-related research through grants to 
various academic/medical institutions: the National Heart Lung & Blood Institute 
(NHLBI), the National Cancer Institute (NCI), and the National Institute on Aging (NIA). 
For example, NHLBI funded the WHI study, the Estrogen Replacement and 
Atherosclerosis (ERA) trial, the Postmenopausal Estrogen/Progestins Interventions 
(PEPI) trial, and the Nurses’ Health Study. NCI funded several studies that explored the 
relationship between HT use and breast cancer risk. The NIA funded studies related to 
memory, cognitive decline, and Alzheimer’s disease, with one of the more notable 
studies based on its epidemiological study, the Baltimore Longitudinal Study on Aging.  
Academic/Medical Institutions. The four academic/medical institutions, Wake 
Forest University, UCSF, UCLA, and Harvard University were featured prominently in 
medical journals, press releases, and news stories due to their roles as grantees in 
executing major clinical trials funded by NIH and Wyeth Pharmaceuticals. Wake Forest 
University’s Bowman Gray School of Medicine was the national clinical coordinating 
center for the PEPI trial, the ERA trial, and the WHIMS study. Harvard Medical School 





NHLBI-funded Nurses’ Health Study. UCSF was the national coordinating center for the 
HERS I and HERS II trials. The Harbor-UCLA Medical Center was a clinical site for the 
WHI study, and its LA Biomedical Research Institute conducted many secondary 
analyses of the breast cancer-related WHI data. 
American Heart Association (AHA). AHA is a 501c3 nonprofit organization with 
a mission “to build healthier lives, free of cardiovascular diseases and stroke.” AHA 
funds heart- and stroke-related research, publishes two scientific journals, and conducts 
educational outreach to health care professionals and the public. During the study time 
period, AHA issued clinical guidelines as the evidence base related to HT and heart and 
stroke outcomes evolved. AHA is supported by donations from individuals, foundations, 
and a broad cross-section of health and non-health oriented corporations. Wyeth-Ayerst 
was listed, along with other pharmaceutical companies, in AHA’s 2010-2011 annual 
report in a section that recognized lifetime giving of $1,000,000 or more (American Heart 
Association, 2012b).  
North American Menopause Society (NAMS). NAMS is a 501c3 nonprofit 
organization “dedicated to promoting the health and quality of life of all women during 
midlife and beyond through an understanding of menopause and healthy aging.” NAMS 
provides continuing education for physicians, publishes a scientific journal, and produces 
and distributes consumer education materials. During the study time period, NAMS 
issued clinical practice guidelines and position statements on the relationship between HT 
and a variety of health and quality of life outcomes. NAMS is funded primarily through 
dues collected from its membership, which consists primarily of physicians, and 





Menopause Society, 2012a). Annual reports from 2006 to 2008 listed primarily 
pharmaceutical companies as corporate supporters, including Wyeth Pharmaceuticals 
each year, but no dollar amounts were available. Beginning in 2009, NAMS’ annual 
reports stopped listing corporate supporters (North American Menopause Society, 
2012b).  
American College of Obstetricians & Gynecologists (ACOG). ACOG is a 501c(3) 
nonprofit membership organization “dedicated to the advancement of women’s health 
care through continuing medical education, practice, and research” (American Congress 
of Obstetricians & Gynecologists, 2012). ACOG provides continuing education 
opportunities for its members, who are primarily practicing obstetricians and 
gynecologists, publishes a scientific journal, and produces a variety of educational 
materials for consumers. During the study time period, ACOG convened a Task Force to 
review the state of the evidence on HT and published clinical practice guidelines. Sources 
of financial support for ACOG include membership fees and donations from individuals 
and corporations. In its 2010-2011 report to donors, its corporate support section listed 
primarily pharmaceutical companies active in women’s health, but these companies were 
not connected to any specific dollar amounts. Wyeth Pharmaceuticals was not listed in 
this report, and no other previous reports were available.  
Food & Drug Administration (FDA). The FDA is federal, publicly-funded, 
regulatory consumer protection agency with authority over food and drug products. 
During the study time period, the FDA reviewed new drug applications for a variety of 
HT products, mandated labeling revisions to HT products based on emerging evidence, 





benefits and risks of HT in the aftermath of the WHI findings. Although the FDA is 
primarily funded by U.S. taxpayers, pharmaceutical companies fund a substantial portion 
of its activities through fees paid when submitting new drug applications (USDHHS 
FDA, 2009).  
Examination of journal articles published by the four academic/medical 
institutions for major trials referenced in this results section were reviewed for financial 
support disclosures. When Wyeth Pharmaceuticals was the sole funder of a trial, as in the 
case of WHIMS and HERS, this information was routinely disclosed. Disclosure of 
Wyeth’s donation of study medications for trials was more rarely identified.  Disclosure 
of study investigators’ individual-level, financial conflicts of interest varied by the 
medical journal and date of publication. JAMA provided the most detailed information, 
but this type of  information only began to emerge in 1998, with earlier JAMA 
publications including much less information. Studies reviewed from NEJM, Circulation, 
and Neurology supplied no information. When individual-level conflicts were disclosed, 
sometimes multiple authors reported receiving grants, consulting, or speaking fees from a 
variety of pharmaceutical companies, including Wyeth. An article in PLOS Medicine, 
which included a list of 28 published journal articles that were later determined through 
litigation to be ghostwritten by Wyeth’s contractor, DesignWrite, was also reviewed 
(Fugh-Berman, 2010). No publications from faculty members from the four 
academic/medical institutions that emerged as top agenda builders appeared on this list.  
Two prominent academics who played key leadership roles at AHA and NAMS during 





Examination of the press releases produced and distributed by the top-ten agenda- 
building organizations revealed that some types of financial conflicts were more likely to 
be disclosed than others. Press releases distributed by the NHLBI routinely disclosed that 
Wyeth had supplied the study drugs for its PEPI, ERA, and WHI trials, and had funded 
the WHIMS sub-study of the WHI. Wyeth also distributed press releases announcing its 
support of these major trials as evidence of its commitment to women’s health. For 
example, in a press release announcing its $16 million investment in WHIMS, its 
contribution of more than 100,000,000 Premarin and Prempro tablets for the larger WHI 
trials, and its $40 million Heart and Estrogen/Progestin Replacement Study (HERS), 
Wyeth Pharmaceuticals, then Wyeth-Ayerst Laboratories, said it was part of their 
“commitment to and long history in understanding the science of women’s specialized 
health needs” (Wyeth-Ayerst Laboratories, 1996). 
The press releases of most academic/medical institutions disclosed the role of 
Wyeth when it was the primary funder of a trial. Disclosure of Wyeth’s support in the 
form of supplying study drugs occurred as well, but more infrequently, and none of the 
releases by academic/medical institutions included any information about the potential 
financial conflicts of its faculty investigators.  For example, Wake Forest University 
disclosed that Wyeth-Ayerst was the funding source for the WHIMS trial and 
acknowledged Wyeth’s and other pharmaceutical companies’ contribution of study drugs 
for the PEPI trial. UCSF releases related to the HERS trials identified Wyeth-Ayerst as 
the study’s sponsor. Harbor-UCLA Medical Center’s releases credited NIH support for 
its analyses of the WHI data, but did not mention Wyeth’s contribution of study drugs. 





published in its journal, Circulation, but did not supply any information about Wyeth’s 
funding of the trial.  
Disclosures by nonprofit organizations about organizational-level financial 
conflicts, such as charitable contributions made by pharmaceutical companies to support 
their mission or specific activities were almost non-existent in press releases. Although of 
the three nonprofit organizations that emerged as successful agenda builders, only AHA 
issued a substantial number of press releases to examine, which is an issue that will be 
discussed in the following section. Still, only one release was found that acknowledged 
pharmaceutical support of an organization. This release, which publicized the results of 
an AHA-funded study on HT and heart disease prevention in younger women, had an 
editor’s note at the bottom of the release acknowledge that “foundations and corporations 
– including pharmaceutical, device, manufacturer and other companies – make donations 
and fund specific American Heart Association/American Stroke Association programs 
and events” (AHA, 2008).   
Information in news stories with respect to financial conflicts of interest were 
similar to what appeared in press releases and on scientific publications, perhaps an 
indicator that when conflict of interest information is made available journalists will 
include it. News reports about WHIMS and HERS often identified Wyeth as the sponsor. 
During this time period, just about all the news stories identified Premarin and Prempro 
as the drugs used in the WHI and Wyeth as their manufacturer, but only a few stated that 
Wyeth had actually donated the study drugs for the trial. The isolated cases in which 
individuals’ financial conflicts were reported tended to be based on studies published in 





on June 22, 2004, about a study published in JAMA from the WHIMS trial included the 
following: “The analysis by Shumaker, Rapp and colleagues was funded by Wyeth and 
Wake Forest. Shumaker has served as a consultant for Wyeth” (Associated Press, 2004).  
RQ6b: Did these organizations tend to collaborate with other organizations to 
produce joint press releases as evidenced by the press release source and contact 
fields? Did mentions of these organizations tend to frequently be associated with 
mentions of other organizations in the text of press releases? How did these patterns of 
organizational associations compare to the patterns of associations found in news 
stories that mentioned these same organizations? 
To answer RQ6b, press releases that mentioned the top-ten agenda builders as 
defined in this study were sorted into the following two categories: releases that were 
actually produced by the ten organizations and releases that were produced by other 
organizations but contained a reference to one or more of the top-ten organizations in the 
body text. Examination of the release source and contact fields yielded few examples of 
joint efforts in producing releases; most releases were identified as the product of one 
organization. What became apparent, however, was that some organizations actively tried 
to build the news media agenda by distributing releases and others appeared to be more 
passive, rising to the top of the agenda through the publicity efforts of other organizations 
that cited them. It should be noted that organizations may have distributed releases 
through channels other than PR Newswire or EurekAlert!, or conducted media relations in 
other ways. Nevertheless, based on the available evidence in this study, some interesting 





Wyeth Pharmaceuticals was the most actively involved organization, distributing 
more press releases than any of the other nine organizations, followed by 
academic/medical institutions and the NIH. Wyeth distributed a total of 58 releases 
across a broad range of topics related to HT, including research findings, regulatory 
issues, clinical practice guidelines, lower-dose formulations of Premarin and Prempro, 
and lawsuits by plaintiffs alleging that Prempro caused their breast cancer. Combined, 
the four academic/medical institutions distributed a total of 35 releases, which focused 
primarily on research study findings. The NIH, including NHLBI, NCI, and NIA 
distributed a total of 21 releases, which were focused on findings from Institute-funded 
studies and announcements about the cessation of the WHI trials. Many of these releases 
included quotes and contact information for principal investigators at the four 
academic/medical institutions, who ran clinical sites or served on NIH steering 
committees or advisory panels. Medical journal publishers also used Eurekalert! to 
distribute press releases announcing articles published by these academic/medical 
institutions in their journals. 
Wyeth played a large role in publicizing not just the findings of studies it directly 
funded, but other studies with implications for its products, through position statements 
issued as press releases. A distinct pattern emerged in terms of how Wyeth framed these 
releases. Studies with findings that were positive for HT were enthusiastically endorsed; 
studies with negative findings were refuted as inconsistent with other evidence, picked 
apart on methodological grounds, reinterpreted as not meaning what the authors thought 
it did, or altogether ignored. For example, studies showing a favorable effect of HT on 





in 2000 were positioned in a Wyeth release as supporting a “a growing body of 
epidemiological studies that have shown ERT and HRT to impact on body systems in a 
way that may help decrease the risk of coronary heart disease” (Wyeth-Ayerst 
Laboratories, 2000). Commenting on a study published in JAMA in 1995, which found no 
breast cancer risk associated with HT use, Wyeth asserted that the study “supports the 
majority of studies that have not shown an association between estrogen use and 
increased breast cancer risk” (Wyeth-Ayerst Laboratories, 1995b). Conversely, in a 2002 
release announcing the unexpected, negative results from its HERS II trial to see if HT 
prevented heart attacks, Wyeth made no mention of its role in designing and funding the 
trial and argued that the findings applied only to “older women with heart disease, not the 
typical woman on HRT” (Wyeth Pharmaceuticals, 2002).  
Other interesting patterns surfaced in the nonprofit category of organizations. 
Although these organizations only distributed a total of 15 releases, references to AHA, 
NAMS, and ACOG were prevalent in the releases of other organizations. A good portion 
of these references appeared in releases reporting research findings presented at these 
organizations’ annual scientific meetings. Pharmaceutical companies also often used 
statistics compiled by these three nonprofit organizations to support a problem or need 
that could be fulfilled by their products. For example, in a press release for a competitor 
product to HT in the heart disease area, an Eli Lilly press release stated: “Heart disease is 
the number-one killer of women in the U.S. and developed countries. According to the 
American Heart Association, more than one in three women over the age of 65 has some 
form of cardiovascular disease” (Eli Lilly & Company, 1998). Announcing FDA 





distributed a press release which said, “According to the North American Menopause 
Society (NAMS), an estimated 10 to 40 percent of post-menopausal women suffer from 
symptoms related to vaginal atrophy” (Barr Pharmaceuticals, 2008).   
Clinical practice guidelines written by NAMS and ACOG were also frequently 
used in pharmaceutical companies’ press releases to justify their products in terms of the 
scientific evidence base. For example, in a press release distributed in 2004, Wyeth 
Pharmaceuticals applauded ACOG’s Hormone Therapy Task Force report, describing it 
as the “evidence-based consensus among leading women’s health experts” and stating 
that: 
The American College of Obstetricians and Gynecologists (ACOG) Hormone 
Therapy Task Force confirms that estrogens and estrogens plus progestins are 
‘highly effective’ in relieving postmenopausal vasomotor symptoms, are the 
‘most effective treatment’ for severe symptoms, and may be the appropriate ‘first 
choice therapy’ for the prevention of osteoporosis in women with menopausal 
symptoms” (Wyeth Pharmaceuticals, 2004).  
The FDA only distributed one press release during the study time period that was 
retrieved via the databases used in this study. A review of the FDA website, however, 
indicated that there were perhaps a few, but not many, press releases distributed by the 
FDA in relation to HT that were not captured by this study’s search strategy. Still, the 
FDA emerged as the top-mentioned organization in press releases, primarily due to the 
large number of press releases distributed by pharmaceutical companies that mentioned 





For news stories reviewed that contained mentions of the top-ten agenda-building 
organizations, some patterns of associations between organizations seemed to hold. 
Based on the frequency analysis conducted for RQ5 alone, presented previously in Table 
35, it is clear that news stories and press releases mentioned similar organizations. News 
stories in general, however, tended to take the next step to explore the viewpoints of 
organizations more than press releases. For example, while news stories cited 
organizations like AHA, ACOG, and NAMS for statistics related to chronic disease 
prevalence and other problems, they also often included quotes from executives and 
physicians associated with those organizations on various issues related to HT. News 
stories also tended to include more opposing viewpoints about topics, whereas, press 
releases typically presented one viewpoint and mentioned the efforts of other 
organizations that supported those viewpoints.  
RQ6c: How did these organizations construct and define menopause, and how 
did these definitions relate to proposed treatment recommendations in press releases 
that were produced by these organizations or that mentioned these organizations? How 
did these definitions and treatment recommendations compare to those used in news 
stories that mentioned these same organizations? 
Menopause was defined differently in press releases in the pre- and post-WHI 
periods as were corresponding treatment recommendations. In the early years of the 
study, menopause was rarely addressed in specific ways. The focus of releases was more 
on HT and its ability to prevent chronic diseases that begin to occur in postmenopausal 
women. Rather than being attributed to the process of aging overall or lifestyle choices, 





depletion. Many releases framed chronic diseases as “the problem” so to speak rather 
than the experience of menopause. This was true of almost all of the ten organizations 
studied. 
One major theme was the tradeoff between heart disease risk and breast cancer 
risk, along with the recurring message that heart disease claims more lives than breast 
cancer. For example, a 1997 Wyeth press release about findings reported in NEJM from 
the observational Nurses’ Health Study, which indicated that nurses who used HT had 
53% less coronary heart disease deaths than nurses who never used HT, included the 
following quote: “After age 45, the risk of death from cardiovascular disease outweighs 
the risk of death from breast cancer. In fact, coronary heart disease kills 233,000 women 
in contrast to 43,000 women who die of breast cancer in the United States each year” 
(Wyeth-Ayerst Laboratories, 1997). Similarly, a NHLBI press release about another 
study published in NEJM that same year, which found that women with higher bone mass 
had higher rates of breast cancer, raising speculation about the potential role of estrogen, 
Dr. Claude Lenfant, Director of the NHLBI, cautioned that “the findings should be kept 
in perspective since, for most women, estrogen may provide crucial benefits against heart 
disease and osteoporosis.” This commentary was followed by text stating that, “Heart 
disease is the leading cause of death among American women. While about 44,000 
women died of breast cancer in 1994, approximately 370,000 died of heart disease” 
(NHLBI, 1996). 
During the post-WHI period, press releases, particularly those released by 
pharmaceutical companies, began to shift toward more focus on the symptoms related to 





the best decision for themselves given the risks and benefits of HT therapy. While hot 
flash reduction was certainly mentioned in the pre-WHI period, it was typically 
mentioned almost as a convenient addition to the chronic disease prevention benefits of 
HT. In the post-WHI period, however, press releases distributed by Wyeth and other 
pharmaceutical companies emphasized that many postmenopausal women suffered from 
menopausal symptoms that significantly lowered their quality of life. For example, in a 
press release by Wyeth on October 24, 2002, urging “practical guidance” for women on 
initiating hormone therapy, Wyeth argued that the benefits of treating “menopausal 
symptoms,” along with “concomitant prevention of postmenopausal osteoporosis 
prevention,” outweigh the risks of HT when used on a short-term basis. The releases went 
on to state: 
While menopausal symptoms represent the primary reason women seek treatment 
with HT, prevention of postmenopausal osteoporosis is also an important 
approved use of HT. Menopausal symptoms have a significant impact on many 
women's lives and can impair their ability to function normally on a daily basis. 
News stories were somewhat similar to press releases in terms of their orientation 
toward the chronic disease prevention benefits of HT in the pre-WHI period. In fact, 
“Study: Estrogen Use Should Begin at Menopause, Continue Indefinitely,” was the 
headline for the first news story for this study, which ran in the Associated Press on 
January 3, 1995. Another Associated Press story on June 19, 1997, about the Nurses’ 
Health Study data published in NEJM that found reduced death due to coronary disease 





Patients often fear breast cancer more than heart disease or hip fracture, although 
the last two afflictions kill a lot more women, the researchers noted. Breast cancer 
claims about 43,000 women a year compared with 233,000 for heart disease – the 
leading killer of women – and 65,000 for hip fracture, they said”(Coleman, 1997). 
A fair number of news stories, however, focused in on the breast cancer risk more 
than press releases, acknowledging that it was a real concern for women, even very early 
on in the pre-WHI period. For example, a story in the Washington Post in response to the 
NEJM study published on June 15, 1995, which found increased rates of breast cancer in 
women who took HT and participated in the Nurses’ Health Study said the report had 
“generated fear and some skepticism among women, many of whom rushed to call their 
doctors to discuss it, physicians reported.” The article also included quotes from women 
who were unconcerned, saying they would continue to take their medication, and from 
women who were scared, confused, and angry (Shen & Smith, 1995). 
During the immediate post-WHI period, several news stories focused on the 
difficult decision women faced about whether to take HT or not, particularly for women 
who experienced hot flashes. These stories tended to include quotes from physicians and 
women about their perspectives on the issue. Several investigators at the top-four 
academic/medical institution were quoted in these stories, likely due to their involvement 
with the trials and knowledge of the science. For example, Dr. Deborah Grady, Director 
of the Mount Zion Women's Health Clinical Research Center at UCSF and one of the 
principal investigators for the HERS studies stated in a July 16, 2002, New York Times 
article that, “If a woman can't sleep and can't work, and estrogen is the only therapy that 





discomfort she's willing to put up with and how much risk she's willing to take" 
(Duenwald, 2002, p. F1).  
Some of the news stories during this time period mentioned non-prescription 
alternatives to treat hot flashes, such as black cohosh, soy, reducing caffeine intake, 
breathing techniques, and dressing in loose and light clothing. These alternatives did not 
appear in the press releases of the top-ten agenda building organizations, although many 
alternative health and supplement manufactures did issue press releases about their 
products during this time period. For the most part, the top-ten agenda-building 
organizations stayed focused on the argument that HT was still a reasonable option for 
short-term use by menopausal women without a history of heart disease. Newer, lower-
dose HT formulations emerging on the market were also suggested as options, although 
both press releases and news stories were careful to make clear that there was no 
evidence that these lower doses were necessarily safer. Commenting on alternative herbal 
and dietary supplements in an Associated Press story on July 19, 2002, Dr. Wulf Utian, 
executive director of NAMS, who was later identified in 2010 for authoring scientific 
articles ghostwritten by Wyeth, stated, "All the snake oil salesmen selling cures for 
menopause will be out there advertising. There is virtually nothing that is much better 
than a placebo unless it is a prescription drug” (Haney, 2002). 
During both the pre-WHI and post-WHI periods a large number of press releases 
and news stories featured the results of research studies. In many cases these studies were 
non-controlled, observational studies, suggestive of HT’s ability to prevent chronic 
diseases, or controlled studies that only measured HT’s effect on surrogate indicators or 





types of studies had little immediate clinical value, as they did not meet the rigorous 
standards required by the FDA to expand HT’s indications. The press releases for these 
types of studies were carefully crafted to be scientifically accurate by using qualifying 
terms like “may” or “suggest.”  For example, press releases distributed by the NIH and 
academic/medical institutions commonly featured headlines like “Effect of Hormone 
Therapy on Risk of Heart Disease May Vary by Age and Years Since Menopause,” 
(NHLBI, 2007), “Study Suggests ERT Stimulates Blood Flow to the Key Memory 
Centers in Brain” (NIA, 2000), and “Hormone Replacement Therapy May Help Prevent 
Heart Vessel Disease, Says Wake Forest Researcher” (Wake Forest University, 2002). A 
review of news stories based on findings from the NIH and academic/medical institutions 
confirmed that journalists were careful to carry over these same types of qualifying terms 
to their news stories. Although these communications were carefully worded, in their 







Chapter V: Discussion 
This longitudinal study used a theoretical framework proposed by Zoch and 
Molleda (2006) that combines agenda building, framing, and information subsidies to 
explore how a variety of health and medical organizations used public relations efforts to 
build and shape the news media agenda for postmenopausal hormone therapy (HT) from 
1995 to 2011. The theoretical framework was applied to a quantitative content analysis of 
675 press releases distributed by PR Newswire and Eurekalert!, and 429 news stories that 
appeared in the Associated Press Newswire (AP), The New York Times, The Washington 
Post, Los Angeles Times, and The Wall Street Journal. Supplemental qualitative content 
analysis procedures were also used to understand the financial relationships and potential 
collaborations that existed between ten organizations that emerged from the quantitative 
content analysis as the most successful agenda builders, and how these organizations 
framed problems associated with menopause and potential treatments. In addition to press 
releases and news stories that were relevant to these organizations, the organizations’ 
websites, annual reports, and key scientific publications were reviewed for financial 
disclosures.  
Findings revealed that six different types of health and medical organizations 
produced information subsidies in the form of press releases about HT: pharmaceutical 
companies, academic/medical institutions, nonprofit organizations, medical/scientific 
journal publishers, miscellaneous for-profit organizations, and U.S. government agencies. 
Substantial evidence supported the premise that the public relations agendas of these 
organizations played a role in setting and shaping the news media agenda for HT. A 





of press releases and news stories was found over the study time period (r = .55, p<.001). 
Findings also supported the transference of specific objects and attributes from the public 
relations agenda to the news agenda. Striking similarities were found between the content 
of press releases and news stories for overall story themes, types of organizations 
mentioned, types of individuals quoted, disclosure of pharmaceutical industry conflicts of 
interest, brand-name HT products mentioned, the benefits and risks associated with HT at 
different points in time, and how those benefits and risks were framed in terms of their 
magnitude and potential tradeoffs. Although press releases and news stories mentioned 
specific benefits and risks with just about the same relative frequency, news stories 
reported on all benefits and risks more often, particularly the potential for breast cancer 
risk. Similarly, although press releases and news stories mentioned the same types of 
organizations, news stories tended to explore the viewpoints of organizations and 
individuals associated with those organizations in more depth. 
Interesting differences by organization type about the benefits and risks of HT 
were found. Although pharmaceutical companies, academic/medical institutions, U.S. 
government agencies, and nonprofit organizations did not differ significantly in terms of 
the quantity of benefits per press release, the specific benefits communicated did vary, 
particularly when it came to more controversial, non-FDA approved, off-label 
indications. Academic/medical institutions and nonprofit organizations were more than 
four times as likely as pharmaceutical companies to mention a potential non-FDA 
approved heart disease-prevention benefit. U.S. government agencies reported more risks 
per release than any other organization type, and pharmaceutical companies reported 





closely to the risks mandated at any point in time by FDA labeling requirements. Overall, 
this study found that pharmaceutical companies were more cautious and careful 
communicators than expected, often pasting the FDA-approved product labeling at the 
end of their releases, perhaps in an effort to avoid regulatory consequences.   
The most successful agenda builders that emerged from the quantitative content 
analysis were Wyeth Pharmaceuticals, NIH, FDA, Wake Forest University, UCSF, 
UCLA, Harvard University, AHA, NAMS, and ACOG. Although some organizations 
actively tried to build the news media agenda by distributing releases, others appeared to 
be more passive, rising to the top of the agenda through the publicity efforts of other 
organizations. Supplemental document analysis found that Wyeth financially subsidized 
the efforts of at least eight of the other organizations and played a primary role in 
generating attention not only to its own organization through press releases, but to the 
efforts of the other nine organizations. Wyeth proactively commented on the findings 
released by the academic/medical institutions about major HT-related clinical trials, 
which all received financial support directly or indirectly from Wyeth. Wyeth, along with 
other pharmaceutical companies, frequently cited the three nonprofit organizations, AHA, 
NAMS, and ACOG in its press releases for statistics on disease prevalence and clinical 
practice guidelines to demonstrate a need for and justify their products.  
There were also similarities in the way the top-ten agenda-building organizations 
framed the problems associated with menopause and proposed treatment 
recommendations, suggesting if not direction collaboration, certainly a high degree of 
synergy between the organizations. In the pre-WHI period, press releases and news 





postmenopausal women. Chronic disease was framed as the “problem,” estrogen 
depletion as the “cause,” and HT as the “solution.” One major theme that emerged was 
the tradeoff between heart disease risk and breast cancer risk for women considering HT, 
along with the recurring message that HT was a beneficial choice because heart disease 
claims more lives than breast cancer. During the post-WHI period, press releases, 
particularly those released by pharmaceutical companies, and news stories, shifted to a 
focus on the symptoms related to menopause, particularly hot flashes, and the need for 
women to be proactive and make the best decision for themselves given the risks and 
benefits of HT, with short-term and/or low-dose HT still offered as a viable solution for 
younger postmenopausal women. Alternative, non-prescription remedies received no 
attention from the ten organizations. News media gave somewhat more attention to 
alternative approaches, but this attention was short-lived and primarily restricted to the 
time period immediately following the WHI announcements.  
Theoretical Implications 
This study provided a systematic look at what types of health and medical 
organizations produce sources of information about prescription drug news; what their 
resources and goals are; how they act individually, and perhaps jointly with other 
organizations, to influence news content; and how these processes might influence the 
quality of news about prescription drugs. Findings from this study contributed to public 
relations scholarship by demonstrating the viability of Zoch and Molleda’s (2006) 
theoretical framework for a health and medical context and by contributing support for 
each component of the framework: agenda building, information subsidies, and framing. 





uncovering how organizations may work not just in isolation, but jointly, through behind-
the-scenes funding mechanisms and third-party techniques to build and frame the news 
media agenda.  
While organizations often issue information subsidies directly to journalists, they 
also do so indirectly through a variety of third-party techniques. Third-party techniques 
refer to getting other experts, organizations, or coalitions that are perceived as more 
disinterested in an issue and credible to deliver a message (Palenchar & Fitzpatrick, 2009; 
Rampton & Stauber, 2002). Although more blatantly unethical practices, such as the use 
of front groups, have been explored in the public relations literature (see Palenchar & 
Fitzpatrick, 2009), literature is lacking on how more legitimate organizations might use 
third-party techniques to communicate messages to news media. This study’s pattern of 
findings suggested that pharmaceutical companies may make substantial use of third-
party strategies by subsidizing the efforts of academic/medical institutions and nonprofit 
health advocacy organizations that communicate to news media about the benefits and 
risks of prescription drugs.  
Agenda building. The finding that the amount of press releases and news stories 
during the study time period were positively and moderately correlated with one another 
contributes substantially to the agenda building literature. Although scholars have argued 
for more studies that trace information studies through the process to see how they  
influence the news media agenda (Cameron et al., 1997; Gandy, 1982; Kiousis et al. 
2006; Shoemaker & Reese, 1996; Zoch & Molleda, 2006), only a few studies have 
examined the relationship between the salience of issues and topics in press releases and 





candidates, political issues, and corporate reputation (Kiousis et al. 2006; Kiousis et al., 
2007; Kiousis, 2009). The results of this exploratory study provided empirical support for 
the agenda-building concept in a health and medical context and lay the foundation for 
future research studies that employ statistical modeling approaches to examine whether a 
causal relationship exists.  
Thematic analyses of the types of content that were associated with heightened 
press release and/or news activity also provided deeper insight into the agenda-building 
process. A continual, up-and-down pattern of spikes and valleys for the quantities of 
press releases and news stories over time, which appeared to be initiated sometimes by 
press releases and sometimes by news stories suggested a high degree of interactivity 
between the public relations and news agendas. Activities performed by organizations, 
such as releasing research findings, engaging in regulatory-related actions and disputes, 
issuing clinical practice guidelines, and responding to legal actions stimulated the most 
news coverage, and press releases that were purely product promotional in nature had 
much less influence. While past scholarship has conceptualized agenda building as an 
interactive, reciprocal process driven by the agendas of organizations and publics and the 
news media and policy agendas all interacting with one another (Cobb & Elder, 1972; 
Corbett & Mori, 1999; Gozenbach, 1996; Kiousis et al., 2007; Lang & Lang, 1981; 
Schneider, 1977; Walters & Gray, 1996), this study was able to highlight the significant 
role organizations played in this process for a health and medical issue. 
Information subsidies. Data obtained in the course of this investigation 
contributed to the information subsidies literature by detailing how organizations use 





ways. Pharmaceutical companies yielded a higher degree of explicit influence on the 
news media agenda than expected based on past scholarship suggesting that journalists 
prefer information subsidies produced by U.S. government agencies, academic/medical 
institutions, and non-profit organizations (e.g., Berkowitz & Adams, 1990; Cho, 2006; 
Curtin, 1999; Dunwoody, 1986; Friedman, 1986b; Gandy, 1982; Gans, 1979; Tanner, 
2004; Van Trigt et al., 1994; Wallington et al., 2007; Qui, 2006). Although 
academic/medical institutions and U.S. government agencies appeared in more than 50% 
of press releases and news stories, pharmaceutical companies were close behind, 
appearing in 47.1% of press releases and 43.8% of news stories, surpassing nonprofit 
organizations. This conclusion may be limited, however, by equating mentions of 
organizations with influence. For example, after the WHI announcements, Wyeth 
Pharmaceuticals was often mentioned in news stories that associated the company with 
the drugs that had caused harm in the WHI trials or with lawsuits by women who claimed 
Prempro caused their breast cancer. Clearly, these are the types of mentions that Wyeth 
would have preferred to avoid.   
Perhaps more compelling were the data generated about how pharmaceutical 
companies may influence the news media agenda in less explicit ways through third-party 
strategies. Although no empirical studies previously existed in this area, literatures 
related to information subsidies, third-party techniques, and conflict of interest in 
medicine (Batt, 2005; Beder et al., 2003; Burton & Rowell, 2003a; Gandy, 1982; IOM, 
2009; Palenchar & Fitzpatrick, 2009; Rampton & Stauber, 2002), suggested that 
pharmaceutical companies would fund the efforts of U.S. government agencies, 





would in turn influence the news media through press releases about these efforts. 
Wyeth’s funding of U.S. government agencies, academic/medical institutions, and 
nonprofit organizations with the ability to advance its strategic interests for HT was 
extensive, disclosure of these financial conflicts by Wyeth and the organizations and 
individuals receiving funding on scientific publications, organizational materials, and 
press releases were poor and inconsistent, and similar frames about HT were 
communicated to the news media by these organizations. Additionally, Wyeth played a 
proactive role in generating attention not only to its own organization through press 
releases, but to the efforts of the other organizations it subsidized. These exploratory 
findings offer initial support to justify future research to delve into these strategies more 
comprehensively. 
Framing. Findings from the quantitative and qualitative components of this study 
provided support for the transference of specific frames from the public relations agenda 
to the news media agenda. Second-level agenda setting research has indicated that news 
media attention can influence how people think about an object by selecting and or 
emphasizing some of its substantive attributes and ignoring or downplaying others 
(Kiousis et al. 2006, 2007; McCombs, 1992; McCombs & Ghanem, 2001). Patterns of 
resemblance between press releases and news stories for HT brand names and the 
benefits and risks associated with HT, not just over the entire study time period, but also 
within the pre- and post-WHI time periods, indicated that attribute frames were 
successfully transferred from organizations to the news media agenda. The finding that 
pharmaceutical companies were more cautious and careful communicators than expected 





and academic medical institutions were more likely to communicate about off-label 
benefits, suggest that in the prescription drug context there may be some underlying 
strategy to what attributes of a product different organizations convey to the news media, 
lending further support to the potential role third-party techniques may play in a 
regulatory environment. 
Past research has also found that the way an issue or problem is framed can lead 
to different causal attributions and treatment recommendations (Entman, 1993; Iyengar, 
1991). This study also found support for the transference of these types of frames to news 
media. Press releases and news stories framed HT as the solution to what was framed as 
estrogen-induced chronic disease in the pre-WHI period and shifted gears in the post-
WHI period framing HT as a solution to menopausal symptoms, particularly hot flashes. 
The finding related to the tradeoff between heart disease and breast cancer risk was one 
of the more intriguing findings in this study. Gandy (1982) suggested that by strategically 
controlling access to information through the production and distribution of information 
subsidies, organized interests can succeed in “changing the stock of information” on 
which decisions are made (Gandy, 1982, p. 13). In the years leading up to the WHI 
announcement, the efforts of multiple organizations succeeded in shifting the risk-benefit 
profile of HT by reinforcing the message that the potential for breast cancer was less 
worrisome than a purported heart-disease prevention benefit, which was never 
empirically supported with a controlled clinical trial or approved by the FDA, through the 
sponsorship, publication and promotion of observational studies or trials that only 
examined surrogate outcomes like risk factors. While many scientists, including those at 





eventually confirm a heart disease prevention benefit, the recommendations were 
premature and served to expand the market for HT considerably for several years while 
Wyeth, and the rest of the medical community, waited for what they mistakenly thought 
would be confirmatory evidence.  
Research on Prescription Drug Promotion 
This study adds a new perspective to the growing literature on prescription drug 
promotion, which thus far has only taken into account overtly promotional sources of 
information such as direct to consumer advertising, by conceptualizing news as 
promotional with potentially similar consequences. Figure 1, Chapter II, pictured below 
outlined the overall focus and scope of the study. This figure proposed that a variety of 
health and medical organizations would produce carefully-framed information subsidies 
to build the news media agenda about HT in ways that furthered their strategic interests. 
These subsidies were conceptualized as having the potential to act like a form of 
prescription drug promotion, similar to direct to consumer advertising, medical journal 
advertising, detailing and sampling, and medical/scientific journal articles, which have 
been shown to influence physician prescribing practices, consumer demand, and 
prescribing rates (e.g., Donohue & Berndt, 2004; FDA, 2004; Gonul et al., 2001; Iizuka 
& Jin, 2006; Mizik & Jacobson, 2004; Rizzo, 1999; Rosenthal, Berndt, Donohue, 
Epstein, & Frank, 2003; Wang, Ausiello, & Stafford, 1999; Zachry et al., 2002).  
The process of effects for press releases was envisioned as an indirect one, in 
which the content of press releases is diffused to physicians and consumers through news 
media. This study only explored the red boxes and arrows in Figure 1. The purpose was 





medical organizations shaped the quantity and quality of news coverage. The link from 
news coverage to potential outcomes, such as prescription drug use, was not explored in 
this study. 



































 The overall pattern of findings summarized in this chapter supported the viability 
of the portion of the model tested in this study. A variety of health and medical 
organizations did in fact attempt to build the news media agenda by producing subsidies 
in the form of press releases about HT. The positive correlation found between the 
amount of press releases and the amount of news stories about HT over the study time 
period offered some initial, preliminary support for the claim that press releases 
influenced the news media agenda. Correlation alone, however, is a rather weak 





related to the actual content of press releases and news stories, which lent further support 
to the positive correlation found.  
While not tested in this particular study, the proposition that news media may play 
a key role in influencing prescription drug use by diffusing information about the uses, 
benefits, and risks of prescription drugs seems promising. News media may also 
disseminate information about prescription drugs that is quite different from FDA-
regulated sources of information because pharmaceutical companies are prohibited by 
law from promoting off-label benefits. Prescription drug information transmitted through 
news media and medical journals, however, is not subject to these FDA regulations, 
which cover paid-promotional efforts only like detailing, medical journal advertising, and 
DTCA (see Leffler, 1981; Morris & Griffin, 1992; Sheehan, 2003). A substantial 
proportion of press releases, particularly those distributed by academic/medical 
institutions and nonprofit organizations, served to promote off-label indications for HT, 
such as prevention of heart disease and Alzheimer’s disease. In the pre-WHI period, 
almost one-third (31.3%) of press releases and two-thirds (66.2%) of news stories 
suggested a heart-disease prevention benefit of HT, and 8.7% of press releases and 25.9% 
of news stories suggested HT could prevent Alzheimer’s disease and other forms of 
cognitive decline.   
Findings from this study suggest that in addition to the specific activities that 
academic/medical institutions and nonprofit organizations perform with pharmaceutical 
industry funding, they may also serve as valuable, unregulated conduits for the industry 
to reach physicians and consumers. Information subsidies, particularly ones delivered 





difficult for consumers of news to fully understand the interests and motivations of the 
organizations or actors behind the information they receive. In the case of HT, this 
situation may have resulted in sub-optimal message processing and decision-making 
outcomes because understanding where information comes from is one way that 
individuals assess its credibility and potential for bias (Bodensteiner, 1997; Fitzpatrick & 
Palenchar, 2006; Lofgran, 2004; Steinman et al., 2006). 
Practical Implications 
The findings from this study have several practical implications for improving the 
quality of prescription drug news in ways that may help avoid misperceptions about their 
FDA-approved indications and facilitate better decision making. Although some have 
blamed news media for presenting a distorted picture of HT by emphasizing its benefits 
and excluding or downplaying its potential risks (for e.g., Fugh-Berman & Pearson, 2002; 
Katz, 2003; Moynihan et al., 2002), this study found that many of the problems related to 
the quality of HT news originated from the health and medical organizations that 
journalists relied on as sources. Therefore, the following recommendations focus on 
public relations practitioners that work for health and medical organizations that 
disseminate information about prescription drugs and journalists. 
When communicating with news media, health and medical organizations have a 
responsibility to communicate evidence-based information about prescription drugs in 
ways that can be clearly understood by consumers. Throughout the study time period, 
efforts by the NIH and academic/medical institutions to publicize their scholarly work, 
along with Wyeth Pharmaceutical’s tactics to draw attention to studies that were 





HT. Although these press releases were carefully worded with qualifying terms like 
“may” or “suggest,” it is unlikely that the public at large understands the implications of 
such nuances. When considered within the context of studies that reported on risks 
associated with HT, often for the same disease areas, it is not surprising that women 
report confusion and frustration about HT recommendations (Buick et al., 2005; Wathen, 
2006). The efforts of scientists and the organizations they work for to publicize 
discoveries one study at a time, which are typically devoid of meaning when separated 
from the context of previous literature, creates a pattern of continual, conflicting findings 
and confusion. A review of the NHLBI website of scientific publications from the WHI 
trials, which had not been updated since May 12, 2011, listed 409 scientific publications 
from the WHI trials alone, with 88 of those publications examining the effects of 
hormone therapy and all reaching a variety of different conclusions (NHLBI, 2011).  
The NIH is in the best position to facilitate change in this area by working with its 
own public information officers and its university grantees to facilitate better 
communication. One recommendation would be to consider the target audience for its 
press releases. If a scientific publication related to the effects of a prescription drug on the 
market has no immediate implications for changes to clinical practice and may suggest 
unapproved indications, they may be better left for scientific circles to debate their merits 
through professional journal publications and scientific conferences until clear 
implications emerge. If organizations do promote these types of scientific articles to   
news media, press releases should include a clear statement that the findings have no 
implications for how the drug should be currently prescribed and consider including 





Based on past scholarship about communicating the risks and benefits of medical 
interventions, the FDA published an evidence-based user’s guide with recommendations 
for communicators. The guide recommends providing quantitative, not just qualitative, 
information about benefits and risks, and conveying quantitative information in absolute 
terms whenever possible, rather than in just relative terms, which tends to inaccurately 
inflate perceptions of the magnitude of benefits and risks (Fischhoff, Brewer, & Downs, 
2011). This study found substantial room for improvement in this area. Roughly one-third 
of press releases and news stories provided quantitative information when identifying 
potential benefits and risks, and relative presentations were by far the most frequently 
used format. Again, the NIH could foster positive change in this area by working with its 
Institute communicators and grantees to make sure these evidence-based guidelines are 
used in all publicity efforts.  
Health and medical organizations can also contribute to more ethical 
communication by transparently disclosing all financial conflicts of interest in press 
releases and other information subsidies. The extent of financial conflicts of interest 
between government agencies, academic/medical institutions, nonprofit organizations, 
and Wyeth Pharmaceuticals found in this study and the low rate of disclosure of those 
conflicts is troubling. Some organizations like the Institute of Medicine (IOM) have 
called for public policies that encourage more disclosure and transparency about financial 
conflicts of interest in medicine (see IOM, 2009). The results of this study support 
recommendations made by the Institute of Medicine (IOM) for Congress “to create a 
national program that requires pharmaceutical, medical device, and biotechnology 





health care institutions, professional societies, patient advocacy and disease-specific 
groups, providers of continuing medical education, and foundations created by any of 
these entities” in the interest of greater disclosure and transparency (IOM, 2009, p. 9).  
Health and medical journalists also need to be more diligent about investigating 
the funding sources behind the information subsidies they receive.  Examination of 
scientific publications, annual reports, and other organizational materials, along with 
questioning of individual sources about any financial conflicts is necessary to accurately 
report on collaborations that may exist between seemingly separate organizations. In the 
absence of such efforts, journalists may fail to detect the role pharmaceutical companies 
may have played in the production of information released about prescription drugs by 
other types of organizations, such as academic/medical institutions and nonprofit health 
advocacy groups. Finally, journalists need to be more discriminating about the use of 
press releases that promote a single study. Single studies are rarely meaningful when they 
are not contextualized within the past medical literature. Journalists should rigorously 
question the sources of such releases so they can better contextualize the findings and 
clearly communicate to readers whether the findings have any immediate implications for 
how a drug should be prescribed or used.    
Study Limitations  
This study had limitations primarily related to its sampling strategy. Retrieval of 
press releases was limited to those distributed by PR Newswire and EurekAlert!, and it is 
possible that organizations may have distributed press releases via other means. Retrieval 
of news stories was limited to AP Newswire, The New York Times, Washington Post, Los 





stories likely published in regional and more local papers, it is possible that regional and 
local papers contained content that was quite different. This study also included only 
print news, and the inclusion of broadcast and cable news may have yielded different 
results.  
Longitudinal studies can pose a challenge due to the difficulty of finding reliable 
indicators that reach far back in time. In the case of EurekAlert!, press releases were only 
available for 1996 and later. For this reason, the total amount of press releases might be 
underestimated for 1995. There are also limitations associated with the creation of any 
search string to retrieve documents electronically. Although the search terms were 
rigorously examined for recall and precision through repeated trials, no search term is 
perfect. It is likely that some combination of terms was omitted, resulting in the omission 
of press releases and news stories that were relevant to the study.  
Another limitation of the study was the use of the press release and news story as 
the unit of analysis for all coding. Although this was necessary due to the volume of texts 
analyzed in this study, it did not allow for content variables to be associated with specific 
sources cited within the body of the texts. For example, if a press release or news story 
contained a claim that HT prevented heart disease, the press release or news story was 
coded as mentioning this benefit. The coding scheme used was not sensitive enough to 
detect whether a claim was attributed to a specific organization or individual cited within 
the text of the press release or news story. In the case of news stories, this also meant that 
the coding did not capture whether specific claims were made by journalists themselves 







Several directions for future research are suggested based on the results obtained 
in this investigation. The first would be employ additional data analysis procedures to 
better compare press releases and news stories on specific content elements. This study 
primarily used chi-square analyses to compare the frequency with which specific content 
elements appeared in press releases and news stories. Although risks and benefits were 
compared for the entire time period and within the pre- and post-WHI period, even these 
period-based analyses spanned a fairly large period of time. For this reason, it is not 
possible to determine whether press releases and news stories were talking about the 
same thing at the same points in time. Another, more time-sensitive approach would be to 
see if specific elements of content in press releases and news stories positively correlate 
with one another over time. 
Another direction would be to complete the picture this longitudinal study has 
created by adding prescribing data for HT products, which is available for the study time 
period via the National Ambulatory and Medical Care Survey. Data to assess 
pharmaceutical spending on direct to consumer advertising, medical journal advertising, 
detailing, and sampling can also be obtained from market research firms. The addition of 
these data sequences would help determine how pharmaceutical companies use 
advertising and public relations tactics synergistically to stimulate demand for their 
products.  
Replicating this study for other prescription drugs would also be important to see 
if the pattern of findings found in this study is relevant for other products. A more 





more extensive effort to investigate their funding sources might also be productive. For 
the case of HT specifically, analysis of women’s magazines to see if the content was 
similar to what was found in this study or different would be useful. Magazines may have 
played a role in transmitting some of the more popular myths about HT’s ability to 
improve well-being and appearance, such as mood and skin, which appeared infrequently 
in this study.  
Conclusion 
This study confirmed the utility of the theoretical framework proposed by Zoch 
and Molleda (2006) for understanding how organizations conduct media relations 
strategically to build and frame the news media agenda. Theoretically, this study 
enhanced understanding of agenda building, information subsidies, and framing by 
exploring the interconnections between them to see how organizations produced and 
framed information subsidies, alone and in collaboration with others, to build the news 
media agenda. Hormone therapy (HT) for postmenopausal women provided a productive 
context to test this theoretical framework and provided further contributions to the 
literatures on prescription drug promotion and conflict of interest in medicine, along with 
practical suggestions to improve communication about the benefits and risks of 
prescription drugs.  
A key strength of this study was its longitudinal design, which allowed me to 
observe how organizations used information subsidies to respond to changing 
circumstances that unfolded over time. Another strength was its use of multiple 
methodologies. Quantitative content analysis established a reproducible, stable fact 





and nuance and archival document analysis to provide historical context. Future scholars 
can build upon this study and its methodology to further advance public relations theory 
in the area of media relations and to better understand the strategies and tactics of the 
pharmaceutical industry and other health and medical organizations that communicate 





Appendix A: Newspaper Circulation Figures 












The Wall Street Journal 2,117,796 1,994,121 1 News Corporation 
 
The New York Times 916,911 1,339, 462 3 The New York 
Times Company 
 
Los Angeles Times 605, 243 948,889 4 Tribune Company 
 
The Washington Post 550,821 852,861 6 The Washington 
Post Company 







Appendix B: Brand Name HT Drugs 
Table B1: Brand Name Prescription HT Drugs/Dates of Entry to Market (1995 to 
Present) 
 
This table was used to generate keywords for database search strings. It was also used for 
contextual background when interpreting the data historically over time to understand 









Alora Estradiol Watson Labs Transdermal; .1MG 12/20/1996 
Alora Estradiol Watson Labs Transdermal; .05MG 12/20/1996 
Alora Estradiol Watson Labs Transdermal; 
.075MG 
12/20/1996 
Alora Estradiol Watson Labs Transdermal; 
.025MG 
4/5/2002 
Cenestin Estrogens, Conjugated 
Synthetic A 
Teva Womens Tablet; Oral; 0.625 
MG 
3/24/1999 
Cenestin Estrogens, Conjugated 
Synthetic A 
Teva Womens Tablet; Oral; 0.9 MG 3/24/1999 
Cenestin Estrogens, Conjugated 
Synthetic A 
Teva Womens Tablet; Oral; 1.25MG 3/13/2000 
Cenestin Estrogens, Conjugated 
Synthetic A 
Teva Womens Tablet; Oral; 0.3MG 6/21/2002 
Cenestin Estrogens, Conjugated 
Synthetic A 
Teva Womens Tablet; Oral; 0.45 
MG 
2/5/2004 
Climara Estradiol Bayer Healthcare Transdermal 
.1MG 
12/22/1994 
Climara Estradiol Bayer Healthcare Transdermal 
.075 MG 
3/23/1998 
Climara Estradiol Bayer Healthcare Transdermal 
.05 MG 
12/22/1994 
Climara Estradiol Bayer Healthcare Transdermal 
.06 MG 
5/27/2003 
Climara Estradiol Bayer Healthcare Transdermal 
.0375 
5/27/2003 
Climara Estradiol Bayer Healthcare Transdermal 
.025 
3/5/1999 
















Estrogen-Only Products (Continued) 
Brand 
Name 




















Elestrin Estradiol Azur Pharma II Transdermal Gel 
0.06% 
12/15/2006 
Enjuvia Estrogens, Conjugated 
Synthetic B 
Teva Womens Tablet; Oral; 1.25MG 5/10/2004 
Enjuvia Estrogens, Conjugated 
Synthetic B 
Teva Womens Tablet; Oral; 0.3MG 12/20/2004 
Enjuvia Estrogens, Conjugated 
Synthetic B 
Teva Womens Tablet; Oral; 0.45 
MG 
12/20/2004 
Enjuvia Estrogens, Conjugated 
Synthetic B 
Teva Womens Tablet; Oral; 0.9 MG 4/27/2007 
 
Enjuvia Estrogens, Conjugated 
Synthetic B 





































































Estratab Estrogens, Esterified Solvay Tablet; Oral 
2.5 MG; 1.25 MG;  
0.625 MG; 0.3MG 
Discont. 






Evamist Estradiol KV Pharm Transdermal Spray 
1.53 MG 
7/27/2007 
Femring Estradiol Acetate Galen Ltd. Vaginal Insert 
0.1MG 
3/20/2003 
Femring Estradiol Acetate Galen Ltd. Vaginal Insert 
0.05 MG 
3/20/2003 
Femtrace Estradiol Acetate Warner Chilcott Tablet; Oral 
1.8 MG 
8/20/2004 








Estrogen-Only Products (Continued) 
Brand 
Name 





Femtrace Estradiol Acetate Warner Chilcott Tablet; Oral 
0.45 MG 
8/20/2004 
Menest Estrogens; Esterified Monarch Pharms Tablet; Oral; 0.3MG Prior 
1/1/1982 




Menest Estrogens; Esterified Monarch Pharms Tablet; Oral; 1.25MG Prior 
1/1/1982 
Menest Estrogens; Esterified Monarch Pharms Tablet; Oral; 2.5MG Prior 
1/1/1982 
Menostar Estradiol Bayer Healthcare Trandermal 
0.014 MG 
6/8/2004 




































Ortho-Est Estropipate Sun Pharm INDS Tablet; Oral 
1.5 MG 
7/17/1991 
Ortho-Est Estropipate Sun Pharm INDS Tablet; Oral 
0.75 MG 
2/27/1991 




Premarin Estrogens; Conjugated Wyeth Tablet; Oral; 0.3MG Prior to 
1/1/1982 




Premarin Estrogens; Conjugated Wyeth Tablet; Oral; 
 0.9 MG 
1/26/1984 












Vagifem Estradiol Novo Nordisk Inc. Tablet; Vaginal 
10 MCG 
11/25/2009 








Estrogen-Only Products (Continued) 
Brand 
Name 





Vivelle Estradiol Novartis Transdermal Film 
0.05 MG 
10/28/1994 
Vivelle-dot Estradiol Novartis Transdermal Film 
0.1MG 
1/8/1999 
Vivelle-dot Estradiol Novartis Transdermal Film 
0.075 MG 
1/8/1999 
Vivelle-dot Estradiol Novartis Transdermal Film 
0.05 MG 
1/8/1999 
Vivelle-dot Estradiol Novartis Transdermal Film 
0.0375 MG 
1/8/1999 
Vivelle-dot Estradiol Novartis Transdermal Film 
0.025 MG 
5/3/2002 
Estrogen + Progestin Products 
Brand 
Name 




Date Activella Estradiol; Norethindrone 
Acetate 
Novo Nordisk Inc Tablet; Oral 
1MG; 0.5MG 
11/18/1998 
Activella Estradiol; Norethindrone 
Acetate 











Bayer Healthcare Tablet; Oral; 
0.25MG;0.5MG 
2/29/2012 
Climara Pro Estradiol; Levonorgestrel Bayer Healthcare 
Transdermal  
0.045 MG/0.015 MG 
11/21/2003 





0.05 MG; 0.25 MG 
 
8/7/1998 








Femhrt Ethinyl Estradiol; 
Norethindrone Acetate 
Warner Chilcott Tablet; Oral 
0.005; 1MG 
10/15/1999 
Femhrt Ethinyl Estradiol; 
Norethindrone Acetate 
Warner Chilcott Tablet; Oral 
0.0025; 0.5MG 
1/14/2005 
Prefest Estradiol; Norgestimate Teva Women’s Tablet; Oral 







Estrogen + Progestin Products (Continued) 
Brand 
Name 












0.625 MG/.625 MG;  




















Tablet, Oral-28;  
0.625 MG/5 MG 
 
01/09/1998 





Tablet, Oral-28;  
0.45 MG/1.5 MG 
 
03/12/2003 





Tablet, Oral-28;  
0.3 MG/1.5 MG 
 
06/04/2003 
Progesterone/Progestin Products (used in conjunction with estrogen) 
Brand 
Name 




Date Prometrium Progesterone Abbott Labs Capsule; Oral 
200 MG 
10/15/1999 



























Data Sources:  
Drugs@FDA (USDHHS, FDA, 2011b) 
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations  





Appendix C: Protocol and Codebook for Press Releases 
Coding Protocol/Instructions for Press Releases 
The protocol below describes each variable and demonstrates how the variable looks on 
the code sheet. The code sheet for press releases follows this protocol of instructions. 
 
Each press release should be coded on a separate coding sheet. 
 
PV1: Coder #  
Please enter the coder # assigned to you in the blank.  
 
PV1: Coder #:______________________ 
 
PV2: Press Release ID# 
Please enter the ID number that is written on the press release that you will code. You can 
find the number in the upper right hand corner of the first page of the release. 
 
PV2: Press Release ID#:__________________ 
 
PV3: Release Date 
Write-in the two digit month, two-digit day, and four-digit year that appears on the press 
release. You will find the date at the top of the first page listed under the source. 
 
PV3: Release Date: _______(Month) _________(Day) ________(Year) 
 
PV4. Primarily about HT 
 
This study is focused on press releases primarily about menopausal hormone therapy 
(HT). Some releases may have qualified for inclusion based on the search terms 
appearing in the headline, but the search terms were really being used in the context of 
something different than menopausal HT. These releases should be eliminated. For 
example, some releases that use the term “hormone therapy” or “hormone therapies” 
refer to therapies given after a sex change or treatments for prostate cancer in men or 
breast cancer in women, not menopause. As another example, the term estrogen may 
come up in a range of releases (e.g., stories about puberty, birth control pills) that have 
nothing to do with HT. Releases may also appear that discuss the role of declining 
estrogen in menopause, but never mention HT treatment in any way. These releases 
should all be eliminated based on the question below: 
 
PV4: Do any of the study search terms that were identified in the headline refer to 
hormone therapy (HT) for menopause or symptoms or conditions associated with 
menopause?  
 






If you indicated “no” above, you can stop coding the document. Place the document in 
the elimination file. Place this code sheet in the completed code sheet file. Code the next 
document. Make sure to use a new code sheet for each document, regardless of whether 
or not the document is eliminated. 
 
PV5: Type of Release Description  
This study is focused on press releases that are primarily about menopausal hormone 
therapy (HT). Sometimes the study search terms may appear in the headline, but the 
release is not focused on HT in a way that provides any substantive information about its 
use in the treatment of menopausal women.  For example, releases that focus on news 
about the organizations involved in the production or distribution of HT (and only 
mention HT briefly, in passing) should be eliminated. This may include releases that 
report on mergers, acquisitions, patent disputes, licensing and marketing agreements 
between firms, personnel news, or quarterly financial earnings. Press releases that 
publicize services by market research/forecasting firms or entertainment products, such 
as film, television, books, or theater productions should also be eliminated. A press 
release that reports on a study about HT that was solely conducted in animals without 
discussion of any findings or implications for humans should also be eliminated. 
 
PV5: Which of the following BEST describes this press release? 
 
 Circle Code 
Publicity primarily about the organization as opposed to HT (e.g. 
mergers/acquisitions/patent disputes/licensing and marketing 
agreements between firms/personnel news/quarterly financial 
earnings reports in which HT is just briefly mentioned in passing) 
 
1 
Publicity by industry/market forecasting firms (e.g., Report 








Story about study conducted in animals only 
4 





If you circled 1, 2, 3, or 4 above, ELIMINATE and stop coding the document. Place the 
document in the elimination file. Place this code sheet in the completed code sheet file. 
Code the next document. Make sure to use a new code sheet for each document, 







PV6: Organization Names/Produced Release 
 
Look at the SOURCE field at the bottom of the press release. Write the full names of any 








PV7: Types of Organizations/Distributed Release 
 
Look at the SOURCE field at the bottom of the press release. For each organization 
listed, classify it into the category below that best describes the type of organization it is. 
Each category has a brief description next to it. Below each category are a few examples 
of organizations that would be coded into each category. To determine nonprofit status 
(501c3 or 501c6) use the GuideStar database. If the organization cannot be found in the 
GuideStar database, review the organization’s website if available.  
 
If an organization type appears more than once in the same release, you only need to 
mark its category in the grid below once. 
 
PV7. Are any of the following types of organizations listed in the SOURCE field of the 
release? 
 
Organization Types Yes (1) No  
(0) 
a) Pharmaceutical Company  
A company that manufacturers/sells prescription drugs 
(e.g., Wyeth, Duramed, Eli Lilly, Solvay Pharmaceuticals) 
  
b) Other For-Profit Company 
Any other for-profit company that is not a pharmaceutical company 
(e.g., Natural Products, Ltd., CVS, Walmart) 
  
c) U.S. Government  
Any federal government agency or entity 
(e.g., National Institutes of Health, Office of Women’s Health, National 
Heart, Lung, & Blood Institute, Food & Drug Administration, Centers for 
Disease Control & Prevention) 
  
d) Academic/Medical Institutions 
Universities, hospitals, medical centers, or other clinical centers involved in 
medical research and treatment 
(e.g., Harvard University, Emory University, Los Angeles Biomedical 
Research Institute at Harbor-UCLA Medical Center, University of 
Massachusetts Medical Center, Hospital of the University of Pennsylvania, 






e) Medical Professional Societies /Trade Associations (501c6) 
Nonprofit 501c6 professional membership organizations 
(e.g., American Medical Association, AMA; American College of 
Obstetricians & Gynecologists (ACOG); the Endocrine Society; and 
Pharmaceutical Research Manufacturers of America (PhRMA)  
  
f) Health Advocacy Organizations (501c3) 
Nonprofit 501c3 patient or disease-specific health-advocacy organizations 
or foundations 
(e.g., National Women’s Health Network, American Heart Association, 
National Osteoporosis Foundation, Alzheimer’s Foundation) 
  
g) Coalition 
An organized group of multiple organizations or constituents 
(e.g., National Breast Cancer Coalition) 
  
h) Medical/Scientific Journal Publishers  
Publishers of medical/scientific journals 
(e.g., Blackwell Publishing, JAMA and Archives Journals)  
  
i) Other (OTH) 
Any organization type not mentioned above, including non-U.S.-based 




PV8: Organization Names/Release Contact  
 
Look at the CONTACT fields of the release. Write the full names of any organizations 






PV9: Types of Organizations/Release Contact  
 
For each organization listed in the CONTACT field classify it into the category below 
that best describes the type of organization it is. Each category has a brief description 
next to it. Below each category are a few examples of organizations that would be coded 
into each category. To determine nonprofit status (501c3 or 501c6) use the GuideStar 
database. If the organization cannot be found in the GuideStar database, review the 
organization’s website if available.  
 
If an organization type appears more than once in the same release, you only need to 










a) Pharmaceutical Company  
A company that manufacturers/sells prescription drugs 
(e.g., Wyeth, Duramed, Eli Lilly, Solvay Pharmaceuticals) 
  
b) Other For-Profit Company  
Any other for-profit company that is not a pharmaceutical company 
(e.g., Natural Products, Ltd., CVS, Walmart) 
  
c) U.S. Government   
Any federal government agency or entity 
(e.g., National Institutes of Health, Office of Women’s Health, National 
Heart, Lung, & Blood Institute, Food & Drug Administration, Centers for 
Disease Control & Prevention) 
  
d) Academic/Medical Institutions 
Universities, hospitals, medical centers, or other clinical centers involved in 
medical research and treatment 
(e.g., Harvard University, Emory University, Los Angeles Biomedical 
Research Institute at Harbor-UCLA Medical Center, University of 
Massachusetts Medical Center, Hospital of the University of Pennsylvania, 
Ralph Lauren Cancer Center, Memorial-Sloan Kettering Cancer Center) 
  
e) Medical Professional Societies /Trade Associations (501c6) 
Nonprofit 501c6 professional membership organizations 
(e.g., American Medical Association, AMA; American College of 
Obstetricians & Gynecologists (ACOG); the Endocrine Society; and 
Pharmaceutical Research Manufacturers of America (PhRMA)  
  
f) Health Advocacy Organizations (501c3) 
Nonprofit 501c3 patient or disease-specific health-advocacy organizations 
or foundations 
(e.g., National Women’s Health Network, American Heart Association, 
National Osteoporosis Foundation, Alzheimer’s Foundation) 
  
g) Coalition  
An organized group of multiple organizations or constituents 
(e.g., National Breast Cancer Coalition) 
  
h) Medical/Scientific Journal Publishers 
Publishers of medical/scientific journals.  
(e.g., Blackwell Publishing, JAMA and Archives Journals)  
  
i) Other (OTH) 
Any organization type not mentioned above, including non-U.S.-based 









This coding activity on HT risks has 4 parts for each potential risk mentioned in the 
release text.  
 
Part 1 
First, if the risk is identified as possible anywhere in the release text, put an X in the 
“yes” category in the “Identified?” column. If it is not identified in the text, put an X in 
the “no” category in the “Identified?” column. 
 
You should code “Identified?” as “yes,” if the possibility of the risk of HT is mentioned 
in the text, even if the text says there is some uncertainty about the risk/science is not 
conclusive, etc. You should code based on what is being identified in the releases as a 
possible risk at the present time. You should not code “yes” if the release says that 
something is not a risk, or was thought be a risk in the past, but no longer is. A mark of 
“yes” indicates that the release is making at least some suggestion that the risk is 
currently possible for some women who take HT.  
 
For example, if a release said: 
“Hormone therapy has been linked to a greater risk of dementia and heart attacks when 
given to women after 65.”  
Dementia and heart disease would both be coded as “yes” in the “Identified?” column. 
 
For example, if a release said: 
 
 “In the past, it was thought that hearing loss was a possible risk of HT, but current 
evidence indicates that this is not the case.”  
 
Hearing loss would be coded as “no” in the “Identified?” category. The words hearing 
loss are present in the text, but the text is clearly suggesting this is not believed to be a 




For each risk that was checked as “yes” in the “Identified?” category, check whether the 
probability of the risk occurring was quantified in any way in the “Quantified?” column. 




For each risk that was checked “yes” in the “Identified?” column, check whether the risk 
was presented in relative terms or not. Relative risk presentations present numbers that 
compare the chance of a risk occurring in individuals exposed to a risk factor vs. those 






For example, you would check “yes” in the “Relative?” column if the following text 
appeared in a release. 
“Among smokers, 3.4 percent of hormone users died of lung cancer, compared with 
2.3 percent in the placebo group.” 
 
You would also check “yes” in the “Relative?” column if the following text appeared in a 
release. 
“This part of the study was halted when researchers saw a 26 percent higher risk of 
breast cancer in women taking Prempro.” 
 
Part 4  
For each risk that was checked “yes” in the “Quantified?” column, check whether the risk 
was presented in absolute terms or not. Absolute risk presentations quantify a risk in 
terms of how many individuals in the population will actually experience the risk in terms 
of a given number of individuals or over a given period of time.  
 
For example, the following passage would be coded as “yes” for the “Relative?” category 
above and “yes” for the “Absolute” category.  
“Several experts stressed, however, that the absolute risk of dying from breast cancer 
was very low - in the new study 25 women died from breast cancer among those 
taking the hormones compared with 12 among those who took a placebo. The risk 
translates into about 1.3 additional deaths from breast cancer each year for every 
10,000 women taking hormones, the study found.” 
 
In the above text, the comparison of 25 women (taking hormones) vs. 12 women 
(placebo) is a relative risk comparison. The last sentence that translates how often the 
event will actually occur per 10,000 women per year is an absolute risk presentation.  
 
Below is how the grid will look on the code sheet: 
 
PV10. For each potential risk of HT below, check whether it was identified as possible or 
not in any part of the release. If identified, check whether the probability of the risk was 

























a) Breast cancer         
b) Cognitive (e.g., 
dementia/Alzheimer’s)  
        
c) Gallbladder disease         
d) Heart attack/Heart 
Disease/Cardiovascular 
disease 
        
e) Stroke         
f) Thrombosis/blood clots         
g) Uterine/endometrial 
cancer (also includes  
ovarian cancer)  
        
h) Other 1 (Specify)         




Follow the same rules as above (as outlined for PV10: Risks) for any of the following 
potential benefits identified in the release.  
 
PV11. For each potential benefit of HT below, check whether it was identified as possible 
or not in any part of the release. If identified, check whether the probability of the benefit 
was quantified in any way. If quantified, check if it was quantified in relative and/or 
absolute terms.  
 

















a) Cognitive Decline 
Reduced (e.g., dementia, 
Alzheimer’s, etc.) 
        
b) Colon/Colorectal 
Cancer Reduced 
        
c) Heart Attack/Heart 
Disease/Cardiovascular 
Disease  
        
d) Hot Flashes/Night 
Sweats (vasomotor 
symptoms) Reduced  
        
e) Mood Problems 
Reduced (e.g., 
depression, irritability) 
        
f) Osteoporosis/Fractures 
Reduced 






g) Sex Life Improved 
(more libido/sexual 
activity, etc.) 
        
h) Skin Improved (less 
wrinkling/aging, etc,) 




        
j) Vaginal Problems 
Reduced (atrophy, 
dryness, etc.) 
        
k) Other1 (Specify)         
l) Other2 (Specify)          
 
PV12. Brand Name Mentions 










Activella/Activelle   Evamist   
Alora   FemHRT   
Angeliq   Femring   
Cenestin   Femtrace   
Climara/Pro   Menest   
CombiPatch   Menostar   
Delestrogen   Ogen   
Depo-Estradiol   Ortho-Est   
Divigel    Prefest   
Elestrin   Premarin   
Enjuvia    Premphase   
Estrace    Prempro   
Estraderm    Prometrium   
Estrasorb    Provera   
Estratab   Vagifem   
Estratest    Vivelle/Vivelle-dot   
Estring   Other1/(Specify): 
 
  








PV13: Medical/Scientific Journal Referenced 
 
If the release refers to or mentions a medical professional or scientific journal anywhere 
in the text, check “yes.” If not, check “no.” Examples of medical professional and 
scientific journals are: the Journal of the American Medical Association (JAMA), the 
New England Journal of Medicine, Journal of Women’s Health, and Science, etc. 




PV14: Journal Name 
 
V14: If any medical professional or scientific journals were mentioned in the text of the 







PV15: Organization Names/Mentioned in Body Text 
 







PV16: Types of Organizations/Mentioned in Body Text 
 
For each organization mentioned in the body text of the release, classify it into the 
category below that best describes the type of organization it is. Each category has a brief 
description next to it. To determine nonprofit status (501c3 or 501c6) use the GuideStar 
database. If the organization cannot be found in the GuideStar database, review the 
organization’s website if available.  
 
If an organization type appears more than once in the same release, you only need to 












a) Pharmaceutical Company 
A company that manufacturers/sells prescription drugs 
(e.g., Wyeth, Duramed, Eli Lilly, Solvay Pharmaceuticals) 
  
b) Other For-Profit Company 
Any other for-profit company that is not a pharmaceutical company 
(e.g., Natural Products, Ltd., CVS, Walmart) 
  
c) U.S. Government   
Any federal government agency or entity 
(e.g., National Institutes of Health, Office of Women’s Health, National 
Heart, Lung, & Blood Institute, Food & Drug Administration, Centers for 
Disease Control & Prevention) 
  
d) Academic/Medical Institutions  
Universities, hospitals, medical centers, or other clinical centers involved in 
medical research and treatment 
(e.g., Harvard University, Emory University, Los Angeles Biomedical 
Research Institute at Harbor-UCLA Medical Center, University of 
Massachusetts Medical Center, Hospital of the University of Pennsylvania, 
Ralph Lauren Cancer Center, Memorial-Sloan Kettering Cancer Center) 
  
e) Medical Professional Societies /Trade Associations (501c6) 
Nonprofit 501c6 professional membership organizations 
(e.g., American Medical Association, AMA; American College of 
Obstetricians & Gynecologists (ACOG); the Endocrine Society; and 
Pharmaceutical Research Manufacturers of America (PhRMA)  
  
f) Health Advocacy Organizations (501c3) 
Nonprofit 501c3 patient or disease-specific health-advocacy organizations 
or foundations 
(e.g., National Women’s Health Network, American Heart Association, 
National Osteoporosis Foundation, Alzheimer’s Foundation) 
  
g) Coalition  
An organized group of multiple organizations or constituents 
(e.g., National Breast Cancer Coalition) 
  
h) Other (OTH) 
Any organization type not mentioned above, including non-U.S.-based 







PV17: Types of Individuals Directly Quoted 
 
For each individual who is directly quoted in the text, classify the individual into the 
category below that best describes the individual. Each category has a brief description 
next to it. A quoted individual can fall into more than one category if they are explicitly 
identified in more than one way. If an individual cannot be coded into the existing 
categories, select the “Other” category.  
 






a) Physician and/or Scientist  
  
  
b) Nurse Practitioner/Nurse/Other Clinicians 
 
  
c) CEO/Exec/Medical Director/PR Director/Official Spokesperson    
d) Attorney  
 
  
e) Celebrity  
 
  
f) Everyday affected woman  
 
  
g) Everyday family member of affected woman  
 
  




PV18: Pharmaceutical Funding of Individuals   
 
This item captures explicit mentions of pharmaceutical funding or financial support of 
individuals. Below are examples of such explicit mentions: 
“Wyeth named Dr. Utian a ‘Partner in Menopause Education’ (requiring a contribution of 
at least $8,000) for the NAMS' 2007 Annual Meeting. Additionally, half of NAMS's 
Board of Trustees for 2007-2008 receives consulting fees or research support from 
Wyeth, including Dr. Utian.” 
 
“The study is published in the journal Neurology. One author is a former employee of 
Wyeth, which sells Prempro.” 
 
V18. Does the release explicitly mention pharmaceutical company funding of any 
individuals? 
 






PV19: Pharmaceutical Funding of Organizations  
This item captures explicit mentions of pharmaceutical funding or financial support of 
organizations and their activities. Below are examples of such explicit mentions: 
 
 “The study was funded by the National Osteoporosis Foundation (NOF). NOF receives 
funding from Wyeth, which sells Prempro.” 
 
“The National Association of Nurse Practitioners in Women's Health developed and 
launched the campaign with financial support from Upsher-Smith Women's Health.” 
 
“The North American Menopause Society has created a comprehensive guidebook. 
Supported by an unrestricted educational grant from Berlex Laboratories, makers of 
Climara, the Menopause Guideboook is available on www.menopause.org. Berlex did not 
influence any of its contents.”  
 
PV19. Does the release explicitly mention pharmaceutical company funding of any 
organizations? 
 
_____1 (Yes) _____0 (No) 
 
PV20: Pharmaceutical Funding of Research Studies   
 
This item captures explicit mentions of pharmaceutical funding or financial support of 
research studies. Research studies can include unpublished clinical studies, published 
studies in scientific/medical journals, or a variety of consumer-oriented research studies 
(e.g., public opinion/survey studies).  Below are examples of such explicit mentions: 
"This study confirms what the medical community and the public already know about 
HRT and the treatment of heart disease," says Victoria Kusiak, M.D., Vice President, 
Global Medical Affairs and North American Medical Director for Wyeth 
Pharmaceuticals, the study's sponsor.” 
 
“David F. Archer, M.D., professor of obstetrics and gynecology at EVMS' Jones Institute 
of Reproductive Medicine, was among a group of researchers in various parts of the 
United States who conducted the five-year study, which involved about 2,700 women and 
was funded by Wyeth-Ayerst Laboratories.”   
 
“The New World of HRT study, sponsored by Pharmacia Corporation, was conducted by 
SRI Business Intelligence Center in April 2000.”  
 
PV20: Does the release explicitly mention pharmaceutical funding of any research 
studies? 
_____1 (Yes) _____0 (No) 





PV1: Coder #:_______  PV2:  Press Release ID #:_______  PV3: Date: _______(Month)________(Day) ________(Year) 
 
PV4: Do any of the study search terms that were identified in the headline refer to hormone therapy (HT) for menopause or 
symptoms or conditions associated with menopause?  
 
_____(1)  Yes _____(0)  No (IF NO, ELIMINATE)   
 
PV5: Which of the following BEST describes this press release? 
 Circle Code 
Publicity primarily about the organization as opposed to HT (e.g. mergers/acquisitions/patent disputes/licensing and 
marketing agreements between firms/personnel news/quarterly financial earnings reports in which HT is just briefly 
mentioned in passing)  
 
1 
Publicity by industry/market forecasting firms (e.g. Report Linker market trend reports, etc.) 
 
2 
Publicity for film/television/book/theater/other entertainment products 3 
Story about study conducted in animals only 4 
None of the above 0 
(IF SELECTED 1, 2, 3, or 4 ABOVE, ELIMINATE) 
 





PV7: Are any of the following types of organizations listed in the SOURCE field of the release? 
Organization Types Yes (1) No (0)  Yes (1) No (0) 
a) Pharmaceutical Company    f) Health Advocacy Organizations (501c3)   
b) Other Company  
 
  g) Coalition    
c) U.S. Government   
 
  h) Medical/Scientific Journal Publishers   
d) Academic/Medical Institution    i) Other    










PV9: Are any of the following types of organizations listed in the CONTACT field of the release? 
Organization Types Yes (1) No (0)  Yes (1) No (0) 
a) Pharmaceutical Company    f) Health Advocacy Organizations (501c3)   
b) Other For-Profit Company  
 
  g) Coalition   
c) U.S. Government   
 
  h) Medical/Scientific Journal Publishers   
d) Academic/Medical Institutions   i) Other   
e) Medical Prof. /Trade Assoc. (501c6)      
 
PV10. For each potential risk of HT below, check the relevant columns. 




Relative? (REL) Absolute? (ABS) 
 Yes (1) No (0) Yes (1) No (0) Yes (1) No (0) Yes (1) No (0) 
a) Breast cancer           
b) Cognitive (e.g., dementia, Alzheimer’s)          
c) Gallbladder disease          
d) Heart attack/Heart disease/Cardiovascular disease         
e) Stroke          
f) Thrombosis/blood clots          
g) Uterine/endometrial cancer (includes ovarian cancer)          
h) Other1 (Specify):         






PV11. For each potential benefit of HT below, check the relevant columns. 




Relative? (REL) Absolute? 
(ABS) 
 Yes (1) No (0) Yes (1) No (0) Yes (1) No (0) Yes (1) No (0) 
a) Cognitive Decline Reduced (e.g., dementia, 
Alzheimer’s) 
        
b) Colon/Colorectal Cancer Reduced           
c) Heart Attack/Heart Disease/Cardiovascular Disease 
Reduced 
        
d) Hot Flashes/Night Sweats (vasomotor symptoms) 
Reduced  
        
e) Mood Problems Reduced (e.g., depression, irritability)          
f) Osteoporosis/Fractures Reduced         
g) Sex Life Improved (e.g., more libido/sexual activity)         
h) Skin Improved (e.g., less wrinkles, aging)          
i) Sleep Problems/Insomnia Reduced          
j) Vaginal Problems Reduced (e.g., atrophy, dryness)          
k) Other1 (Specify):         
























Activella/Activelle   Divigel    Evamist   Prefest   
Alora   Elestrin   FemHRT   Premarin   
Angeliq   Enjuvia    Femring   Premphase   
Cenestin   Estrace    Femtrace   Prempro   
Climara/Pro   Estraderm    Menest   Prometrium   
CombiPatch   Estrasorb    Menostar   Provera   
Delestrogen   Estratab   Ogen   Vagifem   
Depo-Estradiol   Estratest    Ortho-Est   Vivelle/Vivelle-dot   
   Estring   Other1/(Specify):   Other2/(Specify): 
 
  
PV13. Does the release refer to a medical professional or scientific journal anywhere in the text?  
_____Yes (1) _____No (0) 




















PV16: Are any of the following types of organizations mentioned in the BODY TEXT of the release? 
 
Organization Types Yes (1) No (0)  Yes (1) No (0) 
a) Pharmaceutical Company    f) Health Advocacy Organizations (501c3)    
b) Other For-Profit Company  
 
  g) Coalition    
c) U.S. Government 
 
  h) Other    
d) Academic/Medical Institutions 
 
     
e) Medical Prof./Trade Assoc. (501c6)      
 
PV17: Are any of the following types of individuals directly quoted in this release? 
 Yes (1) No (0) 
a) Physician and/or Scientist 
  
  
b) Nurse Practitioner/Nurse/Other Clinicians  
 
  
c) CEO/Exec/Medical Director/PR Director/Official Spokesperson 
 
  
d) Attorney  
 
  
e) Celebrity  
 
  
f) Everyday affected woman 
 
  
g) Everyday family member of affected woman  
 
  




PV18. Does the release explicitly mention pharmaceutical company funding of any individuals?  
_____(1) Yes   _____(0) No 
 
PV19. Does the release explicitly mention pharmaceutical company funding of any organizations?  
_____(1) Yes  _____(0) No 
 
PV20: Does the release explicitly mention pharmaceutical company funding of any research studies?  





Appendix D: Protocol and Codebook for News Stories  
Coding Protocol/Instructions for News Stories 
The protocol below describes each variable and demonstrates how the variable looks on 
the code sheet. The code sheet for news stories follows this protocol of instructions. 
 
Each news story should be coded on a separate coding sheet. 
 
NV1: Coder #  
Please enter the coder # assigned to you in the blank.  
 
NV1: Coder #:______________________ 
 
NV2: News Story ID 
Please enter the ID number that is written on the news story that you will code. You can 
find the number in the upper right hand corner of the first page of the story.  
 
NV2: News Story ID:__________________ 
 
NV3: Publication Date 
Write-in the two digit month, two-digit day, and four-digit year that the news story was 
published. You will find the publication date at the top of the first page listed under the 
source. 
 
NV3: Publication Date: _______(Month) _________(Day) ________(Year) 
 
NV4: Primarily about HT 
 
This study is focused on news stories primarily about menopausal hormone therapy (HT). 
Some stories may have qualified for inclusion based on the search terms appearing in the 
headline, but the search terms were really being used in the context of something 
different than menopausal HT. These releases should be eliminated. For example, some 
stories that use the term “hormone therapy” or “hormone therapies” refer to therapies 
given after a sex change or treatments for prostate cancer in men or breast cancer in 
women, not menopause. As another example, the term estrogen may come up in a range 
of news stories (e.g., stories about puberty, birth control pills) that have nothing to do 
with HT. Stories may also appear that discuss the role of declining estrogen in 
menopause, but never mention HT in any way. These news stories should all be 
eliminated based on the question below: 
 
NV4: Do any of the study search terms that were identified in the headline refer to 
hormone therapy (HT) for menopause or symptoms or conditions associated with 
menopause?  
 





If you indicated “no” above, you can stop coding the document. Place the document in 
the elimination file. Place this code sheet in the completed code sheet file. Code the next 
document. Make sure to use a new code sheet for each document, regardless of whether 
or not the document is eliminated. 
 
NV5. Type of Document Description 
 
This study is focused on news stories and features that are primarily about HT. 
Sometimes the study search terms may appear in the headline, but the document is not a 
news story or feature or is not focused on HT in a way that provides any substantive 
information about its use in the treatment of menopausal women.  For example, stories 
that focus only on news about the organizations involved in the production or distribution 
of HT (and only mention HT briefly, in passing) should be eliminated. This may include 
stories that report on mergers, acquisitions, patent disputes, licensing and marketing 
agreements between firms, personnel news, or quarterly financial earnings. A news story 
that reports on a study about HT that was solely conducted in animals without discussion 
of any findings or implications for humans should also be eliminated.  
 
Columns that are best described as editorial/opinion pieces, letters to the editor, and 
film/television/book/theater or other types of entertainment reviews should be eliminated 
from the study. Q&A-style health columns in which a columnist answers questions 
submitted by readers should be eliminated. If a Q&A text format is embedded within a 
typical news story just as a way of communicating information, however, the document 
should be included in the study. For example, a larger news story about the confusion 
surrounding HT might have a Q&A section within it that lists common questions about 
HT, and the answers to those questions based on the current evidence. In this case, this is 
not a Q&A column, but a presentation format within a news story, and this news story 
should be coded.   
 
NV5: Is this document best described as any of the following? 
 
 Circle Code 
Story primarily about the organization as opposed to HT (e.g. 
mergers/acquisitions/patent disputes/licensing and marketing 
agreements between firms/personnel news/quarterly financial earnings 
reports in which HT is just briefly mentioned in passing) Story 
primarily about organization   
1 
 
Letter to the editor or editorial/opinion piece  2 
 Film/television/book/theater/other entertainment review  3 
 Story about study conducted in animals only 4 
 Q&A-style health advice column  5 
 None of the above  0 
  
If you circled 1, 2, 3, 4, or 5 above, ELIMINATE and stop coding the document. Place 





file. Code the next document. Make sure to use a new code sheet for each document, 
regardless of whether or not the document is eliminated. 
 
NV6. Source  
Please check which news source/newspaper this story appeared in. 
 
NV6: Which source did this story appear in? 
 
 Circle Code 
Associated Press  1 
 
Los Angeles Times  2 
 
The New York Times  3 
 
The Wall Street Journal  4 
 
The Washington Post  5 
 
 
NV7. Brand Name Mentions 










Activella/Activelle   Evamist   
Alora   FemHRT   
Angeliq   Femring   
Cenestin   Femtrace   
Climara/Pro   Menest   
CombiPatch   Menostar   
Delestrogen   Ogen   
Depo-Estradiol   Ortho-Est   
Divigel    Prefest   
Elestrin   Premarin   
Enjuvia    Premphase   
Estrace    Prempro   
Estraderm    Prometrium   
Estrasorb    Provera   
Estratab   Vagifem   
Estratest    Vivelle/Vivelle-dot   
Estring   Other1/(Specify): 
 
  







NV8: Medical/Scientific Journal Referenced 
 
If the news story refers to or mentions a medical professional or scientific journal 
anywhere in the text, check “yes.” If not, check “no.” Examples of medical professional 
and scientific journals are: the Journal of the American Medical Association (JAMA), the 
New England Journal of Medicine, Journal of Women’s Health, and Science, etc. 
NV8. Does the story refer to a medical professional or scientific journal anywhere in 
the text? 
_____Yes (1) _____No (0) 
NV9: Journal Name 
 
NV9: If any medical professional or scientific journals were mentioned in the text of the 








This coding activity on HT risks has 4 parts for each potential risk mentioned in the news 
story text.  
 
Part 1 
First, if the risk is identified as possible anywhere in the story text, put an X in the “yes” 
category in the “Identified?” column. If it is not identified in the text, put an X in the “no” 
category in the “Identified?” column. 
 
You should code “Identified?” as “yes,” if the possibility of the risk of HT is mentioned 
in the text, even if the text says there is some uncertainty about the risk/science is not 
conclusive, etc. You should code based on what is being identified in the news story as a 
possible risk at the present time. You should not code “yes” if the story says that 
something is not a risk, or was thought be a risk in the past, but no longer is. A mark of 
“yes” indicates that the news story is making at least some suggestion that the risk is 
currently possible for some women who take HT.  
 
For example, if a news story said: 
“Hormone therapy has been linked to a greater risk of dementia and heart attacks when 
given to women after 65.”  
Dementia and heart disease would both be coded as “yes” in the “Identified?” column. 
 






 “In the past, it was thought that hearing loss was a possible risk of HT, but current 
evidence indicates that this is not the case.”  
 
Hearing loss would be coded as “no” in the “Identified?” category. The words hearing 
loss are present in the text, but the text is clearly suggesting this is not believed to be a 




For each risk that was checked as “yes” in the “Identified?” category, check whether the 
probability of the risk occurring was quantified in any way in the “Quantified?” column. 




For each risk that was checked “yes” in the “Identified?” column, check whether the risk 
was presented in relative terms or not. Relative risk presentations present numbers that 
compare the chance of a risk occurring in individuals exposed to a risk factor vs. those 
not exposed.  These numbers are often percents, but could also be in the form of rates or 
ratios. 
 
For example, you would check “yes” in the “Relative?” column if the following text 
appeared in a news story. 
“Among smokers, 3.4 percent of hormone users died of lung cancer, compared with 
2.3 percent in the placebo group.” 
 
You would also check “yes” in the “Relative?” column if the following text appeared in a 
news story. 
“This part of the study was halted when researchers saw a 26 percent higher risk of 
breast cancer in women taking Prempro.” 
 
Part 4  
For each risk that was checked “yes” in the “Quantified?” column, check whether the risk 
was presented in absolute terms or not. Absolute risk presentations quantify a risk in 
terms of how many individuals in the population will actually experience the risk in terms 
of a given number of individuals or over a given period of time.  
 
For example, the following passage would be coded as “yes” for the “Relative?” category 
above and “yes” for the “Absolute” category.  
“Several experts stressed, however, that the absolute risk of dying from breast cancer 
was very low - in the new study 25 women died from breast cancer among those 
taking the hormones compared with 12 among those who took a placebo. The risk 
translates into about 1.3 additional deaths from breast cancer each year for every 






In the above text, the comparison of 25 women (taking hormones) vs. 12 women 
(placebo) is a relative risk comparison. The last sentence that translates how often the 
event will actually occur per 10,000 women per year is an absolute risk presentation.  
 
Below is how the grid will look on the code sheet: 
 
NV10. For each potential risk of HT below, check whether it was identified as possible or 
not in any part of the news story. If identified, check whether the probability of the risk 
was quantified in any way. If quantified, check if it was quantified in relative and/or 
absolute terms.  
 

















a) Breast cancer         
b) Cognitive (e.g., 
dementia/Alzheimer’s)  
        
c) Gallbladder disease 
 
        
d) Heart attack/Heart 
Disease/Cardiovascular 
disease 
        
e) Stroke         
f) Thrombosis/blood 
clots 




        
h) Other 1 (Specify) 
 
        
i) Other 2 (Specify) 
 











Follow the same rules as above (as outlined for NV10: Risks) for any of the following 
potential benefits mentioned in the story.  
 
NV11. For each potential benefit of HT below, check whether it was identified as 
possible or not in any part of the news story. If identified, check whether the probability 
of the risk was quantified in any way. If quantified, check if it was quantified in relative 
and/or absolute terms.  

















a) Cognitive Decline Reduced 
(e.g., dementia, Alzheimer’s, 
etc.) 
        
b) Colon/Colorectal Cancer 
Reduced 
        
c) Heart Attack/Heart 
Disease/Cardiovascular 
Disease  
        
d) Hot Flashes/Night Sweats 
(vasomotor symptoms) 
Reduced  
        
e) Mood Problems Reduced 
(e.g., depression, irritability) 
        
f) Osteoporosis/Fractures 
Reduced 
        
g) Sex Life Improved (more 
libido/sexual activity, etc.) 
        
h) Skin Improved (less 
wrinkling/aging, etc,) 
        
i) Sleep Problems/Insomnia 
Reduced 
        
j) Vaginal Problems Reduced 
(atrophy, dryness, etc.) 
        
k) Other1 (Specify) 
 
        
l) Other2 (Specify)  
 








NV12: Individuals Quoted 
 
For each individual who is directly quoted in the text, classify the individual into the 
category below that best describes the individual. Each category has a brief description 
next to it.  A quoted individual can fall into more than one category if they are explicitly 
identified in more than one way. If an individual cannot be coded into the existing 
categories, select the “Other” category.  
 






a) Physician and/or Scientist 
  
  
b) Nurse Practitioner/Nurse/Other Clinicians  
 
  
c) CEO/Exec/Medical Director/PR Director/Official Spokesperson     
 
  
d) Attorney  
 
  
e) Celebrity  
 
  
f) Everyday affected woman 
 
  
g) Everyday family member of affected woman  
 
  




NV13: Organization Names/Mentioned in Body Text 
 







NV14: Types of Organizations/Mentioned in Body Text 
 
For each organization mentioned in the body text of the news story, classify it into the 
category below that best describes the type of organization it is. Each category has a brief 
description next to it. To determine nonprofit status (501c3 or 501c6) use the GuideStar 
database. If the organization cannot be found in the GuideStar database, review the 
organization’s website if available.  
 
If an organization type appears more than once in the same story, you only need to mark 
its category in the grid below once. 
 







Organization Types Yes (1) No (0) 
a) Pharmaceutical Company  
A company that manufacturers/sells prescription drugs 
(e.g., Wyeth, Duramed, Eli Lilly, Solvay Pharmaceuticals) 
  
b) Other For-Profit Company  
Any other for-profit company that is not a pharmaceutical 
company (e.g., Natural Products, Ltd., CVS, Walmart) 
  
c) U.S. Government   
Any federal government agency or entity 
(e.g., National Institutes of Health, Office of Women’s Health, 
National Heart, Lung, & Blood Institute, Food & Drug 
Administration, Centers for Disease Control & Prevention) 
  
d) Academic/Medical Institutions 
Universities, hospitals, medical centers, or other clinical centers 
involved in medical research and treatment 
(e.g., Harvard University, Emory University, Los Angeles 
Biomedical Research Institute at Harbor-UCLA Medical 
Center, University of Massachusetts Medical Center, Hospital 
of the University of Pennsylvania, Ralph Lauren Cancer Center, 
Memorial-Sloan Kettering Cancer Center) 
  
e) Medical Professional Societies /Trade Associations (501c6) 
Nonprofit 501c6 professional membership organizations 
(e.g., American Medical Association, AMA; American College 
of Obstetricians & Gynecologists (ACOG); the Endocrine 
Society; and Pharmaceutical Research Manufacturers of 
America (PhRMA)  
  
f) Health Advocacy Organizations (501c3) 
Nonprofit 501c3 patient or disease-specific health-advocacy 
organizations or foundations 
(e.g., National Women’s Health Network, American Heart 
Association, National Osteoporosis Foundation, Alzheimer’s 
Foundation) 
  
g) Coalition  
An organized group of multiple organizations or constituents 
(e.g., National Breast Cancer Coalition) 
  
h) Other 
Any organization type not mentioned above, including non-










NV15: Pharmaceutical Funding of Individuals   
 
This item captures explicit mentions of pharmaceutical funding or financial support of 
individuals. Below are examples of such explicit mentions: 
“Wyeth named Dr. Utian a ‘Partner in Menopause Education’ (requiring a contribution of 
at least $8,000) for the NAMS' 2007 Annual Meeting. Additionally, half of NAMS's 
Board of Trustees for 2007-2008 receives consulting fees or research support from 
Wyeth, including Dr. Utian.” 
 
“The study is published in the journal Neurology. One author is a former employee of 
Wyeth, which sells Prempro.” 
 
NV15. Does the news story explicitly mention pharmaceutical company funding of any 
individuals? 
 
_____1 (Yes) _____0 (No) 
 
NV16: Pharmaceutical Funding of Organizations  
 
This item captures explicit mentions of pharmaceutical funding or financial support of 
organizations and their activities. Below are examples of such explicit mentions: 
 
 “The study was funded by the National Osteoporosis Foundation (NOF). NOF receives 
funding from Wyeth, which sells Prempro.” 
 
“The National Association of Nurse Practitioners in Women's Health developed and 
launched the campaign with financial support from Upsher-Smith Women's Health.” 
 
“The North American Menopause Society has created a comprehensive guidebook. 
Supported by an unrestricted educational grant from Berlex Laboratories, makers of 
Climara, the Menopause Guideboook is available on www.menopause.org. Berlex did not 
influence any of its contents.”  
 
NV16. Does the news story explicitly mention pharmaceutical company funding of any 
organizations? 
 
_____1 (Yes) _____0 (No) 
 
NV17: Pharmaceutical Funding of Research Studies   
 
This item captures explicit mentions of pharmaceutical funding or financial support of 
research studies. Research studies can include unpublished clinical studies, published 
studies in scientific/medical journals, or a variety of public opinion or survey studies.  





"This study confirms what the medical community and the public already know about 
HRT and the treatment of heart disease," says Victoria Kusiak, M.D., Vice President, 
Global Medical Affairs and North American Medical Director for Wyeth 
Pharmaceuticals, the study's sponsor.” 
 
“David F. Archer, M.D., professor of obstetrics and gynecology at EVMS' Jones Institute 
of Reproductive Medicine, was among a group of researchers in various parts of the 
United States who conducted the five-year study, which involved about 2,700 women and 
was funded by Wyeth-Ayerst Laboratories.”   
 
“The New World of HRT study, sponsored by Pharmacia Corporation, was conducted by 
SRI Business Intelligence Center in April 2000.”  
 
NV17: Does the news story explicitly mention pharmaceutical funding of any research 
studies? 
_____1 (Yes) _____0 (No) 
 






NV1: Coder #:_________ NV2: News Story ID: _________NV3: Date:_____(Month) ___________(Day) __________(Year) 
 
 
NV4: Does the headline refer to hormone therapy (HT) for menopause or symptoms or conditions associated with menopause?   
_____(1)  Yes _____(0)  No (IF NO, ELIMINATE)   
 
NV5: Which of the following BEST describes this news story?           NV6: Which source did this story appear in?  
  Circle Code   Circle Code 
 Story primarily about the organization as opposed to HT  1 
 
 Associated Press  1 
 
 Letter to the editor or editorial/opinion piece  2 
 
 Los Angeles Times  2 
 
 Film/television/book/theater/other entertainment review  3 
 
 The New York Times 3 
 
 Story about study conducted in animals only 4 
 
 The Wall Street Journal  4 
 
 Q&A-style health advice column  5 
 
 The Washington Post  5 
 
 None of the above (0) 0 
 
   
(IF SELECTED 1, 2, 3, 4, OR 5 ABOVE, ELIMINATE) 
 
NV7. For each brand name below, check whether it appeared or not in any part of the news story.  
















 Activella/Activelle   Divigel    Evamist   Prefest   
 Alora   Elestrin   FemHRT   Premarin   
 Angeliq   Enjuvia    Femring   Premphase   
 Cenestin   Estrace    Femtrace   Prempro   
 Climara/Pro   Estraderm    Menest   Prometrium   
 CombiPatch   Estrasorb    Menostar   Provera   
 Delestrogen   Estratab   Ogen   Vagifem   
 Depo-Estradiol   Estratest    Ortho-Est   Vivelle/Vivelle-dot   







NV8. Does the story refer to a medical professional or scientific journal anywhere in the text?  
_____Yes (1) _____No (0) 
 







NV10. For each potential risk of HT below, check the relevant columns. 
 Potential Risks Identified? (ID) Quant? (QT) Relative? (REL) Absolute? (ABS)  
  Yes (1) No (0) Yes (1) No (0) Yes (1) No (0) Yes (1) No (0) 
 a) Breast cancer           
 b) Cognitive (e.g., dementia, Alzheimer’s)          
 c) Gallbladder disease          
 d) Heart attack/Heart disease/Cardiovascular 
disease  
        
 e) Stroke          
 f) Thrombosis/blood clots          
 g) Uterine/endometrial cancer (also includes 
ovarian cancer)  
        
 h) Other1 (OTH1) (Specify):         

















  Yes (1) No (0) Yes (1) No (0) Yes (1) No (0) Yes (1) No (0) 
 a) Cognitive Decline Reduced (e.g., dementia, 
Alzheimer’s) 
        
 b) Colon/Colorectal Cancer Reduced           
 c) Heart Attack/Heart Disease/Cardiovascular Disease 
Reduced 
        
 d) Hot Flashes/Night Sweats (vasomotor symptoms) 
Reduced  
        
 e) Mood Problems Reduced (e.g., depression, 
irritability)  
        
 f) Osteoporosis/Fractures Reduced         
 g) Sex Life Improved (e.g., more libido/sexual activity)         
 h) Skin Improved (e.g., less wrinkles, aging)          
 i) Sleep Problems/Insomnia Reduced          
 j) Vaginal Problems Reduced (e.g., atrophy, dryness)          
 k) Other1 (Specify):         





NV12: Are any of the following types of individuals directly quoted in this release? (CHECK ALL THAT APPLY) 
 
 Individuals Quoted Yes (1) No (0)  Yes (1) No (0) 
 a) Physician and/or Scientist  
 
  e) Celebrity 
 
  
 b) Nurse Practitioner/Nurse/Other 
Clinicians  
 




 c) CEO/Exec/Medical Director/PR 
Director/Official Spokesperson    
 
  g) Everyday family 




 d) Attorney (ATTY) 
 











NV14: Are any of the following types of organizations listed in the BODY TEXT of the release? 
 








 a) Pharmaceutical Company    f) Health Advocacy Organizations (501c3)    
 b) Other For-Profit Company  
 
  g) Coalition    
 c) U.S. Government 
 
  h) Other    
 d) Academic/Medical Institutions 
 
     








NV15. Does the release explicitly mention pharmaceutical company funding of any individuals?  
 
_____(1) Yes   _____(0) No 
 
NV16. Does the release explicitly mention pharmaceutical company funding of any organizations?  
 
_____(1) Yes  _____(0) No 
 
 
NV17: Does the release explicitly mention pharmaceutical company funding of any research studies?  
 







Appendix E: Reliabilities for Content Analysis Variables 
Table E1: Reliabilities for Content Analysis Variables 
 




Date of press release or news story PV3, NV3  
     Month  .98 
     Day  .99 
     Year  .99 
Headline refers to HT PV4, NV4 .98 
Press release/news story eliminated or not based on 
type 
PV5, NV5 .94 
Type of organization that produced/distributed release   
     Pharmaceutical company PV7a .98 
     Other for-profit company (not a pharmaceutical) PV7b .82 
     U.S. government agency PV7c 1.00 
     Academic/Medical institutions PV7d .83 
     Medical professional societies/trade assocs. (501c6) PV7e .84 
     Health advocacy organizations (501c3) PV7f .81 
     Coalition PV7g 0* 
     Medical/scientific journal publishers PV7h .84 
     Other PV7i .74 
News source  NV6 .94 
Potential Risks of HT   
     Breast cancer identified PV10a, NV10a .93 
          quantified  .89 
          quantified in relative terms  .86 
          quantified in absolute terms  .81 
     Cognitive (e.g., dementia, Alzheimer’s) PV10b, NV10b .93 
          quantified   .80 
          quantified in relative terms  .80 
          quantified in absolute terms  1.00 
     Gallbladder disease PV10c, NV10c .83 
          quantified   0* 
          quantified in relative terms  0* 
          quantified in absolute terms  0* 
     Heart attack/heart disease/cardiovascular disease PV10d, NV10d .86 
          quantified   .93 
          quantified in relative terms  .77 
          quantified in absolute terms  .87 
     Stroke PV10e, NV10e .92 
          quantified   .83 
          quantified in relative terms  .75 
          quantified in absolute terms  .81 










     Thrombosis/blood clots PV10f, NV10f .90 
          quantified   .80 
          quantified in relative terms  .75 
          quantified in absolute terms  .75 
     Uterine/endometrial cancer (includes ovarian)  PV10g, NV10g .88 
          quantified   .84 
          quantified in relative terms  .74 
          quantified in absolute terms  .75 
Potential Benefits of HT   
     Cognitive decline reduced (dementia, Alzheimer’s) PV11a, NV11a .78 
          quantified   0* 
          quantified in relative terms  0* 
          quantified in absolute terms  0* 
     Colon/Colorectal cancer reduced PV11b, NV11b .84 
          quantified   1.00 
          quantified in relative terms  .86 
          quantified in absolute terms  .87 
     Heart attack/heart or cardiovascular disease reduced PV11c, NV11c .86 
          quantified   .94 
          quantified in relative terms  .84 
          quantified in absolute terms  .75 
     Hot flashes/night sweats/vasomotor symptoms  PV11d, NV11d .87 
          quantified   .87 
          quantified in relative terms  .80 
          quantified in absolute terms  0* 
     Mood problems (e.g., depression, irritability) PV11e, NV11e .80 
          quantified   0* 
          quantified in relative terms  0* 
          quantified in absolute terms  0* 
     Osteoporosis/fractures reduced PV11f, NV11f .84 
          quantified   .80 
          quantified in relative terms  .81 
          quantified in absolute terms  .87 
     Sex life improved (e.g, more libido/sexual activity) PV11g, NV11g .86 
          quantified   0* 
          quantified in relative terms  0* 
          quantified in absolute terms  0* 
     Skin improved (e.g., less wrinkles, aging) PV11h, NV11h .75 
          quantified   1.00 
          quantified in relative terms  1.00 
          quantified in absolute terms  0* 
     Sleep problems/insomnia reduced PV11i, NV11i .85 
          quantified   0* 
          quantified in relative terms  0* 
          quantified in absolute terms  0* 










     Vaginal problems reduced (e.g., atrophy, dryness) PV11j, NV11j .80 
          quantified   1.00 
          quantified in relative terms  0* 
          quantified in absolute terms  0* 
HT Brand Names Mentioned PV12, NV7  
     Activella/Activelle  1.00 
     Alora  0* 
     Angeliq  .86 
     Cenestin  1.00 
     Climara/Climara Pro  .78 
     CombiPatch  0* 
     Delestrogen  0* 
     Depo-Estradiol  0* 
     Divigel  1.00 
     Elestrin  .80 
     Enjuvia  0* 
     Estrace  0* 
     Estraderm  0* 
     Estrasorb  0* 
     Estratab  0* 
     Estratest  0* 
     Estring  0* 
     Evamist  1.00 
     FemHRT  1.00 
     Femring  0* 
     Femtrace  1.00 
     Menest  0* 
     Menostar  1.00 
     Ogen  0* 
     Ortho-Est  1.00 
     Prefest  0* 
     Premarin  .89 
     Premphase  .75 
     Prempro  .90 
     Prometrium  0* 
     Provera  0* 
     Vagifem  0* 
     Vivelle/Vivelle-dot  0* 










Medical/Scientific Journal Referenced PV13, NV8 .95 
Organizations Mentioned in Body Text   
     Pharmaceutical company PV16a, NV13a .93 
     Other for-profit company (not a pharmaceutical) PV16b, NV13b .74 
     U.S. government agency PV16c, NV13c .88 
     Academic/Medical institutions PV16d, NV13d .90 
     Medical professional societies/trade assocs. (501c6) PV16e, NV13e .74 
     Health advocacy organizations (501c3) PV16f, NV13f .85 
     Coalition PV16g, NV13g 0* 
     Other PV16h, NV13h .82 
Types of Individuals Directly Quoted   
     Physician and/or scientist PV17a, NV12a .87 
     Nurse practitioner/nurse/other clinicians  PV17b, NV12b 0* 
     CEO/Medical Dir./PR Dir./Official Spokesperson PV17c, NV12c .72 
     Attorney PV17d, NV12d 1.00 
     Celebrity PV17e, NV12e 0* 
     Everyday affected woman PV17f, NV12f .87 
     Everyday affected family member of affected 
woman 
PV17g, NV12g 0* 
     Other PV17h, NV12h 0* 
Pharmaceutical Industry Funding   
     Explicit mention of funding individuals  PV18, NV15 1.00 
     Explicit mention of funding organizations PV19, NV16 .76 
     Explicit mention of funding research studies PV20, NV17 .78 
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